WO2008076225A2 - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors Download PDF

Info

Publication number
WO2008076225A2
WO2008076225A2 PCT/US2007/025012 US2007025012W WO2008076225A2 WO 2008076225 A2 WO2008076225 A2 WO 2008076225A2 US 2007025012 W US2007025012 W US 2007025012W WO 2008076225 A2 WO2008076225 A2 WO 2008076225A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
independently
ring
compound
pharmaceutically acceptable
Prior art date
Application number
PCT/US2007/025012
Other languages
French (fr)
Other versions
WO2008076225A3 (en
Inventor
Neville J. Anthony
Robert Gomez
Samson M. Jolly
Dai-Shi Su
John Lim
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to JP2009538427A priority Critical patent/JP5123949B2/en
Priority to CA002673093A priority patent/CA2673093A1/en
Priority to AU2007334598A priority patent/AU2007334598B2/en
Priority to EP07862604.1A priority patent/EP2121638B1/en
Publication of WO2008076225A2 publication Critical patent/WO2008076225A2/en
Publication of WO2008076225A3 publication Critical patent/WO2008076225A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Definitions

  • the present invention is directed to certain substituted indazoles, benzotriazoles, and related bicyclic compounds and their pharmaceutically acceptable salts and their use for the inhibition of HIV reverse transcriptase, the prophylaxis of HIV infection and HIV replication, the treatment of HIV infection and HIV replication, the prophylaxis of AIDS, the treatment of AIDS, and the delay in the onset and/or progression of AIDS.
  • HIV human immunodeficiency virus
  • HIV-I HIV type-1
  • HIV-2 HIV-2
  • AIDS immunosuppressive disease
  • HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS.
  • ARC AIDS related complex
  • Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections.
  • Replication of HIV by a host cell requires integration of the viral genome into the host cell's DNA. Since HIV is a retrovirus, the HTV replication cycle requires transcription of the viral RNA genome into DNA via an enzyme know as reverse transcriptase (RT).
  • RT reverse transcriptase
  • Reverse transcriptase has three known enzymatic functions: The enzyme acts as an RNA-dependent DNA polymerase, as a ribonuclease, and as a DNA-dependent DNA polymerase. In its role as an RNA-dependent DNA polymerase, RT transcribes a single-stranded DNA copy of the viral RNA. As a ribonuclease, RT destroys the original viral RNA and frees the DNA just produced from the original RNA. And as a DNA-dependent DNA polymerase, RT makes a second, complementary DNA strand using the first DNA strand as a template. The two strands form double-stranded DNA, which is integrated into the host cell's genome by the integrase enzyme.
  • AIDS are the RT inhibitors 3'-azido- 3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'- dideoxycytidine (ddC), d4T, 3TC, nevirapine, delavirdine, efavirenz and abacavir. While each of the foregoing drugs is effective in treating HIV infection and AIDS, there remains a need to develop additional HTV antiviral drugs including additional RT inhibitors. A particular problem is the development of mutant HIV strains that are resistant to the known inhibitors. The use of RT inhibitors to treat AIDS often leads to viruses that are less sensitive to the inhibitors.
  • the present invention is directed to certain substituted indazoles, benzotriazoles, and related bicyclic compounds and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HFV, the treatment of infection by HFV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. More particularly, the present invention includes compounds of Formula I and pharmaceutically acceptable salts thereof:
  • V is C(RlO), C(O), N(Rl 1), N or N oxide
  • W is C(R3), C(O), N(Rl 2), N or N oxide
  • Y is C or N
  • Z is C or N, with the proviso that no more than two of V, W, Y and Z contain N;
  • X is O, S, S(O), S(O) 2 , N(RA), C(RA)(RB), or C(O);
  • Rl is AryA or HetA
  • R2, R3 and RlO are each independently selected from the group consisting of:
  • Rl 1 and Rl2 are each independently selected from the group consisting of H, halogen, Ci-6 alkyl and CycE;
  • ring A is an unsaturated 6-membered ring wherein " ' ⁇ --' " denotes the ring contains at least two double bonds;
  • ring B is fused to ring A and forms together with shared atoms Y and Z of ring A a 4- to 7- membered saturated or unsaturated ring optionally containing from 1 to 3 heteroatoms each of which is independently N, O or S, wherein the total count of heteroatoms in ring B includes either or both Y and Z when either or both are N, and wherein each S is optionally S(O) or S(O)2 and each N is optionally an N-oxide, and wherein from zero to 2 ring carbons are optionally substituted with oxo;
  • R4 and R.5 are each independently selected from the group consisting of:
  • j is an integer equal to zero or 1 ;
  • k is an integer equal to zero or 1 ;
  • R6 is attached to the ring atom in B which is adjacent to shared atom Z or which is adjacent to the ring atom that is adjacent to Z, and is:
  • each ring N is optionally an N-oxide
  • R7 and R ⁇ are each independently selected from the group consisting of:
  • R9 is H or C 1-6 alkyl
  • each RA is independently H, Cl -6 alkyl, or Cl -6 haloalkyl
  • each RB is independently H, Ci -6 alkyl, or Cl -6 haloalkyl
  • each RC is independently H, Cl -6 alkyl, or Ci -6 haloalkyl; each RD is independently H, C ⁇ . ⁇ alkyl, or C 1-6 haloalkyl;
  • each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated or mono-unsaturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2; wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Cl -6 alkyl, (2) Ci -6 fluoroalkyl, (3) (CH2)l-2G wherein G is OH, O-Ci-6 alkyl, O-Ci-6 fluoroalkyl, N(RA)RB 5 C(O)N(RA)RB 5 C(O)RA, C ⁇ 2R A , or S ⁇ 2R A , (4) 0-C I -6 alkyl, (5) 0-C I -6 fluoroalkyl, (6) OH, (7) oxo, (8)
  • AryA is aryl optionally substituted with a total of from 1 to 6 substituents, wherein: (i) from zero to 6 substituents are each independently:
  • N(RA)C02R B N(RA)S(0)2R B , N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB 5 N(RA)C(O)N(RA)RB, or N(RA)C(O)C(O)N(RA)RB,
  • HetA is heteroaryl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
  • O-Ci-6 alkyl (4) 0-C l -6 alkyl, in which the alkyl is substituted with OH, O-C I -6 alkyl, O-Ci-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA C ⁇ 2R A , SRA, S(O)RA, S(0)2R A , S(0)2N(RA)RB, N(RA)C(O)RB, N(RA)C02R B , N(RA)S(0)2R B , N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, O r N(RA)C(O)C(O)N(RA)RB,
  • aryl is (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocylic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
  • heteroaryl is (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, (ii) a 9- or 10-membered bicyclic fused ring system, or (iii) an 11- to 16-membered tricyclic fused ring system, wherein the fused ring system of (ii) or (iii) contains from 1 to 6 heteroatoms independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatom, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2;
  • AryB independently has the same definition as AryE;
  • HetB independently has the same definition as HetE;
  • HetC independently has the same definition as HetF;
  • each CycE is independently C3-8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci -6 alkyl, OH, O-Ci-6 alkyl, Cl -6 haloalkyl, or O-Ci-6 haloalkyl;
  • each AryE is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, CN, NO2, Ci_6 alkyl, C 1 _6 haloalkyl, OH, O-C 1 -6 alkyl, O-C 1 -6 haloalkyl, C(O)N(RA)RB 5 C(O)RA, CO2RA, SRA S(O)RA, SO2RA, SO2N(RA)RB 5 or SO2N(RA)C(O)RB;
  • each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, CN, NO2, Cl -6 alkyl, Cl -6 haloalkyl, O-C 1-6 alkyl, O-Ci-6 haloalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02R B , C(O)N(RA)RB, C(O)RA, C ⁇ 2R A , SO2RA, S ⁇ 2N(RA)RB, O ⁇ phenyl, with the proviso that no more than 1 of the optional substituents is phenyl; and
  • each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 4 substituents, each of which is independently halogen, CN, C 1-6 alkyl, OH, oxo, O-Ci-6 alkyl, C 1-6 haloalkyl, O-Ci-6 haloalkyl, C(O)N(RA)RB, C(O)RA, C ⁇ 2R A , S ⁇ 2R A , or
  • the compounds of Formula I above, and pharmaceutically acceptable salts thereof, are HIV reverse transcriptase inhibitors.
  • the compounds are useful for inhibiting HIV reverse transcriptase and for inhibiting HIV replication in vitro and in vivo. More particularly, the compounds of Formula I inhibit the polymerase function of HIV-I reverse transcriptase. Based upon the testing of representative compounds of the invention in the assays set forth in Example 31 below, it is known that compounds of Formula I inhibit the RNA-dependent DNA polymerase activity of HIV-I reverse transcriptase.
  • Representative compounds of the present invention also exhibit activity against drug resistant forms of HIV (e.g., mutant strains of HIV-I in which reverse transcriptase has a mutation at lysine 103 — > asparagine (Kl 03N) and/or tyrosine 181 ⁇ cysteine (Yl 81C) ), and thus can exhibit decreased cross-resistance against currently approved antiviral therapies.
  • drug resistant forms of HIV e.g., mutant strains of HIV-I in which reverse transcriptase has a mutation at lysine 103 — > asparagine (Kl 03N) and/or tyrosine 181 ⁇ cysteine (Yl 81C)
  • a first embodiment of the present invention is a compound of Formula I (alternatively and more simply referred to as “Compound I”) as originally defined (i.e., as defined in the Summary of the Invention above), or a pharmaceutically acceptable salt thereof; and provided that:
  • a second embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • V is C(RlO), N(Rl 1), N or N oxide
  • W is C(R3), N(Rl 2), N or N oxide
  • Y is C or N
  • Z is C or N, with the proviso that no more than two of V, W, Y and Z contain N;
  • R6 is attached to the ring atom in B which is adjacent to shared atom Z and is R9 , wherein each ring N is optionally an N-oxide, and wherein the asterisk denotes the point of attachment to the rest of the compound;
  • R? and R8 are each independently selected from the group consisting of substituents (1) to (30) as originally defined above (i.e., the following substituents are excluded from the group: (31) N(RA)S(O)2R B , (32) N(RA)C(O)RB, and (33) N(RA)C(O)N(RA)RB).
  • each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, C 1-6 alkyl, Ci -6 haloalkyl, O-Ci-6 alkyl, OCi -6 haloalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, O r N(RA)CO2R B ;
  • each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 4 substituents, each of which is independently halogen, CN, Ci -6 alkyl, OH, oxo, O-Ci-6 alkyl, C 1-6 haloalkyl, or O-Ci-6 haloalkyl;
  • a third embodiment of the present invention is a compound of
  • a fourth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X is O; and all other variables are as originally defined or as defined in any one of Embodiments El, E2, and E3.
  • a fifth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); W is C(R3); Y is C; Z is C; ring A is aromatic (i.e., benzo); and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4.
  • Embodiment E5 corresponds to a compound of Formula II:
  • a sixth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein V is N; W is C(R3); Y is C; Z is C; ring A is aromatic (i.e., pyrido); and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4.
  • Embodiment E6 corresponds to a compound of Formula III:
  • a seventh embodiment of the present invention is a compound of Formula I 5 or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); W is C(R ⁇ ); Y is C; Z is N; and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4.
  • Embodiment E7 corresponds to a compound of Formula IV:
  • An eighth embodiment of the present invention is a compound of Formula I 5 or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); ⁇ y is C(R3); Y is N; Z is C; and all other variables are as originally defined or as defined in any one of Embodiments El 5 E2, E3 and E4.
  • Embodiment E8 corresponds to a compound of Formula V:
  • a ninth embodiment of the present invention is a compound of Formula I 5 or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); W is N; Y is C; Z is C; ring A is aromatic (i.e., pyrido); and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4.
  • Embodiment E9 corresponds to a compound of Formula VI:
  • Embodiment ElO is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); w is C(R3); Y is C; Z is C; ring A has two carbon-carbon double bonds; and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4.
  • Embodiment ElO corresponds to a compound of Formula VII:
  • An eleventh embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl is AryA; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twelfth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2, R3 and RlO are each independently selected from the group consisting of:
  • a thirteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the group consisting of:
  • a fourteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl; RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a fifteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and CH3; RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a sixteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 is Br or Cl; R3 is H; RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • R2 is Cl; R3 is H; and RlO is H.
  • a seventeenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl 2 are each independently H or Cl -6 alkyl; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • An eighteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl 2 are each independently H or Ci .4 alkyl; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a nineteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl 2 are each independently H or CH3; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twentieth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl2 are both H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twenty-first embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are each independently selected from the group consisting of: (1) H, (2) Ci_6 alkyl,
  • a twenty-second embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4 and R.5 are each independently selected from the group consisting of:
  • a twenty-third embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.4 and R.5 are each independently selected from the group consisting of H, Ci .4 alkyl, Cl, Br and F; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twenty-fourth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.4 and R.5 are each independently selected from the group consisting of H, CH3, OCH3, CF3, OCF3, Cl, Br and F; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twenty-fifth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are both H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twenty-sixth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each independently selected from the group consisting of: (1) H,
  • a twenty-seventh embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each independently selected from the group consisting of:
  • a twenty-eighth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 is H; R ⁇ is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a twenty-ninth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 is H; R.8 is H or NH2; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a thirtieth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • L is N or N oxide
  • a thirty-first embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R6 is:
  • Jl and J2 are each independently H, halogen, CN, NO2, Ci-4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or SO2N(RA)RB ;
  • J3 is H, halogen, CN, Ci-4 alkyl, OH, oxo, O-Ci-4 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, CO2RA SO2RA, or S02N(RA)RB ;
  • L is N or N oxide
  • Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-C1.3 alkyl, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and J3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-Ci-3 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2.
  • a thirty-second embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R6 is:
  • a thirty-third embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R6 is:
  • AryA is as originally defined in Embodiment E34, except that the list of optional substituents excludes C ⁇ C
  • a thirty-fifth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is: ; wherein Tl and T2 and T3 are each independently H, Ci_4 alkyl, halogen, CN,
  • CH CH-CN, C(O)RA, O r (CH2)l-2N(R A )RB; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • a thirty-sixth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
  • a thirty-seventh embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
  • Tl is H or Cl
  • T2 is CN, CH(O), CH2NH2, or CH2N(H)CH3 ; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
  • AryA is as originally defined in Embodiment 38, except that Tl and T2 are each independently H, Cl .4 alkyl, halogen,
  • a thirty-ninth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
  • a fortieth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetA is a heteroaryl selected from the group consisting of thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, isobenzofuranyl, benzisoxazolyl, benzoxazolyl, benzimidazolyl, benzopiperidinyl, chromenyl, quinolinyl, isoquinolinyl, c
  • HetA is as originally defined in Embodiment E40, except that each of the optional 1 to 3 substituents is independently Ci-4 alkyl, CF3, O-C1.4 alkyl, OCF3, OH, halogen, CN, NO2, N(RA)RB, C(O)N(RA)RB 5 C(O)RA, C(0)CF3, CO2RA, or SO2RA.
  • a forty-first embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RA and RB are each independently H or Cl -6 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-second embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RA and RB are each independently H or Cl .4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-third embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RA and RB are each independently H or CH3; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-fourth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RC and RD are each independently H or Cl -6 alkyl; or alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(0)2; and wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Ci-4 alkyl, (2) CF3, (3) C(O)N(RA)RB 5 (4) C(O)RA, (5) C(0)-CF3,
  • a forty-fifth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RC and RD are each independently H or C 1.4 alkyl; or alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of ⁇ , Ss - ⁇ , and ⁇ — ' ; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-sixth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.C and RD are each independently H or C 1.4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-seventh embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.C and RP are each independently H or CH3; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-eighth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.9 is H or Ci .4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a forty-ninth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a fiftieth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each CycE is independently C3-7 cycloalkyl which is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, Ci .4 alkyl, OH, O-Ci-4 alkyl, Cl -4 fluoroalkyl, or O-C1-.4 fluoroalkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a fifty-first embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each AryE is independently phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently Cl, Br, F, CN, NO2, Cl .4 alkyl, Cl .4 fluoroalkyl, OH, O-Ci-4 alkyl, O-Ci-4 fluoroalkyl, C(O)N(RA)RB, C(O)RA, C ⁇ 2R A , SRA, S(O)RA, SO2RA, S ⁇ 2N(RA)RB, O r S ⁇ 2N(RA)C(O)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a fifty-second embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, C 1.4 alkyl, Cl .4 fluoroalkyl, O-C1.4 alkyl, O-Ci-4 fluoroalkyl, OH, N(RA)RB 5 N(RA)C(O)N(RA)RB, or N(RA)C02R B ; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a fifty-third embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 3 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono- unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 3 substituents, each of which is independently Cl, Br, F, CN, C 1-4 alkyl, OH, oxo, O-Ci-4 alkyl, Ci_4 fluoroalkyl, or O-Ci-4 fluoroalkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a fifty-fourth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each AryB is independently phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently Cl, Br, F, CN, NO2, C 1.4 alkyl, C 1.4 fluoroalkyl, OH, O-C 1.4 alkyl, O-C 1.4 fluoroalkyl, C(O)N(RA)RB, C(O)RA, C ⁇ 2R A , SRA, S(O)RA, SO2RA, S ⁇ 2N(RA)RB, O r S ⁇ 2N(R A)C(O)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • a fifty-fifth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryB is phenyl which is optionally substituted with from 1 to 2 substituents each of which is independently Cl, Br, F, CN, NO2, C 1-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB 5 C(O)RA, CO2RA, SO2RA, or S ⁇ 2N(RA)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • AryB is phenyl which is optionally substituted with from 1 to 2 substituents each of which is independently Cl, Br, F, CN, NO2, C 1-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB 5 C(O)RA, CO2RA, SO2RA, or S ⁇ 2N(RA)RB; and all other variables are as originally defined
  • a fifty-sixth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3,
  • HetB is as originally defined in Embodiment E56, except that the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, Cl .4 alkyl, Cl .4 fluoroalkyl, O-C 1.4 alkyl, O-C 1.4 fluoroalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02R B , 802N(RA)RB, O ⁇ phenyl, with the proviso that no more than 1 of the optional substituents is phenyl.
  • substituents each of which is independently Cl, Br, F, Cl .4 alkyl, Cl .4 fluoroalkyl, O-C 1.4 alkyl, O-C 1.4 fluoroalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02R B , 802N(RA)
  • a fifty-seventh embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetB is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, pyridyl and pyrimidinyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents, each of which is independently Cl, Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, S ⁇ 2N(R A)RB, O r phenyl, with the proviso that no more than 1 of the optional substituents is phenyl; and all other variables are as originally defined or as defined in any of the preceding
  • a fifty-eighth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetC is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 3 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(0)2, and wherein the saturated or mono- unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 3 substituents, each of which is independently Cl, Br, F, CN, Cl .4 alkyl, OH, oxo, O-Ci-4 alkyl, Ci .4 fluoroalkyl, O-C1.4 fluoroalkyl, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or S ⁇ 2N(RA)RB ; and all other variables are as originally defined or as defined in any of the
  • a fifty-ninth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetC is a saturated heterocyclic ring selected from the group consisting of 1-pyrrolidinyl, 1 -piperidinyl, 4-morpholinyl, 4-thiomorpholinyl in which the S is optionally oxidized to S(O) or S(0)2, and
  • 1-piperazinyl wherein the saturated heterocyclic ring is optionally substituted with from 1 to 2 substituents each of which is Cl, Br, F, CN, C 1.4 alkyl, OH, oxo, O-C1.4 alkyl, CF3, OCF3,
  • a first class of compounds of the present invention includes compounds, and pharmaceutically acceptable salts thereof, selected from compounds of Formula VIII:
  • a sub-class of Class Cl i.e., Sub-class SCl-I
  • SCl-I includes the compounds of Formula VIII in which X is O and pharmaceutically acceptable salts thereof.
  • Other sub-classes of Class Cl include the compounds of Formula VIII and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
  • a second class of compounds of the present invention includes compounds and pharmaceutically acceptable salts thereof, selected from compounds of Formula:
  • a sub-class of Class C2 includes the compounds in which X is O and pharmaceutically acceptable salts thereof.
  • Other sub-classes of Class C2 include the compounds of Formulas Ha to Vila and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
  • a third class of compounds of the present invention is identical to Class C2 except that compounds of Formula IVc and Formula Vila and their salts are excluded.
  • a sub-class of Class C3 i.e., Sub-class SC3-1) includes the compounds in which X is O and pharmaceutically acceptable salts thereof.
  • Other sub-classes of Class C3 include the compounds of the various formulas (excluding IVc and Vila) and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
  • a fourth class of compounds of the present invention includes compounds of Formula He as shown in Class C3 and pharmaceutically acceptable salts thereof, wherein all variables therein are as originally defined.
  • a sub-class of Class C4 i.e., Sub-class SC4-1) includes the compounds of Formula lie in which X is O and pharmaceutically acceptable salts thereof.
  • Other sub-classes of Class C4 include the compounds of Formula lie and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
  • a fifth class of compounds of the present invention includes compounds of Formula Hi as shown in Class C3 and pharmaceutically acceptable salts thereof, wherein all variables therein are as originally defined.
  • a sub-class of Class C5 i.e., Sub-class SC5-1) includes the compounds of Formula Hi in which X is O and pharmaceutically acceptable salts thereof.
  • Other sub-classes of Class C3 include the compounds of Formula IIi and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
  • a sixth class of compounds of the present invention includes compounds of Formula I and pharmaceutically acceptable salts thereof, wherein: X is O;
  • Rl is AryA
  • R.2, R3 and RlO are each independently selected from the group consisting of:
  • Ci_6 alkyl (5) Ci -6 fluoroalkyl, (6) O-Ci-6 alkyl, and (7) O-Ci-6 fiuoroalkyl;
  • Rl 1 and Rl 2 are each independently H or C ⁇ - ⁇ alkyl;
  • R4 and R5 are each independently selected from the group consisting of: (1) H,
  • R6 is: (l) , (2) , (3) *-CH2C(O)N(RA)-AryB,
  • L is N or N oxide
  • R7 and R8 are each independently selected from the group consisting of: (1) H, (2) OH, (3) halogen, (4) CN, (5) NO 2 , (6) Ci-6 alkyl, (7) O-Ci-6 alkyl, (8) O(CH2)2-3N(RA)RB, (9) 0(CH 2 ) 1-3 C(O)RA (i ⁇ ) Ci-6 fluoroalkyl, (11) O-Ci-6 fluoroalkyl, (12) N(RC)RD 5 (13) N(RA).(CH2)2-3 -N(RC)RD, (14) C(O)N(RA)RB, (15) C(O)RA (16) C(O)ORA, (17) SRA, (is) S(O)RA (19) S(O)2R A , and
  • R9 is H or C 1-4 alkyl
  • AryB is phenyl which is optionally substituted with from 1 to 2 substituents each of which is independently Cl 5 Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, S(0)2R A , or S(O)2N(RA)RB ;
  • HetB is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, pyridyl and pyrimidinyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents, each of which is independently Cl, Br, F, CN, NC-2, C1-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB 5 C(O)RA, CO2RA, S ⁇ 2R A , 802N(RA)RB, O r phenyl, with the proviso that no more than 1 of the optional substituents is phenyl;
  • a sub-class of Class C6 includes the compounds of Formula I and their pharmaceutically acceptable salts, wherein V is CH; W is C(R3); either (i) Z and Y are both C and ring A is benzo, or (ii) Z is N and Y is C and ring A is pyrido or dihydropyrido; ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms; and all other variables are as originally defined in Class C6.
  • Sub-class SC6-2 includes the compounds of Formula I and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C6; and provided that:
  • R4 is other than H, then R6 is not
  • a seventh class of compounds of the present invention includes compounds of Formula I and pharmaceutically acceptable salts thereof, wherein:
  • a sub-class of Class C7 includes the compounds of Formula I and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C7; and provided that:
  • An eighth class of compounds of the present invention includes compounds of Formula I and pharmaceutically acceptable salts thereof, wherein: V and W are both CH; Z and Y are both C; ring A is benzo; ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms; and all other variables are as defined in Class C7.
  • a ninth class of compounds of the present invention includes compounds of Formula EX:
  • R2 and R3 are each independently selected from the group consisting of: (1) H, (2) halogen, (3) N(RA)RB, (4) Ci-4 alkyl, (5) CF3, (6) O-Cl-4 alkyl, and (7) OCF3;
  • Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-C 1.4 alkyl, OCF3 , C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or S ⁇ 2N(RA)RB ;
  • J3 is H, Cl, Br, F, CN, CM alkyl, OH, oxo, O-C1-4 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, C ⁇ 2R A , SO2RA, or S ⁇ 2N(RA)RB ;
  • L is N or N oxide
  • R4 and R5 are each independently selected from the group consisting of: (1) H, (2) Ci-4 alkyl, (3) O-C1.4 alkyl, (4) CF3, (5) OCF3, and (6) halogen;
  • R7 and R8 are each independently selected from the group consisting of: (1) H, (2) OH, (3) halogen, (4) CN, (5) NO2, (6) Ci-4 alkyl, (7) O-C1.4 alkyl,
  • each RA is independently H or Cl .4 alkyl
  • each RB is independently H or Cl .4 alkyl
  • each RC is independently H or Cl .4 alkyl
  • each RD is independently H or C 1-4 alkyl; and alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
  • a sub-class of Class C9 includes the compounds of Formula DC and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C9; and provided that:
  • Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-C1.3 alkyl, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2;
  • J 3 is H, Cl, Br, F, CN, C1-3 alkyl, OH, oxo, O-C1.3 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class C9 or Sub-class SC9-1.
  • a tenth class of compounds of the present invention includes compounds of Formula DCa:
  • Sub-class SC 10-2 includes the compounds of Formula IXa and their pharmaceutically acceptable salts, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-C1.3 alkyl, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class ClO or Sub-class SClO-I.
  • An eleventh class of compounds of the present invention includes compounds of Formula Kb:
  • Tl is H or Cl; R.2 and R3 are each independently selected from the group consisting of H, Cl, Br,
  • R4 is H, C 1.4 alkyl, Cl, Br, or F;
  • L is N or N oxide; and one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other ofR7 and R8 is H.
  • Another sub-class of Class CI l includes the compounds of
  • a twelfth class of compounds of the present invention includes compounds of Formula IXc: and pharmaceutically acceptable salts thereof, wherein:
  • Tl is H or Cl
  • T2 is CN, CH(O), CH2NH2, or CH2N(H)CH3;
  • R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(0)N(H)CH3, or C(O)N(CH3)2;
  • Class C 13 includes compounds of Formula FXd:
  • R2 and R3 are each independently selected from the group consisting of: (1) H, (2) halogen, (3) CM alkyl, (4) CF3, (5) O-C1.4 alkyl, (6) OCF3, and (7) N(RA)RB;
  • R4 and R5 are each independently selected from the group consisting of: (1) H, (2) CM alkyl, (3) O-C1.4 alkyl, (4) CF3, (5) OCF3, and (6) halogen;
  • R7 and R8 are each independently selected from the group consisting of: (1) H, (2) OH, (3) halogen, (4) CN, (5) NO2, (6) C 1.4 alkyl, (7) O-C1.4 alkyl, (8) O(CH 2 )2-3N(RA)RB, ( 9 ) 0(CH 2 )1.3C(O)RA 5 (10) CF 3 , (11) OCF 3 , (12) O(CH 2 )l-2CF 3 , (12) N(RC)RD, (13) N(RA)-(CH 2 ) 2 .
  • each RA is independently H or Cl .4 alkyl
  • each RB is independently H or Cl .4 alkyl
  • each RC is independently H or Cl .4 alkyl
  • each RD is independently H or Cl .4 alkyl
  • each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
  • a fourteenth class of compounds of the present invention includes compounds of Formula DCe:
  • R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl;
  • R4 is H, C 1-4 alkyl, Cl, Br, or F;
  • R8 is H, OH, Cl, Br, F, CH 3 , OCH 3 , O(CH 2 ) 2 . 3 NH 2 , CF 3 , OCF 3 , OCH 2 CF 3 , NH 2 , N(H)CH 3 , N(CH 3 ) 2 , C(O)NH 2 , C(O)N(H)CH 3 , or C(O)N(CH 3 ) 2 .
  • a fifteenth class of compounds of the present invention includes compounds of Formula X:
  • a sub-class of Class Cl 5 (Sub-class SCl 5-1) includes the compounds of Formula
  • Class Cl 5 includes the compounds of Formula X and their pharmaceutically acceptable salts, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J 3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-C1.3 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class C 15. y
  • Sub-class SC15-3 includes the compounds of Formula X and their pharmaceutically acceptable salts, wherein:
  • Tl and T2 and T 3 are each independently H, Cl .4 alkyl, halogen, or CN;
  • R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl; one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(0)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other of R? and R8 is H.
  • Another sub-class of Class Cl 5 includes the compounds of Formula X and their pharmaceutically acceptable salts, wherein:
  • Tl and T2 and T ⁇ are each independently H, CH3, Cl, or CN, with the proviso that at least one of Tl and T2 and T3 is Cl and at least one of Tl and T2 and T3 is CN;
  • R2 and R.3 are each independently selected from the group consisting of H, Cl, Br, F and C 1.4 alkyl;
  • R7 and R8 are H, OH, Cl, Br, F, CH3, OCH3, NH2, N(H)CH3, or N(CH3)2-
  • a sixteenth class of compounds of the present invention includes compounds of Formula XI :
  • a sub-class of Class C16 (Sub-class SC 16-1) includes the compounds of Formula
  • Class C16 includes the compounds of Formula XI and their pharmaceutically acceptable salts, wherein Jl and j2 are each independently H, Cl, Br, F, CN, NO2, C 1.3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J 3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-Ci-3 alkyl, CF3, OCF3, C(0)NH2, C(0)N(H)CH3, C(O)N(CH3)2, C(O)H, C(0)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class C 15.
  • Sub-class SC 16-3 includes the compounds of Formula XI and their pharmaceutically acceptable salts, wherein: Tl and T2 and T3 are each independently H, C 1-4 alkyl, halogen, or CN;
  • R2 and R.3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl; one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other of R7 and R8 is H.
  • Sub-class SC 16-4 Another sub-class of Class Cl 6 (Sub-class SC 16-4) includes the compounds of Formula XI and their pharmaceutically acceptable salts, wherein:
  • Tl and T2 and T3 are each independently H, CH3, Cl, or CN, with the proviso that at least one of Tl and T2 and T3 is Cl and at least one of Tl and T2 and T3 is CN;
  • R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl;
  • Class C 17 includes compounds selected from the group consisting of the compounds set forth in Examples 1-7, 9-13 and 15-29 and their pharmaceutically acceptable salts.
  • a sub-class of Class Cl 7 includes compounds selected from the group consisting of the compounds set forth in Examples 1 to 4 and their pharmaceutically acceptable salts.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as originally defined or as defined in any of the foregoing embodiments, aspects, classes or sub-classes, wherein the compound or its salt is in a substantially pure form.
  • substantially pure means suitably at least about 60 wt.%, typically at least about 70 wt.%, preferably at least about 80 wt.%, more preferably at least about 90 wt.% (e.g., from about 90 wt.% to about 99 wt.%), even more preferably at least about 95 wt.% (e.g., from about 95 wt.% to about 99 wt.%, or from about 98 wt.% to 100 wt.%), and most preferably at least about 99 wt.% (e.g., 100 wt.%) of a product containing a compound of Formula I or its salt (e.g., the product isolated from a reaction mixture affording the compound or salt) consists of the compound or salt.
  • a product containing a compound of Formula I or its salt e.g., the product isolated from a reaction mixture affording the compound or salt
  • the level of purity of the compounds and salts can be determined using a standard method of analysis such as thin layer chromatography, gel electrophoresis, high performance liquid chromatography, and/or mass spectrometry. If more than one method of analysis is employed and the methods provide experimentally significant differences in the level of purity determined, then the method providing the highest purity level governs.
  • a compound or salt of 100% purity is one which is free of detectable impurities as determined by a standard method of analysis.
  • a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer.
  • the present invention also includes prodrugs of the compounds of Formula I.
  • prodrug refers to a derivative of a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is converted in vivo into Compound I.
  • Prodrugs of compounds of Formula I can exhibit enhanced solubility, absorption, and/or lipophilicity compared to the compounds per se, thereby resulting in increased bioavailability and efficacy.
  • the in vivo conversion of the prodrug can be the result of an enzyme-catalyzed chemical reaction, a metabolic chemical reaction, and/or a spontaneous chemical reaction (e.g., solvolysis).
  • Other examples include the following:
  • the prodrug can be an ester or an amide, and when the compound of Formula I contains a primary amino group or another suitable nitrogen that can be derivatized, the prodrug can be an amide, carbamate, urea, imine, or a
  • Embodiment PDl Another embodiment of the present invention (alternatively referred to as "Embodiment PDl ”) is a prodrug of a compound of Formula I as originally defined above.
  • Embodiment PD2 Another embodiment of the present invention is a compound of Formula I -P:
  • R.6P is attached to the ring atom in B which is adjacent to shared atom Z or which is adjacent to
  • each ring N is optionally an N-oxide
  • R9P is PO(OH)O- -M + ; PO(O-)2 -2M+; PO(O-)2 -M 2+ ; or an acid salt of:
  • M + is a pharmaceutically acceptable monovalent counterion
  • M2+ is a pharmaceutically acceptable divalent counterion
  • Rl5 is H, Ci-6 alkyl, (CH2)2-3CF3, AryA, or HetA;
  • Rl6a and Rl6b are each independently H, C ⁇ - ⁇ alkyl, (CH2)2-3CF3, AryA, or HetA; each Rl 7 is independently H or Ci -6 alkyl; each Rl 8 is independently H or C ⁇ . ⁇ alkyl; alternatively, Rl 5 together with an Rl 7 or Rl 8 and the atoms to which each is attached and any carbons in a chain therebetween form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 5 is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S (0)2; alternatively, Rl 6a together with an Rl 7 or Rl 8 and the atoms to which each is attached and any carbons in a chain therebetween form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the
  • Rl9 is H or C 1-6 alkyl
  • R20 is H or C 1-6 alkyl
  • R21 is H or C 1-6 alkyl
  • R22a and R22b are each independently H, C 1-6 alkyl, (CH2)2-3CF3, AryA, or HetA;
  • R23 is H or Ci_6 alkyl
  • R24 is H or C 1-6 alkyl; alternatively, Rl 9 together with R23 or R24 and the atoms to which each is attached form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 9 i s attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, R20 and R21 together with the carbon atom to which both are attached form a 5- or
  • d is an integer equal to 2, 3, or 4;
  • the ring is formed by combining Rl 5 with the Rl 7 or Rl 8 on a non-adjacent carbon, there is at least one carbon therebetween as exemplified by structure B below. Analogous considerations apply with respect to the monocyclic ring formed by combining Rl 6a together with an Rl7 or Rl8.
  • Embodiment PD3 Another embodiment of the present invention (Embodiment PD3) is a compound of Formula I-P as defined in Embodiment PD2; and provided that
  • Embodiment PD4 Another embodiment of the present invention (Embodiment PD4) is a compound of Formula I-P as defined in Embodiment PD2, wherein R6P is attached to the ring atom in B which is adjacent to shared atom Z; HetE and HetF are as defined in Embodiment E2; and all other variables are as defined in Embodiment PD2.
  • Embodiment PD5 Another embodiment of the present invention is a compound of Formula I-P as defined in Embodiment PD4; and provided that
  • Embodiment PD6 is a compound of Formula I -P, wherein the compound is selected from the group consisting of:
  • V-P (V-P), (VI-P), and (VII-P);
  • Embodiment PD2 wherein all of the variables are as defined in Embodiment PD2 or Embodiment PD3.
  • Embodiment PD7 is a compound of Formula I -P, wherein the compound is selected from the group consisting of compounds of Formula H-P, III-P, IV-P, V-P, and VI-P as defined in Embodiment PD6 wherein all of the variables are as defined in Embodiment PD4 or Embodiment PD5.
  • Embodiment PD8 is a compound of Formula I -P, wherein the compound is selected from the group consisting of compounds of Formula Ha-P, 1Ib-P, Hc-P, Hd-P, 1Ie-P, Hf-P, Hg-P, Hh-P, 1Ii-P, Hj-P, Hk-P, IH-P, 1Im-P, Hn-P, Ho-P, Hp-P, Hq-P, Hr-P, IHa-P, IVa-P, IVb-P, IVc-P, Va-P, VIa-P, and VIIa-P wherein these formulas are identical to Formulas Ha, Hb, He, Hd, He, Hf, ⁇ g, Hh, Hi, Hj, Ilk, III, Hm, Hn, Ho, Hp, Hq, Hr, Ilia, FVa, FVb, FVc, Va, Via and Vila respectively as set forth above
  • Embodiment PD9 is a compound of Formula I -P, wherein the compound is selected from the group consisting of compounds of Formula Ha-P, Hb-P, Hc-P, Hd-P, ⁇ e-P, Hf-P, ⁇ g-P, IHi-P, Hi-P, Hj-P, 1Ik-P, ⁇ i-P, Hm-P, Hn-P, Ho-P, Hp-P, Hq-P, 1Ir-P, HIa-P, IVa-P, FVb-P, Va-P and VIa-P wherein these formulas are identical to Formulas Ha, ⁇ b, He, Hd, ⁇ e, Hf, Hg, Hh, m, ⁇ j, Hk, III, Hm, Hn, no, Up, Hq, Hr, Ilia, IVa, IVb, Va and Via respectively as set forth above in Class C2, except that R.6 is replaced with R.6P
  • Embodiment PDlO Another embodiment of the present invention (Embodiment PDlO) is a compound
  • R5, R7, R8, RlO, Rl I 5 Rl2, AryA, RA, RB 5 RC and RD are each as defined in Class C6 set forth above; and all other variables (including R9P) are as defined in Embodiment PD2.
  • Embodiment PDl 1 Another embodiment of the present invention (Embodiment PDl 1) is a compound of Formula I -P, or a pharmaceutically acceptable salt thereof, wherein all the variables are as originally defined in Embodiment PD
  • Embodiment PD 12 is a compound of Formula I -P, wherein V and W are both CH; Z and Y are both C; ring A is benzo; ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms; and all other variables are as defined in Embodiment PDlO or Embodiment PDl 1.
  • Embodiment PD 13 Another embodiment of the present invention (Embodiment PD 13) is a compound of Formula VIII-P:
  • Embodiment PD 14 is a compound of Formula DC-P: wherein L, Q, Tl, T2, R2, R3, R4, R5, R7, R8 ; RA, RB, RC and RD are as defined in Class C9; and R9P is as defined in Embodiment PD2.
  • Embodiment PD 16 is a compound of Formula DC-P, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Cl .3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, Cl -3 alkyl, OH, oxo, O-Ci-3 alkyl, CF 3 , OCF 3 , C(O)NH 2 , C(O)N(H)CH 3 , C(O)N(CH 3 ) 2 , C(O)H, C(O)CH 3 , CO 2 H, CO 2 CH3, SO 2 CH3, or SO 2 NH 2 ; and all other variables are as defined in Embod
  • Embodiment PD 15 15.
  • Embodiment PD 18 is a compound of Formula DCa-P:
  • Another embodiment of the present invention is a compound of Formula DCb-P:
  • Embodiment PD22 is a compound selected from the group consisting of:
  • R.9P is as defined in Embodiment PD2.
  • Embodiment PD23 is a compound as defined in any one of Embodiments PD2 to PD22, wherein R.9P is PO(OH)O- -M + ; P0(0")2 •2M+; P0(0-)2 -M2+; or an acid salt of:
  • M + is a pharmaceutically acceptable monovalent counterion
  • M2+ is a pharmaceutically acceptable divalent counterion
  • Rl5 is H or Ci_4 alkyl
  • Rl 6a and Rl 6b are each independently H or C 1-4 alkyl
  • Rl9 is H or Ci_4 alkyl
  • R20 is H or C 1-4 alkyl
  • R22a and R22b are each independently H or C 1-4 alkyl; and d is an integer equal to 2, 3, or 4.
  • Embodiment PD24 is a compound as defined in any one of Embodiments PD2 to PD22, wherein R9P is an acid salt of:
  • a class of the preceding embodiment includes compounds as defined in Embodiment PD24, wherein the acid salt in the definition of R9P is a hydrochloride salt.
  • Embodiment PD25 is a compound selected from the group consisting of:
  • Pharmaceutically acceptable monovalent counterions (M + ) suitable for use in the prodrugs of the invention described in the foregoing embodiments include NH4+, alkali metal cations (e.g., Na + or K + ), and cations from alkylamines, hydroxyalkylamines (e.g., tris(hydroxymethyl)methylamine), choline, lysine, arginine, histidine, and N-methyl-D- glucamine.
  • Suitable divalent counterions (M2+) include the cations of alkaline earth metals such as Mg2+ and Ca2+. Additional pharmaceutically acceptable salts of basic drugs (pharmaceutically acceptable monovalent and divalent counterions) are described in P. L. Gould, Int. J. Pharm. 1986, vol. 33 pp. 201-217 and S. M. Berge et al., J Pharm. ScI, 1977, vol. 66, pp. 1-19.
  • Acid salts suitable for use in the prodrugs of the invention described in the foregoing embodiments include the salts of organic and inorganic acids.
  • Suitable salts of inorganic acids include the salts of hydrochloric acid, sulfuric acid, alkali metal bisulfates (e.g., KHSO4), and the like.
  • Suitable salts of organic acids include the salts of carboxylic acids and sulfonic acids, such as alkylcarboxylic acids (e.g., acetic acid, propanoic acid, butyric acid, etc.), fluoroalkylcarboxlic acids (e.g., trifluoroacetic acid), arylcarboxylic acids (benzoic acid), alkylsulfonic acids (e.g., ethylsulfonic acid), fluoroalkylsulfonic acids (e.g., trifiuoromethylsulfonic acid), and arylsulfonic acids (e.g., benzenesulfonic acid or toluenesulfonic acid).
  • alkylcarboxylic acids e.g., acetic acid, propanoic acid, butyric acid, etc.
  • fluoroalkylcarboxlic acids e.g., trifluoroacetic acid
  • This reaction is exemplified as follows for a hydrochloride salt:
  • compositions comprising an effective amount of a compound of Formula I as defined above, or a prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula I as defined above, or a prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • an anti-HIV agent selected from the group consisting of HTV antiviral agents, immunomodulators, and anti-infective agents.
  • composition of (c), wherein the anti-HIV agent is an antiviral selected from the group consisting of HIV protease inhibitors, HTV reverse transcriptase inhibitors other than a compound of Formula I, HTV integrase inhibitors,HTV fusion inhibitors, and HIV entry inhibitors.
  • a combination which is (i) a compound of Formula I as defined above, or a prodrug or pharmaceutically acceptable salt thereof, and (ii) an anti-HTV agent selected from the group consisting of HIV antiviral agents, immunomodulators, and anti-infective agents; wherein Compound I and the anti-HF/ agent are each employed in an amount that renders the combination effective for inhibition of HTV reverse transcriptase, for treatment or prophylaxis of infection by HIV, or for treatment, prophylaxis of, or delay in the onset or progression of AIDS.
  • anti-HIV agent is an antiviral selected from the group consisting of HIV protease inhibitors, HIV reverse transcriptase inhibitors other than a compound of Formula I, HIV integrase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.
  • a method for the inhibition of HIV reverse transcriptase in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I or a prodrug or pharmaceutically acceptable salt thereof.
  • a method of the prophylaxis or treatment of infection by HIV e.g., HTV- 1 in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I or a prodrug or pharmaceutically acceptable salt thereof.
  • (k) The method of (j), wherein the compound is administered in combination with an effective amount of at least one other HIV antiviral other than a compound of Formula I, selected from the group consisting of HIV protease inhibitors, HTV integrase inhibitors, non- nucleoside HTV reverse transcriptase inhibitors, nucleoside HFV reverse transcriptase inhibitors, HTV fusion inhibitors, and HIV entry inhibitors.
  • HIV protease inhibitors HTV integrase inhibitors
  • non- nucleoside HTV reverse transcriptase inhibitors nucleoside HFV reverse transcriptase inhibitors
  • HTV fusion inhibitors nucleoside HFV reverse transcriptase inhibitors
  • HIV entry inhibitors selected from the group consisting of HIV protease inhibitors, HTV integrase inhibitors, non- nucleoside HTV reverse transcriptase inhibitors, nucleoside HFV reverse transcriptase inhibitors, HTV fusion inhibitors, and HIV entry inhibitors.
  • a method for the inhibition of HIV reverse transcriptase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • (m) A method for the prophylaxis or treatment of infection by HIV (e.g., HIV- 1) in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • (n) A method for the prophylaxis, treatment, or delay in the onset or progression of AIDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • the present invention also includes a compound of Formula I, or a prodrug or pharmaceutically acceptable salt thereof, (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) therapy (e.g., of the human body), (b) medicine, (c) inhibition of HTV reverse transcriptase, (d) treatment or prophylaxis of infection by HIV, or (e) treatment, prophylaxis of, or delay in the onset or progression of AIDS.
  • the compounds of the present invention can optionally be employed in combination with one or more anti-HFV agents selected from HTV antiviral agents, anti-infective agents, and immunomodulators.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses (i)(a)-(e) through (iii)(a)-(e) set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes or sub-classes described above. Ln all of these embodiments etc., the compound may optionally be used in the form of a prodrug or pharmaceutically acceptable salt.
  • Additional embodiments of the present invention include each of the pharmaceutical compositions, combinations, methods and uses set forth in the preceding paragraphs, wherein the compound of the present invention or its salt employed therein is substantially pure.
  • a pharmaceutical composition comprising a compound of Formula I or its prodrug or salt and a pharmaceutically acceptable carrier and optionally one or more excipients
  • the term "substantially pure” is in reference to a compound of Formula I or its prodrug or salt per se.
  • Still additional embodiments of the present invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses (i)(a)-(e) through (iii)(a)-(e) set forth above, wherein the HIV of interest is HIV-I.
  • the compound of Formula I is employed in an amount effective against HIV-I and the anti-HIV agent is an HIV-I antiviral selected from the group consisting of HIV-I protease inhibitors, HTV-I reverse transcriptase inhibitors other than a compound of Formula I, HIV-I integrase inhibitors, HIV-I fusion inhibitors and HIV-I entry inhibitors.
  • HIV-I antiviral selected from the group consisting of HIV-I protease inhibitors, HTV-I reverse transcriptase inhibitors other than a compound of Formula I, HIV-I integrase inhibitors, HIV-I fusion inhibitors and HIV-I entry inhibitors.
  • alkyl refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
  • C 1-6 alkyl refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso- propyl, ethyl and methyl.
  • C 1-4 alkyl refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • alkenyl refers to a monovalent straight or branched chain aliphatic hydrocarbon radical containing one carbon-carbon double bond and having a number of carbon atoms in the specified range.
  • C2-C6 alkenyl refers to all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1 -propenyl, 2-propenyl, and ethenyl (or vinyl).
  • alkynyl refers to a monovalent straight or branched chain aliphatic hydrocarbon radical containing one carbon-carbon triple bond and having a number of carbon atoms in the specified range.
  • C2-C6 alkynyl refers to all of the hexynyl and pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-butynyl, 1-propynyl, 2-propynyl, and ethynyl.
  • alkylene refers to any divalent linear or branched chain aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
  • -Ci -6 alkylene- refers to any of the Ci to Ce linear or branched alkylenes
  • -Ci .4 alkylene- refers to any of the Ci to C4 linear or branched alkylenes.
  • a class of alkylenes of interest with respect to the invention is -(CH2)l-6- > and sub-classes of particular interest include -(CH2)l-4-, -(CH2)2-4-, -(CH2)l-3-, -(CH2)2-3-, -(CH2)l-2-, and -CH2-.
  • Another sub-class of interest is an alkylene selected from the group consisting of -CH2-, -CH(CH3)-, and -C(CH3)2-.
  • cycloalkyl refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range.
  • C3-8 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • halogen refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
  • haloalkyl refers to an alkyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen (i.e., F, Cl, Br and/or I).
  • a halogen i.e., F, Cl, Br and/or I.
  • Ci -6 haloalkyl or “C1-C6 haloalkyl” refers to a Cl to Ce linear or branched alkyl group as defined above with one or more halogen substituents.
  • fluoroalkyl has an analogous meaning except that the halogen substituents are restricted to fluoro.
  • Suitable fluoroalkyls include the series (CH2) ⁇ -4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3- trifluoro-n-propyl, etc.).
  • a fluoroalkyl of particular interest is CF3.
  • C(O) refers to carbonyl.
  • S(O)2 and “SO2” each refer to sulfonyl.
  • S(O) refers to sulfinyl.
  • aryl refers to (i) phenyl, (ii) 9- or 10-membered bicyclic, fused carbocylic ring systems in which at least one ring is aromatic, and (iii) 11- to 14-membered tricyclic, fused carbocyclic ring systems in which at least one ring is aromatic.
  • Suitable aryls include, for example, phenyl, naphthyl, tetrahydronaphthyl (tetralinyl), indenyl, anthracenyl, and fluorenyl.
  • a class of aryls of interest with respect to the invention is phenyl and napthyl.
  • An aryl of particular interest is phenyl.
  • heteroaryl refers to (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, (ii) a 9- or 10-membered bicyclic fused ring system, or (iii) an 11- to 16-membered tricyclic fused ring system, wherein the fused ring system of (ii) or (iii) contains from 1 to 6 heteroatoms independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatom, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2- Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl
  • Suitable 9- and 10-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolyl, benzodioxolyl (e.g., isochromanyl, benzothienyl, benzofuranyl, imidazo[l,2-a]pyridinyl, benzotriazolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalin
  • Suitable tricyclic heteroaryls include, for example, xanthyl and carbazolyl.
  • Examples of 4- to 7-membered, saturated heterocyclic rings within the scope of this invention include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl.
  • Examples of 4- to 7-membered, mono-unsaturated heterocyclic rings within the scope of this invention include mono-unsaturated heterocyclic rings corresponding to the saturated heterocyclic rings listed in the preceding sentence in which a single bond is replaced with a double bond (e.g., a carbon-carbon single bond is replaced with a carbon-carbon double bond).
  • any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results.
  • a heteroaromatic ring described as containing from “1 to 4 heteroatoms” means the ring can contain 1 , 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range.
  • a heterocyclic ring described as containing from “1 to 4 heteroatoms” is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms.
  • an aryl or heteroaryl described as optionally substituted with "from 1 to 6 substituents" is intended to include as aspects thereof, an aryl or heteroaryl substituted with 1 to 6 substituents, 2 to 6 substituents, 3 to 6 substituents, 4 to 6 substituents, 5 to 6 substituents, 6 substituents, 1 to 5 substituents, 2 to 5 substituents, 3 to 5 substiuents, 4 to 5 substituents, 5 substituents, 1 to 4 substituents, 2 to 4 substituents, 3 to 4 substituents, 4 substituents, 1 to 3 substituents, 2 to 3 substituents, 3 substituents, 1 to 2 substituents, 2 substituents, and 1 substituent.
  • any variable e.g., RA or R.B
  • its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • substitution by a named substituent is permitted on any atom in a ring (e.g., cycloalkyl, aryl, or heteroaryl) provided such ring substitution is chemically allowed and results in a stable compound.
  • keto-enol tautomerism As a result of the selection of substituents and substituent patterns, certain compounds of the present invention can exhibit tautomerism such as keto-enol tautomerism. All tautomeric forms of these compounds, whether present individually or in mixtures, are within the scope of the present invention. For example, in compounds of the present invention where a hydroxy (-OH) substituent is permitted on a heteroaromatic ring and keto-enol tautomerism is possible, it is understood that the substituent might in fact be present, in whole or in part, in the keto form.
  • a “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
  • the compounds of the present invention are limited to stable compounds embraced by Formula I.
  • certain compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether individually or in mixtures, are within the scope of the present invention.
  • the methods of the present invention involve the use of compounds of the present invention in the inhibition of HIV reverse transcriptase (e.g., wild type HIV-I and/or mutant strains thereof), the prophylaxis or treatment of infection by human immunodeficiency virus (HIV) and the prophylaxis, treatment or delay in the onset or progression of consequent pathological conditions such as AIDS.
  • HIV reverse transcriptase e.g., wild type HIV-I and/or mutant strains thereof
  • HIV human immunodeficiency virus
  • prophylaxis treatment or delay in the onset or progression of consequent pathological conditions such as AIDS.
  • Prophylaxis of AIDS, treating AIDS, delaying the onset or progression of AIDS, or treating or prophylaxis of infection by HIV is defined as including, but not limited to, treatment of a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV.
  • the present invention can be employed to treat infection by HFV after suspected past exposure to HIV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the present invention can also be employed to prevent transmission of HIV from a pregnant female infected with HIV to her unborn child or from an HIV-infected female who is nursing (i.e., breast feeding) a child to the child via administration of an effective amount of Compound I or a pharmaceutically acceptable salt thereof.
  • the compounds can be administered in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
  • administration and variants thereof (e.g., “administering” a compound) in reference to a compound of Formula I mean providing the compound or a prodrug of the compound to the individual in need of treatment or prophylaxis.
  • active agents e.g., antiviral agents useful for treating or prophylaxis of HIV infection or AIDS
  • administration and its variants are each understood to include provision of the compound or prodrug and other agents at the same time or at different times.
  • composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • the term "effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • the effective amount is a "therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated.
  • the effective amount is a "prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition being prevented.
  • the term also includes herein the amount of active compound sufficient to inhibit HIV reverse transcriptase (wild type and/or mutant strains thereof) and thereby elicit the response being sought (i.e., an "inhibition effective amount").
  • the active compound i.e., active ingredient
  • references to the amount of active ingredient are to the free form (i.e., the non-salt form) of the compound.
  • the compounds of Formula I can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the compounds of the invention can, for example, be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • Liquid preparations suitable for oral administration e.g., suspensions, syrups, elixirs and the like
  • Solid preparations suitable for oral administration can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like.
  • Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as a solubility aid.
  • injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose.
  • the compounds of Formula I can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
  • mammal e.g., human
  • One preferred dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
  • Another preferred dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
  • the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
  • a compound of Formula I such as the compound of Example 1 can be administered to adult humans orally in the form of a tablet or capsule containing the compound in an amount in a range of from about 40 mg to about 900 mg, wherein the tablet or capsule is administered once per day or twice per day.
  • a compound of Formula I such as the compound of Example 1 can be administered to adult humans orally in the form of a tablet or capsule containing the compound in an amount in a range of from about 40 mg to about 320 mg, wherein the tablet or capsule is administered once per day or twice per day.
  • an anti-HIV agent is any agent which is directly or indirectly effective in the inhibition of HIV reverse transcriptase or another enzyme required for HIV replication or infection, the treatment or prophylaxis of HTV infection, and/or the treatment, prophylaxis or delay in the onset or progression of AIDS. It is understood that an anti- HIV agent is effective in treating, preventing, or delaying the onset or progression of HIV infection or AIDS and/or diseases or conditions arising therefrom or associated therewith.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more anti- HIV agents selected from HIV antiviral agents, imunomodulators, antiinfectives, or vaccines useful for treating HFV infection or AIDS, such as those disclosed in Table 1 of WO 01/38332 or in the Table in WO 02/30930.
  • Suitable HFV antivirals for use in combination with the compounds of the present invention include, for example, those listed in Table A as follows:
  • Some of the drugs listed in the table are used in a salt form; e.g., abacavir sulfate, indinavir sulfate, atazanavir sulfate, nelfinavir mesylate.
  • HIV antiviral agents and other agents will typically be employed in these combinations in their conventional dosage ranges and regimens as reported in the art, including, for example, the dosages described in the Physicians' Desk Reference, Thomson PDR, Thomson PDR, 57 th edition (2003), the 58 th edition (2004), the 59 th edition (2005), and subsequent editions thereof.
  • the dosage ranges for a compound of the invention in these combinations are the same as those set forth above.
  • ACN acetonitrile
  • AIDS acquired immunodeficiency syndrome
  • BOC or Boc t- butyloxycarbonyl
  • (BOC)2 ⁇ (or BOC2O) di-t-butyl carbonate
  • Bn-p-OMe p-methoxybenzyl
  • BrdUTP bromodeoxyuridine triphosphate
  • n-Bu n-butyl
  • t-Bu t-butyl
  • CHAPS 3-[(3- cholamidopropyl)-dimethylammonio]-l-propane-sulfonate
  • DCE 1 ,2-dichloroethane
  • DCM dichloromethane
  • DMAP 4-dimethylaminopyridine
  • DMF dimethylformamide
  • DMPU 1,3- dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (or N,N'-dimethylpropyleneurea)
  • DMSO dimethylsulfoxide
  • dNTP deoxynucleoside triphosphate
  • DPPA diphenylphosphoryl azide
  • EDC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
  • EGTA ethylene glycol bis(2- aminoethy
  • NMR nuclear magnetic resonance
  • Ph phenyl
  • PMB para-methoxybenzyl
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • Tos tosyl.
  • the compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily obtainable starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above.
  • Scheme A depicts a general method suitable for the preparation of compounds of the invention with a nitrogen atom in ring B adjacent to a carbon shared with ring A, wherein the fused bicyclic A-I is coupled with l-Boc-lH-pyrazolo[3,4-b]pyridin-3-yl methylene bromide A-2 in the presence of a base (e.g., an alkali metal carbonate such as CsCO3) and then the Boc protective group is removed by treating the coupled product with a suitable acid (e.g., TFA) to afford A-3.
  • a suitable acid e.g., TFA
  • An alkyl group can be introduced at the 1 -position of the pyrazolopyridinyl group by reaction of A-3 with an alkyl halide.
  • starting substrate A-I include the following:
  • Scheme C depicts the preparation of benzotriazolyl compounds of the present invention, wherein the nitro group on the 2-amino-nitrobenzene derivative C-I can be reduced to the corresponding dianiline C-2 through catalytic hydrogenation or by the action of tin II chloride.
  • the dianiline can undergo cyclization to the corresponding triazole C-3 upon diazotization.
  • Alkylation of the triazole can be accomplished through reaction with a suitable electrophile such as R.6 (which may require protection) in the presence of a base to afford either C-4 or C-6.
  • Scheme D depicts the preparation of pyrazolopyridine and imidazopyridine compounds of the invention, wherein a hydrazino or aminomethyl pyridine D-I can be acylated with the requisite carboxylic acid to provide acylate D-2, which can be cyclized dehydratively using phosphorous oxychloride to afford D-3.
  • Scheme E depicts the preparation of benzopyrazolyl and indazolyl compounds of the invention wherein the arylboronic acid E-I can be coupled with a suitable phenol or aniline (i.e., RlXH) in the presence of a copper carboxylate (e.g., copper acetate) to provide the aryl ether or aryl amine E-2, which can be deprotonated and acylated to provide aldehyde or ketone E-3.
  • a suitable phenol or aniline i.e., RlXH
  • a copper carboxylate e.g., copper acetate
  • Scheme F depicts another route for preparing compounds of the invention, wherein the aryl ether or aryl amine E-2 can be deprotonated and quenched with methylchloroformate to provide the ester IM.
  • Nucleophilic displacement of the fluorine in FA with a suitably protected amine can provide £ ⁇ 2, which can be converted to the corresponding diamine Fj ⁇ through a Curtius rearrangement.
  • the diamine can be converted to a variety of heterocycles including, for example, the triazole F-4 shown in Scheme F.
  • Scheme G depicts a representative preparation of a pro-drug of the present invention, wherein the benzotriazolyl compound of the present invention G-I can be treated with a Boc-protected amine in the presence of a phosgene to afford acylated amine G-2, which can then be deprotected by treatment with a suitable acid (e.g., HCl or TFA) to provide desired prodrug G ⁇ .
  • a suitable acid e.g., HCl or TFA
  • room temperature means a temperature of from about 2O 0 C to about 25°C.
  • the reaction was treated dropwise with a solution of 3.16 mL (30.90 mmol) of the Weinreb amide (i.e., N-methoxy-n-methylacetamide) in 30 mL of THF.
  • the resulting solution was stirred 18 hours, allowing the bath to slowly evaporate and the reaction temperature to rise to room temperature.
  • the reaction was treated with 5 mL of IN HCl, and was concentrated to remove most of the THF.
  • the residue was extracted twice with EtOAc, and the combined extracts were washed with IN HCl, saturated aqueous NaHCO3 solution, and brine, and were dried over anhydrous MgS ⁇ 4.
  • Step 3 tert-butyl 3 -methyl- 1 H-pyrazolo [3 ,4-b]pyridine- 1 -carboxylate
  • Step 4 1 -(tert-butyl)-3 -(bromomethyl)- 1 H-pyrazolo [3 ,4-b]pyridine- 1 -carboxylate
  • Step 1 tert-Butyl 6-fluoro-l-(4-methoxybenzyl)-lH-pyrazolo[3,4-b]pyridine-3- carboxylate
  • Step 2 tert-Butyl l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH-pyrazolo[3,4- b]pyridine-3 -carboxylate
  • Step 3 ⁇ l-(4-Methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH-pyrazolo[3,4-b]pyridin-
  • Step 4 3 -(Chloromethyl)-N, 1 -bis(4-methoxybenzyl)- 1 H-pyrazolo [3 ,4-b]pyridin-6-amine
  • Step 5 3-Chloro-5- ⁇ [5-chloro-l-(lH-pyrazolo[3,4- ⁇ ]pyridin-3-ylmethyl)-lH-indazol-4- yl] oxy ⁇ benzonitrile
  • Step 1 3-Bromo-5-chlorophenyl 2-chloro-5-fluorophenyl ether
  • K2CO3 11.410 kg; 82.56 moles; 3.00 eqs.
  • DMSO 40 L
  • l-bromo-3-chloro-5-fluorobenzene 5.82 kg, 27.79 moles; 1.00 eq.
  • the resulting white slurry was degassed for 10 minutes using a subsurface stream of nitrogen, after which 2-chloro-5-fluorophenol (1.2 kg) was added through a dropping funnel.
  • the reaction mixture was then heated to 150°C, and a second portion 2-chloro-5-fluorophenol (4.56 kg) was added in batches of about 0.5-0.6 kg batch over 7 hours.
  • the mixture was then aged at 150°C for 12 hours, and cooled to room temperature.
  • About half of the mixture was transferred to an extractor (100 L) filled with water (30 L), extracted with heptane (45 L), and then washed with water (18 L). The other half of the mixture was worked up in the same manner.
  • Step 2 2-(3-Bromo-5-chlorophenoxy)-3-chloro-6-fluorobenzaldehyde A round bottom flask was charged with diisopropylamine (1.336 kg, 13.20 moles;
  • reaction mixture was kept below -6O 0 C and aged for 1.5 hours, after which DMF (3.683 kg; 50.4 moles; 1.2 eq.) was added over 15 minutes. After aging the mixture a further 50 minutes, the reaction mixture was warmed to -20°C and quenched with water (5 L). The mixture was then warmed to 15°C, transferred to an extractor (100 L) filled with water (20 L), and extracted with EtOAc (28 L). The organic layer was washed with water (22 L), IN HCl (25 L), and brine (18 L), and then concentrated to 15L. Heptane (25 L) was added to the concentrate, and the resulting solution was heated to 6O 0 C and then concentrated to 18 L as it was cooled to 11°C. The dark yellow suspension was filtered and washed with heptane (5 L), and dried overnight to provide the title product as a solid.
  • DMF 3.683 kg; 50.4 moles; 1.2 eq.
  • Step 4 3-Chloro-5-[(5-chloro-lH-indazol-4-yl)oxy]benzonitrile Bromine (154 g; 0.964 mole; 0.10 eq.) was added to a slurry of zinc (particle size
  • reaction mixture was then degassed for 15 minutes using a subsurface stream of nitrogen, heated to 85°C, and then aged for 4.5 hours. The reaction mixture was then cooled to room temperature and stirred overnight. The reaction mixture was then diluted with THF (18 L) and heated to 50 0 C, after which aqueous EDTA 3Na (0.5M, 20L) was added and the mixture aged at 50°C-60°C for 1 hour. The mixture was then filtered through solka floe and washed with THF (20L), and the filtrate transferred to an extractor (100 L) filled with brine (15L) and separated.
  • the aqueous layer was extracted with EtOAc (15 L), and the combined organic layers were washed with a second portion of EDTA 3Na (0.5M, 20L), then water (20 L), and then brine (15 L).
  • the solution was treated with activated carbon (Darko KB), filtered through solka floe, concentrated to a slurry of less than 10 L, switched to toluene (6 L), concentrated to half volume, heated to 40°C, added heptane (6 L), and cooled below 25°C.
  • the resulting slurry was filtered, washed with extra toleuene:heptane (1 :3; 4 L), heptane (4 L), and dried to provide the title product as a solid.
  • Step 5 3-chloro-5- ⁇ [5-chloro-l-(l-t-butyloxycarbonyl-lH-pyrazolo[3,4-6]pyridin-3- ylmethyl)-lH-indazol-4-yl]oxy ⁇ benzonitrile
  • the mixture was cooled to 3.1°C with ice-water, after which DBU (1.46 L; 9.79 moles; 1.60 eqs.) was added over 30 minutes while keeping the internal temperature below about 21°C.
  • the reaction mixture was then cooled to 6 0 C and aged at that temperature until complete conversion of the indazole as determined by HPLC.
  • MTBE (10 L), AcOEt (5 L), H2O (10 L) were then added and the mixture transferred to an extractor (100 L).
  • the flask was rinsed with MTBE (1.2 L), EtOAc (1.2 L) and H2O (1.2 L), the rinse was stirred for 10 minutes, and then allowed to settle. The aqueous layer was cut away, and the organic layer was drummed off.
  • the aqueous layer was transferred to the extractor, after which MTBE (7.4 L) and EtOAc (3.7 L) were added, and the mixture stirred for 10 minutes, and then allowed to settle. The aqueous layer was cut away.
  • the first organic layer was transferred to the extractor, and the drum was rinsed with MTBEiEtOAc (2:1; 1.5 L). Water (11.2 L) was added to the extractor, and the mixture was stirred for 10 minutes, then allowed to settle.
  • the aqueous layer was cut away, the organic layer was drummed off, and the extractor was rinsed with AcOEt (I L x 2).
  • the combined organic layers were concentrated in vacuo with rotavap at a bath temperature of 30°C-35 °C to 4.775 kg (with solvent).
  • the concentrate was then separated via a silica gel column (40 kg) using heptane-EtOH.
  • the desired fractions were concentrated in a round bottom flask (75 L) using a batch concentrator to about 15 L.
  • EtOAc (4 L) was added to the concentrate and the mixture stirred at room temperature overnight.
  • the resulting crystalline slurry was then heated to 45 °C, stirred for 40 minutes at 45 °C and then allowed to cool to room temperature.
  • the crystals were then separated by filtration using a filter pot, and the resulting wet cake was rinsed with EtO Ac-heptane (1 :2; 6 L) and then dried with a nitrogen stream to afford the desired title product as crystals.
  • Step 6 3 -Chloro-5- ⁇ [5-chloro- 1 -( 1 H-pyrazolo [3 ,4- ⁇ ]pyridin-3 -ylmethyl)- 1 H-indazol-4- yl] oxy ⁇ benzonitrile
  • a jacketed reaction vessel (30 L) equipped with a thermocouple was charged with 3 -chloro-5- ⁇ [5-chloro- 1 -( 1 -t-butyloxycarbonyl- 1 ⁇ -pyrazolo [3 ,4-6]pyridin-3 -ylmethyl)- 1 ⁇ - indazol-4-yl]oxy ⁇ benzonitrile (1.338 kg; 2.499 moles; 1.0 eq.) and then with DMF (10.7 L) and IPA (2.68 L). Concentrated HCl (2.68 L) was then charged to the veseel during which time the internal temperature rose from 16°C to 44°C. The mixture was then heated to 60 °C.
  • Step 1 3-Chloro-5-[(3,5-dichloro-lH-indazol-4-yl)oxy]benzonitrile
  • Step 2 3-Chloro-5- ⁇ [3 ,5 -dichloro- 1 -( 1 H-pyrazolo [3 ,4-b]pyridin-3-ylmethyl)- 1 H-indazol-
  • Step 1 3-Chloro-5- ⁇ [5-chloro-l-( ⁇ l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-
  • Step 2 3-( ⁇ l-[(6-Amino-lH-pyrazolo[3,4-b]pyridin-3-yl)methyl]-5-chloro-lH-indazol-4- yl ⁇ oxy)-5 -chlorobenzonitrile
  • Step 3 3 - ⁇ [5 -Chloro-4-(3 -chloro-5 -cyanophenoxy)- 1 H-indazol- 1 -yl] methyl ⁇ - 1 H- pyrazolo [3 ,4- ⁇ ]pyridin-6-aminium chloride
  • Step 1 l-(4-methoxybenzyl)-lH-l,2,3-benzotriazol-4-ol
  • Step 3 3-Chloro-5- ⁇ [5-chloro-l-(4-methoxybenzyl)-l//-l,2,3-benzotriazol-4- yl] oxy ⁇ benzonitrile
  • Step 1 2-(3-bromo-5-chlorophenoxy)-l-chloro-3-nitrobenzene 2,3-dichloronitrobenzene (764 mg, 3.99 mmol), 3-bromo-5-chlorophenol (1.65 g,
  • Step 4 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole
  • Step 5 3 -chloro- 5 - [(5 -chloro- 1 H- 1 ,2,3 -benzotriazol-4-yl)oxy] benzonitrile 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole (5.0 g, 14 mmol), tetrakis triphenylphosphine palladium (0) (4.83 g, 4.83 mmol) and zinc cyanide (1.96 g, 16.7 mmol) were suspended in dry DMF (50 mL) under N 2 and placed in an oil bath at 9O 0 C. After 2.5 hours, the reaction was allowed to cool to room temperature.
  • Step 6 te/t-Butyl 3- ⁇ [5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yljmethyl ⁇ - 1 H-pyrazolo [3 ,4-6]pyridine- 1 -carboxylate
  • Step 7 3-Chloro-5- ⁇ [5-chloro-l-(lH-pyrazolo[3,4-6]pyridin-3-ylmethyl)-lH-l,2,3- benzotriazol-4-yl]oxy ⁇ benzonitrile tert-Butyl 3 - ⁇ [5-chloro-4-(3 -chloro-5 -cyanophenoxy)- IH-1 ,2,3 -benzotriazol- 1 - yl]methyl ⁇ -lH-pyrazolo[3,4-6]pyridine-l-carboxylate (0.001 g, 1.86 ⁇ mol) was dissolved in
  • Step 1 3 -chloro-5 - ⁇ [5 -chloro- 1 -( ⁇ 1 -(4-methoxybenzyl)-6- [(4-methoxybenzyl)amino] - 1 H- pyrazolo [3 ,4-6]pyridin-3 -yl ⁇ methyl)- IH-1 ,2,3-benzotriazol-4-yl]oxy ⁇ benzonitrile
  • Step 2 3-( ⁇ l-[(6-amino-lH-pyrazolo[3,4- ⁇ ]pyridin-3-yl)methyl]-5-chloro-l//-l,2,3- benzotriazol-4-yl ⁇ oxy)-5 -chlorobenzonitrile 3-chloro-5- ⁇ [5-chloro-l-( ⁇ l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH- pyrazolo [3 ,4- ⁇ ]pyridin-3-yl ⁇ methyl)- IH-I ,2,3-benzotriazol-4-yl]oxy ⁇ benzonitrile (135 mg, 0.195 mmol) was dissolved in TFA (10 mL) and placed in an oil bath at 75 0 C.
  • Step 1 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-benzimidazole
  • Step 2 3-chloro-5-[(5-chloro-lH-benzimidazol-4-yl)oxy]benzonitrile
  • DMF dimethyl methyl sulfoxide
  • palladium tetrakistriphenylphosphine 416 mg, 0.360 mmol
  • zinc cyanide 141 mg, 1.201 mmol
  • Step 3 3 -chloro-5 - ⁇ [5-chloro- 1 -( 1 H-pyrazolo[3 ,4-b]pyridin-3 -ylmethyl)- 1 H- benzimidazol-4-yl] oxy ⁇ benzonitrile dihydrochloride
  • Step 1 tert-butyl ⁇ 2-[[(3- ⁇ [5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-
  • Step 2 2-[[(3- ⁇ [5-chloro-4-(3-cMoro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl] methyl ⁇ - 1 H-pyrazolo [3 ,A-b ⁇ pyridin- 1 -yl)carbonyl] (methyl)amino] -JV- methylethanaminium chloride tert-butyl ⁇ 2- [[(3 - ⁇ [5-chloro-4-(3 -chloro-5 -cyanophenoxy)- 1 H- 1 ,2,3 -benzotriazol- 1 -yl] methyl ⁇ - 1 H-pyrazolo [3,4-6] pyridin- 1 -yl)carbonyl] (methyl)amino] ethyl ⁇ methylcarbamate (125 mg, 0.192 mmol) was dissolved in TFA (5mL).
  • Step 1 3-chloro-5- ⁇ [5-chloro-l-( ⁇ l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH- pyrazolo [3 ,4-b]pyridin-3 -yl ⁇ methyl)- 1 H-benzimidazol-4-yl]oxy jbenzonitrile bis(trifluoroacetate)
  • reaction mixture was then purified by reverse phase HPLC (Luna column, lO ⁇ , Cl 8, 250x21.2 cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the desired compound.
  • LRMS (M+l) 689.5.
  • Step 2 3-( ⁇ l-[(6-amino-lH-pyrazolo[3,4-b]pyridin-3-yl)methyl]-5-chloro-lH- benzimidazol-4-yl ⁇ oxy)-5-chlorobenzonitrile bis(trifluoroacetate)
  • Step 2 2-[[(3- ⁇ [5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl]methyl ⁇ - 1 H-pyrazolo[3 ,4-6]pyridin- 1 - yl)carbonyl] (methyl)amino] ethanaminium chloride
  • Step 1 fert-butyl [5-Chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl] acetate
  • Step 3 1 - ⁇ [5-chloro-4-(3-chloro-5-cyanophenoxy)- IH- 1 ,2,3-benzotriazol- 1 - yl]acetyl ⁇ piperidine-3-carboxamide [5 -chloro-4-(3 -chloro-5 -cyanophenoxy)- IH-1 ,2 ,3 -benzotriazol- 1 -yl] acetic acid (13 mg, 0.036 mmol) (see step 2 in Example 16), piperidine-3-carboxamide (4.6 mg, 0.036 mmol), 3- ⁇ [(ethylimino)methylene]amino ⁇ -iV,jV-dimethylpropan-l-aminium chloride (6.9 mg, 0.036 mmol), 3H-[l,2,3]triazolo[4,5-6]pyridin-3-ol (4.9 mg, 0.036 mmol), and triethylamine (0.005 mL,
  • reaction mixture was diluted with aqueous MeOH (1 mL) and purified by reverse phase chromatography eluting with 30-95% MeCN/ ⁇ 2 ⁇ + 0.1% TFA. Product fractions were lyophilized to yield the title product.
  • Step 1 l-bromo-2,5-dichloro-3-methoxybenzene Methanol (5 mL) was added to potassium tert-butoxide (3.94 g, 123 mmol) suspended in toluene/DMPU (3:1, 240 mL), and the mixture was placed in an oil bath at 8O 0 C under N2 with a reflux condenser for 25 minutes to obtain a solution.
  • Step 4 3-(3-bromo-2,5-dichlorophenoxy)-4-chloro-2-nitroaniline 1,1,1 -trimethylhydrazinium iodide (14.7 g, 72.7 mmol) was added to potassium tert-butoxide (8.20 g, 72.7 mmol) and copper (I) chloride (0.180 g, 1.82 mmol) in DMF (50 mL) at O 0 C.
  • Step 6 4-(3-bromo-2,5-dichlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole
  • Step 8 tert-buty ⁇ 3- ⁇ [5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-lH-l,2,3-benzotriazol-
  • Step 9 2,5-dichloro-3- ⁇ [5-chloro-l-(lH-pyrazolo[3,4- ⁇ ]pyridin-3-ylmethyl)-lH-l,2,3- benzotriazol-4-yl]oxy ⁇ benzonitrile tert-Butyl 3 - ⁇ [5-chloro-4-(2,5 -dichloro-3 -cyanophenoxy)- IH-1 ,2,3 -benzotriazol- l-yl]methyl ⁇ -lH-pyrazolo[3,4-&]pyridine-l-carboxylate (569 mg, 0.997 mmol) was dissolved in TFA (5 mL).
  • Step 1 tert-butyl 3- ⁇ [5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-2//-l ,2,3-benzotriazol-
  • Step 2 2,5-dichloro-3- ⁇ [5-chloro-2-(lH-pyrazolo[3,4- ⁇ ]pyridin-3-ylmethyl)-2//-l,2,3- benzotriazol-4-yl]oxy ⁇ benzonitrile tert-butyl 3- ⁇ [5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-2H-l,2,3-benzotriazol- 2-yl]methyl ⁇ -lH-pyrazolo[3,4-6]pyridine-l-carboxylate (100 mg, 0.175 mmol) was dissolved in TFA (5 mL) at room temperature.
  • Step 1 2,5-dichloro-3- ⁇ [5-chloro-l-( ⁇ l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-
  • Step 2 3-( ⁇ l-[(6-amino-lH-pyrazolo[3,4- ⁇ ]pyridin-3-yl)methyl]-5-chloro-lH-l,2,3- benzotriazol-4-yl ⁇ oxy)-2,5-dichlorobenzonitrile
  • Step 1 3-fluoro-4-methylpyridine-2-carbonitrile
  • Step 3 1 -[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-yl]methanamine
  • Step 4 ⁇ [3 -(3 -bromo-5-chlorophenoxy)-4-methylpyridin-2-yl]methyl ⁇ -2-( 1 H- pyrazolo [3 ,4-b]pyridin-3-yl)acetamide
  • Step 5 3- ⁇ [8-(3-bromo-5-chlorophenoxy)-7-methylimidazo[l,5-a]pyridin-3-yl]methyl ⁇ -
  • Step 6 3-chloro-5- ⁇ [7-methyl-3-(lH-pyrazolo[3,4-b]pyridin-3-ylmethyl)imidazo[l ,5- a]pyridin-8-yl]oxy ⁇ benzonitrile trifluoroacetate
  • 3- ⁇ [8-(3-bromo-5-chlorophenoxy)-7-methylimidazo[l ,5- a]pyridin-3-yl]methyl ⁇ -lH-pyrazolo[3,4-b]pyridine 44 mg, 0.094 mmol
  • zinc cyanide (12.12 mg, 0.103 mmol)
  • palladium tetratriphenylphosphine (21.7mg, 0.019 mmol
  • Step 1 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carboxylic acid
  • Step 2 3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-amine
  • TEA 1.627mL, 11.68 mmol
  • pyridine 944ul, 11.68 mmol
  • t-butanol 2.79mL, 29.2 mmol
  • diphenylphosphoryl azide 1.89mL, 8.76 mmol
  • Step 6 N'-[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-yl]-2-(lH-pyrazolo[3,4- b]pyridin-3-yl)acetohydrazide
  • Step 7 8-(3-bromo-5-chlorophenoxy)-7-methyl-3-(lH-pyrazolo[3,4-b]pyridin-3- ylmethyl)[l,2,4]triazolo[4,3-a]pyridine
  • Step 8 3-chloro-5- ⁇ [7-methyl-3-(lH-pyrazolo[3,4-b]pyridin-3- ylmethyl)[l ,2,4]triazolo[4,3-a]pyridin-8-yl]oxy ⁇ benzonitrile trifluoroacetate
  • Step 3 t-butyl 5-(acetyloxy)-3,4-dihydroquinoline-l(2H)-carboxylate
  • Step 4 t-butyl 5-hydroxy-3,4-dihydroquinoline-l(2H)-carboxylate
  • Step 5 6-chloro-t-butyl 5-hydroxy-3,4-dihydroquinoline-l(2H)-carboxylate t-butyl 5-hydroxy-3,4-dihydroquinoline-l(2H)-carboxylate (530 mg, 2.13 mmol) was dissolved in 20 mL of THF, after which NCS (284 mg, 2.13 mmol) was added and the mixture heated to reflux for 2 hours. The mixture was then cooled to room temperature and concentrated, and the crude reaction mixture was purified on a silica gel column (5% to 35% EtOAc/hexanes) to afford the desired product.
  • LRMS (M+l) 228.2 (M-56, loss of t-butyl)
  • Step 6 3-chloro-5-[(6-chloro-l ,2,3,4-tetrahydroquinolin-5-yl)oxy]benzonitrile
  • Step 7 3 -chloro-5 - ⁇ [6-chloro- 1 -( 1 H-pyrazolo [3 ,4-b]pyridine-3 -ylmethyl)- 1,2,3,4- tetrahydroquinolin-5-yl]oxy ⁇ benzonitrile
  • a capsule formulation suitable for oral administration can be prepared by filling standard two-piece gelatin capsules each with 100 mg of the title compound of Example 1, 150 mg of lactose, 50 mg of cellulose, and 3 mg of stearic acid. Encapsulated oral compositions containing any one of the title compounds of Examples 2 to 29 can be similarly prepared.
  • V blender Powerson Kelley
  • the blend was then lubricated for 5 minutes with intragranular magnesium stearate in the same blender, after which the blend was roller compacted into ribbons using a roller compactor (TFC Labo) fitted with a knurled roll at 4.0 MPa of pressure.
  • the ribbons were then milled using a rotary fine granulator (TFC Labo) fitted with a 1.0 mm screen.
  • the granules were then lubricated with extragranular magnesium stearate in the V-blender for 5 minutes.
  • the lubricated granules were then compressed on a tablet press (Manesty Single Station F-press) using capsule shaped tooling to provide tablets with a hardness range of 14.5-29.3 kP.
  • Tablets containing 25 mg of Compound 1 were prepared in the same manner as the 125 mg tablets, wherein the lubricated granules were compressed on a tablet press employing standard round concave tooling to provide tablets with a hardness of 6.1-22.7 kP. Tablets containing 5 mg of Compound 1 were also prepared in the same manner except that 20 wt.% HPCMAS-LF, 35 wt.% microcrystalline cellulose, and 35.75 wt.% lactose monohydrate were employed in the preparation of the lubricated granules (the identity and concentration of the remaining components were unchanged). The lubricated granules were compressed on a tablet press employing standard round concave tooling to provide tablets with a hardness of 3.5-5.1 kP.
  • HTV-I RT enzyme (0.1 nM) was combined with inhibitor or DMSO (10%) in assay buffer (50 mM Tris-HCl, pH 7.8, 1 mM dithiothreitol, 6 mM MgCl2, 80 mM KCl, 0.025% CHAPS, 0.1 mM EGTA), and the mixture preincubated for 30 minutes at room temperature in microtiter plates (Costar #3359).
  • reaction mixtures were initiated with a combination of primer-template substrate (10 nM final concentration) and dNTPs (0.6 ⁇ M dNTPs, 1.25 ⁇ M BrdUTP ).
  • the heterodimeric nucleic acid substrate was generated by annealing the DNA primer pD500 (described in Shaw-Reid et al., J Biol. Chem. , 278: 2777-2780; obtained from Integrated DNA Technologies) to t500, a 500 nucleotide RNA template created by in vitro transcription (see Shaw-Reid et al., J Biol. Chem., 278: 2777-2780).
  • Analogous assays were conducted substituting mutant HIV strains to determine the in vitro inhibition of compounds of the present invention against mutant HIV reverse transcriptase.
  • the reverse transcriptase has the Yl 81C mutation and in the other strain the reverse transcriptase has the K103N mutation.
  • the mutations were generated with the QUIKCHANGE site-directed mutagenesis kit (Stratagene).
  • Representative compounds of the present invention exhibit inhibition of the reverse transcriptase enzyme in these assays.
  • the title compounds set forth above in Examples 1-4 were tested in the assays and were found to have IC50 values of less than 10 micromolar in the Yl 81C assay and of less than 10 micromolar in the K103N assay.
  • the title compounds set forth above in Examples 1-7, 9-13 and 15-29 were tested in the assays and were found to have IC50 values as set forth in
  • IC50 values reported for Examples 2, 5-7, 10, 15-18, 20 and 22-29 are the results for a single run, and the values for the other examples are based on the results of at least 2 runs.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compounds of Formula I are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R1, R2, R4, R5, R6, ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Description

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
This application claims the benefit of U.S. Provisional Application No. 60/874,629, filed December 13, 2006, the disclosure of which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present invention is directed to certain substituted indazoles, benzotriazoles, and related bicyclic compounds and their pharmaceutically acceptable salts and their use for the inhibition of HIV reverse transcriptase, the prophylaxis of HIV infection and HIV replication, the treatment of HIV infection and HIV replication, the prophylaxis of AIDS, the treatment of AIDS, and the delay in the onset and/or progression of AIDS.
BACKGROUND OF THE INVENTION
The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type-1 (HIV-I) and type-2 (HIV-2) viruses, have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. Replication of HIV by a host cell requires integration of the viral genome into the host cell's DNA. Since HIV is a retrovirus, the HTV replication cycle requires transcription of the viral RNA genome into DNA via an enzyme know as reverse transcriptase (RT). Reverse transcriptase has three known enzymatic functions: The enzyme acts as an RNA-dependent DNA polymerase, as a ribonuclease, and as a DNA-dependent DNA polymerase. In its role as an RNA-dependent DNA polymerase, RT transcribes a single-stranded DNA copy of the viral RNA. As a ribonuclease, RT destroys the original viral RNA and frees the DNA just produced from the original RNA. And as a DNA-dependent DNA polymerase, RT makes a second, complementary DNA strand using the first DNA strand as a template. The two strands form double-stranded DNA, which is integrated into the host cell's genome by the integrase enzyme.
It is known that compounds that inhibit enzymatic functions of HIV RT will inhibit HTV replication in infected cells. These compounds are useful in the treatment of HIV infection in humans. Among the compounds approved for use in treating HIV infection and
AIDS are the RT inhibitors 3'-azido- 3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'- dideoxycytidine (ddC), d4T, 3TC, nevirapine, delavirdine, efavirenz and abacavir. While each of the foregoing drugs is effective in treating HIV infection and AIDS, there remains a need to develop additional HTV antiviral drugs including additional RT inhibitors. A particular problem is the development of mutant HIV strains that are resistant to the known inhibitors. The use of RT inhibitors to treat AIDS often leads to viruses that are less sensitive to the inhibitors. This resistance is typically the result of mutations that occur in the reverse transcriptase segment of the pol gene. The continued use of antiviral compounds to prevent HIV infection will inevitably result in the emergence of new resistant strains of HIV. Accordingly, there is a particular need for new RT inhibitors that are effective against mutant HIV strains.
SUMMARY OF THE INVENTION
The present invention is directed to certain substituted indazoles, benzotriazoles, and related bicyclic compounds and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HFV, the treatment of infection by HFV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. More particularly, the present invention includes compounds of Formula I and pharmaceutically acceptable salts thereof:
Figure imgf000003_0001
wherein:
V is C(RlO), C(O), N(Rl 1), N or N oxide; W is C(R3), C(O), N(Rl 2), N or N oxide; Y is C or N; and Z is C or N, with the proviso that no more than two of V, W, Y and Z contain N;
X is O, S, S(O), S(O)2, N(RA), C(RA)(RB), or C(O);
Rl is AryA or HetA;
R2, R3 and RlO are each independently selected from the group consisting of:
(1) H, (2) halogen,
(3) CN,
(4) NO2, (5) C(O)RA,
(6) C(O)ORA,
(7) C(O)N(RA)RB,
(8) SRA, (9) S(O)RA,
(10) S(O)2RA,
(11) S(O)2N(RA)RB5
(12) N(RA)RB,
(13) N(RA)S(O)2RB, (14) N(RA)C(O)RB,
(15) N(RA)C(O)ORB,
(16) N(RA)S(O)2N(RA)RB,
(17) OC(O)N(RA)RB,
(18) N(RA)C(O)N(RA)RB, (19) Ci-6 alkyl,
(20) Ci-6 haloalkyl,
(21) C2-6 alkenyl,
(22) C2-6 alkynyl,
(23) OH, (24) O-Ci-6 alkyl,
(25) O-Ci-6 alkyl in which the alkyl is substituted with ORA or N(RA)RB5
(26) O-Ci-6 haloalkyl,
(27) C 1-6 alkyl substituted with from 1 to 3 substituents each of which is independently halogen (provided that the alkyl is further substituted with at least one non-halogen group), OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, CN, NO2,
N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA5 S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, Or N(RA)C(O)N(R A)RB,
(28) CycE, (29) O-CycE,
(30) C(O)O-CycE,
(31 ) C(O)N(RA)-CycE, and
(32) N(RA)-CycE;
Rl 1 and Rl2 are each independently selected from the group consisting of H, halogen, Ci-6 alkyl and CycE; ring A is an unsaturated 6-membered ring wherein " '^--' " denotes the ring contains at least two double bonds;
ring B is fused to ring A and forms together with shared atoms Y and Z of ring A a 4- to 7- membered saturated or unsaturated ring optionally containing from 1 to 3 heteroatoms each of which is independently N, O or S, wherein the total count of heteroatoms in ring B includes either or both Y and Z when either or both are N, and wherein each S is optionally S(O) or S(O)2 and each N is optionally an N-oxide, and wherein from zero to 2 ring carbons are optionally substituted with oxo;
R4 and R.5 are each independently selected from the group consisting of:
(1) H,
(2) Ci-6 alkyl,
(3) C i -6 alkyl substituted with OH, O-C I -6 alkyl, O-C i -6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB, C(O)RA, Cθ2RA, SRA, S(O)RA, S(O)2RA,
S(O)2N(RA)RB5 N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(0)2RB, N(RA)S(0)2N(RA)RB; OC(O)N(RA)RB, N(RA)C(O)N(RA)RB5 or N(RA)C(O)C(O)N(RA)RB5
(4) O-Ci-6 alkyl, (5) C 1-6 haloalkyl,
(6) O-C 1-6 haloalkyl,
(7) OH,
(8) halogen,
(9) CN, (10) NO2,
(11) C(O)N(RA)RB,
(12) C(O)RA5
(13) C(O)-C 1-6 haloalkyl,
(14) C(O)ORA, (15) SRA,
(16) S(O)RA,
(17) S(O)2RA
(18) S(O)2N(RA)RB,
Figure imgf000005_0001
(21) N(RA)C(O)RB5
(22) N(RA)C(O)ORB, (23) N(RA)S(O)2N(RA)RB5
(24) OC(O)N(RA)RB, and
(25) N(RA)C(O)N(RA)RB;
j is an integer equal to zero or 1 ;
k is an integer equal to zero or 1 ;
R6 is attached to the ring atom in B which is adjacent to shared atom Z or which is adjacent to the ring atom that is adjacent to Z, and is:
(1)
Figure imgf000006_0001
, wherein each ring N is optionally an N-oxide,
(2) *-CH2C(O)N(RA)-AryB,
(3) *-CH2C(O)N(RA)-HetB,
(4) *-CH2C(O)N(RA)-Ci-3 alkylene-AryB,
(5) *-CH2C(0)N(RA)-C 1 -3 alkylene-HetB,
(6) *-CH2C(O)O-Ci-3 alkylene-AryB,
(7) *-CH2C(O)O-Ci-3 alkylene-HetB,
(8) *-CH2-HetB,
(9) *-CH2C(O)-HetB,
(10) *-CH2C(O)-HetC, or
(H) *-CH2CH2OH; wherein the asterisk denotes the point of attachment to the rest of the compound;
R7 and R^ are each independently selected from the group consisting of:
(1) H,
(2) OH,
(3) halogen,
(4) CN, (5) NO2,
(6) Ci-6 alkyl,
(7) C 1 -6 alkyl substituted with OH, O-C I -6 alkyl, O-C I -6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA, Cθ2RA, SRA, S(O)RA5 S(O)2RA, S(O)2N(RA)RB5 N(RA)C(O)RB5 N(RA)C02RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB5 OC(O)N(RA)RB5 N(RA)C(O)N(RA)RB5 Or N(RA)C(O)C(O)N(RA)RB5
(8) O-Ci-6 alkyl,
(9) O-C i -6 alkyl in which the alkyl is substituted with O-C I -6 alkyl, N(RA)RB, C(O)N(RA)RB, C(O)RA, Or Cθ2RA,
(10) Ci-6 haloalkyl,
(11) O-Ci-6 haloalkyl,
(12) N(RC)RD,
(13) N(RA)-C 1.6 alkylene-N(RC)RD, (14) C(O)N(RA)RB,
(15) C(O)RA
(16) C(O)-C 1 _6 haloalkyl,
(17) C(O)ORA,
(18) SRA, (19) S(O)RA,
(20) S(O)2RA,
(21) S(O)2N(RA)RB5
(22) CycE,
(23) O-CycE, (24) C(O)O-CycE,
(25) C(O)N(RA)-CycE,
(26) N(RA)-CycE,
(27) Cl -6 alkyl substituted with CycE,
(28) O-C 1 -6 alkyl substituted with N(RA)-CycE, (29) O-C 1 -6 alkyl substituted with C(O)-CycE,
(30) HetE,
(31) N(RA)S(O)2RB5
(32) N(RA)C(O)RB5 and
(33) N(RA)C(O)N(RA)RB;
R9 is H or C 1-6 alkyl;
each RA is independently H, Cl -6 alkyl, or Cl -6 haloalkyl;
each RB is independently H, Ci -6 alkyl, or Cl -6 haloalkyl;
each RC is independently H, Cl -6 alkyl, or Ci -6 haloalkyl; each RD is independently H, C\.β alkyl, or C 1-6 haloalkyl;
alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated or mono-unsaturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2; wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Cl -6 alkyl, (2) Ci -6 fluoroalkyl, (3) (CH2)l-2G wherein G is OH, O-Ci-6 alkyl, O-Ci-6 fluoroalkyl, N(RA)RB5 C(O)N(RA)RB5 C(O)RA, Cθ2RA, or Sθ2RA, (4) 0-C I -6 alkyl, (5) 0-C I -6 fluoroalkyl, (6) OH, (7) oxo, (8) halogen, (9) C(O)N(RA)RB, (1O) C(O)RA5 (i i) C(0)-Ci_6 fluoroalkyl, (12) C(O)ORA5 Or (13) S(0)2RA;
AryA is aryl optionally substituted with a total of from 1 to 6 substituents, wherein: (i) from zero to 6 substituents are each independently:
(1) Ci-6 alkyl,
(2) C i _6 alkyl substituted with OH, 0-C I -6 alkyl, 0-C i -6 haloalkyl, CN, N02, N(RA)RB5 C(O)N(RA)RB, C(O)RA, Cθ2RA, SRA5 S(O)RA, S(O)2RA, S(0)2N(RA)RB, N(RA)C(O)RB, N(RA)C02RB, N(RA)S(O)2RB, N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB5
N(RA)C(O)N(RA)RB5 or N(RA)C(0)C(0)N(RA)RB,
(3) O-Ci-6 alkyl,
(4) 0-C 1 -6 alkyl, in which the alkyl is substituted with OH, 0-C i -6 alkyl, 0-C 1-6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB, C(O)RA, C02RA, SRA, S(O)RA, S(O)2RA, S(0)2N(RA)RB, N(RA)C(O)RB,
N(RA)C02RB, N(RA)S(0)2RB, N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB5 N(RA)C(O)N(RA)RB, or N(RA)C(O)C(O)N(RA)RB,
(5) C 1-6 haloalkyl,
(6) 0-C 1-6 haloalkyl, (7) OH,
(8) halogen,
(9) CN,
(10) NO2,
(11) N(RA)RB, (12) C(O)N(RA)RB5
(13) C(O)RA
(14) C(O)-C 1-6 haloalkyl, (15) C(O)ORA,
(16) OC(O)N(RA)RB5
(17) SRA,
(18) S(O)RA,
(19) S(O)2RA,
(20) S(O)2N(RA)RB,
Figure imgf000009_0001
(22) N(RA)S(O)2N(RA)RB,
(23) N(RA)C(O)RB,
(24) N(RA)C(O)N(RA)RB,
(25) N(RA)C(O)-C(O)N(RA)RB,
(26) N(RA)CO2RB,
(27) C2-6 alkenyl substituted with CN, NO2, N(RA)RB, Or C(O)N(RA)RB5 Or
(28) C2-6 alkynyl substituted with CN, NO2, N(RA)RB, Or C(O)N(RA)RB, and
(ϋ) from zero to 2 substituents are each independently:
(1) CycE,
(2) AryE,
(3) O-AryE,
(4) HetE,
(5) HetF,
(6) C 1-6 alkyl substituted with CycE, AryE, O-AryE, HetE, or HetF,
(7) C2-6 alkenyl substituted with AryE,
(8) C2-6 alkynyl substituted with AryE, or
(9) C2-6 alkynyl substituted with HetE;
HetA is heteroaryl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently: (1) Ci-6 alkyl,
(2) C i -6 alkyl substituted with OH, O-C l -6 alkyl, O-C i _6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA5 CO2RA5 SRA S(O)RA, S(O)2RA5 S(O)2N(RA)RB5 N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB5 or N(RA)C(O)C(O)N(RA)RB5
(3) O-Ci-6 alkyl, (4) 0-C l -6 alkyl, in which the alkyl is substituted with OH, O-C I -6 alkyl, O-Ci-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA Cθ2RA, SRA, S(O)RA, S(0)2RA, S(0)2N(RA)RB, N(RA)C(O)RB, N(RA)C02RB, N(RA)S(0)2RB, N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, Or N(RA)C(O)C(O)N(RA)RB,
(5) C 1-6 haloalkyl,
(6) O-C 1-6 haloalkyl,
(7) OH,
(8) oxo, (9) halogen,
(10) CN,
(11) NO2,
(12) N(RA)RB,
(13) C(O)N(RA)RB, (14) C(O)RA,
(15) C(O)-C 1-6 haloalkyl,
(16) C(O)ORA
(17) OC(O)N(RA)RB,
(18) SRA, (19) S(O)RA,
(20) S(O)2RA,
Figure imgf000010_0001
(23) N(RA)S(O)2N(RA)RB, (24) N(RA)C(O)RB,
(25) N(RA)C(O)N(RA)RB,
(26) N(RA)C(O)-C(O)N(RA)RB, Or
Figure imgf000010_0002
(ii) from zero to 2 substituents are each independently: (1) CycE,
(2) AryE,
(3) O-AryE,
(4) HetE,
(5) HetF, or (6) Ci-6 alkyl substituted with CycE, AryE, O-AryE, HetE, or HetF; aryl is (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocylic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
heteroaryl is (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, (ii) a 9- or 10-membered bicyclic fused ring system, or (iii) an 11- to 16-membered tricyclic fused ring system, wherein the fused ring system of (ii) or (iii) contains from 1 to 6 heteroatoms independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatom, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2;
AryB independently has the same definition as AryE;
HetB independently has the same definition as HetE;
HetC independently has the same definition as HetF;
each CycE is independently C3-8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci -6 alkyl, OH, O-Ci-6 alkyl, Cl -6 haloalkyl, or O-Ci-6 haloalkyl;
each AryE is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, CN, NO2, Ci_6 alkyl, C 1 _6 haloalkyl, OH, O-C 1 -6 alkyl, O-C 1 -6 haloalkyl, C(O)N(RA)RB5 C(O)RA, CO2RA, SRA S(O)RA, SO2RA, SO2N(RA)RB5 or SO2N(RA)C(O)RB;
each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, CN, NO2, Cl -6 alkyl, Cl -6 haloalkyl, O-C 1-6 alkyl, O-Ci-6 haloalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02RB, C(O)N(RA)RB, C(O)RA, Cθ2RA, SO2RA, Sθ2N(RA)RB, OΓ phenyl, with the proviso that no more than 1 of the optional substituents is phenyl; and
each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 4 substituents, each of which is independently halogen, CN, C 1-6 alkyl, OH, oxo, O-Ci-6 alkyl, C 1-6 haloalkyl, O-Ci-6 haloalkyl, C(O)N(RA)RB, C(O)RA, Cθ2RA, Sθ2RA, or
Figure imgf000012_0001
Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of Formula I above, and pharmaceutically acceptable salts thereof, are HIV reverse transcriptase inhibitors. The compounds are useful for inhibiting HIV reverse transcriptase and for inhibiting HIV replication in vitro and in vivo. More particularly, the compounds of Formula I inhibit the polymerase function of HIV-I reverse transcriptase. Based upon the testing of representative compounds of the invention in the assays set forth in Example 31 below, it is known that compounds of Formula I inhibit the RNA-dependent DNA polymerase activity of HIV-I reverse transcriptase. Representative compounds of the present invention also exhibit activity against drug resistant forms of HIV (e.g., mutant strains of HIV-I in which reverse transcriptase has a mutation at lysine 103 — > asparagine (Kl 03N) and/or tyrosine 181 → cysteine (Yl 81C) ), and thus can exhibit decreased cross-resistance against currently approved antiviral therapies.
A first embodiment of the present invention (alternatively referred to herein as "Embodiment El") is a compound of Formula I (alternatively and more simply referred to as "Compound I") as originally defined (i.e., as defined in the Summary of the Invention above), or a pharmaceutically acceptable salt thereof; and provided that:
(A) when ring B is
Figure imgf000012_0002
and R4 is other than H, then R6 is not
Figure imgf000012_0003
and
Figure imgf000012_0004
wherein the asterisks on ring B denote the points of attachment to ring A.
A second embodiment of the present invention (Embodiment E2) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
V is C(RlO), N(Rl 1), N or N oxide; W is C(R3), N(Rl 2), N or N oxide; Y is C or N; and Z is C or N, with the proviso that no more than two of V, W, Y and Z contain N;
R6 is attached to the ring atom in B which is adjacent to shared atom Z and is
Figure imgf000013_0001
R9 , wherein each ring N is optionally an N-oxide, and wherein the asterisk denotes the point of attachment to the rest of the compound;
R? and R8 are each independently selected from the group consisting of substituents (1) to (30) as originally defined above (i.e., the following substituents are excluded from the group: (31) N(RA)S(O)2RB, (32) N(RA)C(O)RB, and (33) N(RA)C(O)N(RA)RB).
each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, C 1-6 alkyl, Ci -6 haloalkyl, O-Ci-6 alkyl, OCi -6 haloalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, Or N(RA)CO2RB;
each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 4 substituents, each of which is independently halogen, CN, Ci -6 alkyl, OH, oxo, O-Ci-6 alkyl, C 1-6 haloalkyl, or O-Ci-6 haloalkyl;
and all other variables are as originally defined. A third embodiment of the present invention (Embodiment E3) is a compound of
Formula I as defined in Embodiment E2, or a pharmaceutically acceptable salt thereof; and provided that: , then R.4 is H; and
Figure imgf000014_0001
A fourth embodiment of the present invention (Embodiment E4) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X is O; and all other variables are as originally defined or as defined in any one of Embodiments El, E2, and E3.
A fifth embodiment of the present invention (Embodiment E5) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); W is C(R3); Y is C; Z is C; ring A is aromatic (i.e., benzo); and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. Embodiment E5 corresponds to a compound of Formula II:
Figure imgf000014_0002
wherein the variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4.
A sixth embodiment of the present invention (Embodiment E6) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein V is N; W is C(R3); Y is C; Z is C; ring A is aromatic (i.e., pyrido); and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. Embodiment E6 corresponds to a compound of Formula III:
Figure imgf000014_0003
wherein the variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. A seventh embodiment of the present invention (Embodiment E7) is a compound of Formula I5 or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); W is C(R^); Y is C; Z is N; and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. Embodiment E7 corresponds to a compound of Formula IV:
Figure imgf000015_0001
wherein the variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. It is noted that since Y is C, Y is part of a double bond in ring B.
An eighth embodiment of the present invention (Embodiment E8) is a compound of Formula I5 or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); \y is C(R3); Y is N; Z is C; and all other variables are as originally defined or as defined in any one of Embodiments El5 E2, E3 and E4. Embodiment E8 corresponds to a compound of Formula V:
Figure imgf000015_0002
wherein the variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. It is noted that since Z is C, Z is part of a double bond in ring B.
A ninth embodiment of the present invention (Embodiment E9) is a compound of Formula I5 or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); W is N; Y is C; Z is C; ring A is aromatic (i.e., pyrido); and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. Embodiment E9 corresponds to a compound of Formula VI:
Figure imgf000015_0003
wherein the variables are as originally defined or as defined in any one of Embodiments El5 E2, E3 and E4. A tenth embodiment of the present invention (Embodiment ElO) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein V is C(RlO); w is C(R3); Y is C; Z is C; ring A has two carbon-carbon double bonds; and all other variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. Embodiment ElO corresponds to a compound of Formula VII:
Figure imgf000016_0001
wherein the variables are as originally defined or as defined in any one of Embodiments El, E2, E3 and E4. It is noted that since Y is C and Z is C, Y and Z are parts of double bonds in ring B.
An eleventh embodiment of the present invention (Embodiment El 1) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl is AryA; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twelfth embodiment of the present invention (Embodiment E 12) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2, R3 and RlO are each independently selected from the group consisting of:
(1) H,
(2) halogen,
(3) N(RA)RB,
(4) Ci-6 alkyl, (5) C 1-6 fluoroalkyl,
(6) O-Ci-6 alkyl, and
(7) O-Ci-6 fluoroalkyl; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. A thirteenth embodiment of the present invention (Embodiment El 3) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the group consisting of:
(1) H,
(2) halogen, (3) N(RA)RB5
(4) Ci-4 alkyl,
(5) CF3, (6) O-Ci-4 alkyl, and
(7) OCF3;
RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. A fourteenth embodiment of the present invention (Embodiment E 14) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl; RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. A fifteenth embodiment of the present invention (Embodiment E 15) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and CH3; RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A sixteenth embodiment of the present invention (Embodiment El 6) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R2 is Br or Cl; R3 is H; RlO is H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. In an aspect of Embodiment El 6 R2 is Cl; R3 is H; and RlO is H. A seventeenth embodiment of the present invention (Embodiment E 17) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl 2 are each independently H or Cl -6 alkyl; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
An eighteenth embodiment of the present invention (Embodiment El 8) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl 2 are each independently H or Ci .4 alkyl; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A nineteenth embodiment of the present invention (Embodiment El 9) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl 2 are each independently H or CH3; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. A twentieth embodiment of the present invention (Embodiment E20) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Rl 1 and Rl2 are both H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-first embodiment of the present invention (Embodiment E21) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are each independently selected from the group consisting of: (1) H, (2) Ci_6 alkyl,
(3) O-Ci-6 alkyl,
(4) Ci-6 fluoroalkyl,
(5) O-Ci-6 fluoroalkyl, and (6) halogen; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-second embodiment of the present invention (Embodiment E22) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4 and R.5 are each independently selected from the group consisting of:
(1) H,
(2) Ci-4 alkyl,
(3) O-Ci-4 alkyl,
(4) CF3, (5) OCF3, and
(6) halogen; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-third embodiment of the present invention (Embodiment E23) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.4 and R.5 are each independently selected from the group consisting of H, Ci .4 alkyl, Cl, Br and F; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-fourth embodiment of the present invention (Embodiment E24) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.4 and R.5 are each independently selected from the group consisting of H, CH3, OCH3, CF3, OCF3, Cl, Br and F; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-fifth embodiment of the present invention (Embodiment E25) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are both H; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-sixth embodiment of the present invention (Embodiment E26) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each independently selected from the group consisting of: (1) H,
(2) OH,
(3) halogen, (4) CN,
(5) NO2,
(6) Ci-β alkyl,
(7) O-Ci-6 alkyl,
Figure imgf000019_0001
(10) Ci-6 fluoroalkyl,
(H) O-Ci-6 fluoroalkyl,
(12) N(RC)RD,
(13) N(RA)-(CH2)2-3-N(RC)RD,
(14) C(O)N(RA)RB5
(15) C(O)RA,
(16) C(O)ORA,
(17) SRA,
(18) S(O)RA,
(19) S(O)2RA5 and
(20) S(O)2N(RA)RB; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-seventh embodiment of the present invention (Embodiment E27) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each independently selected from the group consisting of:
(1) H,
(2) OH,
(3) halogen,
(4) CN,
(5) NO2,
(6) Ci-4 alkyl,
(7) O-Ci-4 alkyl,
(8) O(CH2)2.3N(RA)RB5
Figure imgf000019_0002
(10) CF3,
(H) OCF3,
(12) O(CH2)i-2CF3,
(12) N(RC)RD5
(13) N(RA)-(CH2)2.3-N(RC)RD5 and
(14) C(O)N(RA)RB; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-eighth embodiment of the present invention (Embodiment E28) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 is H; R^ is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A twenty-ninth embodiment of the present invention (Embodiment E29) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R7 is H; R.8 is H or NH2; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A thirtieth embodiment of the present invention (Embodiment E30) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
R6 i is
(1)
Figure imgf000020_0001
, (2) , (3) *-CH2C(O)N(RA)-AryB,
(4) *-CH2C(O)N(RA)-HetB, (5) *-CH2C(O)N(RA)-CI_3 alkylene-AryB, (6) *-CH2C(O)N(RA)-Ci-3 alkylene-HetB, (7) *-CH2C(O)O-Ci-3 alkylene-AryB, (8) *-CH2-HetB, (9) *-CH2C(O)-HetB, (10) *-CH2C(O)-HetC, or (11) *-CH2CH2θH;
L is N or N oxide; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A thirty-first embodiment of the present invention (Embodiment E31) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R6 is:
Figure imgf000020_0002
Figure imgf000021_0001
(10) *-CH2CH2θH;
Jl and J2 are each independently H, halogen, CN, NO2, Ci-4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or SO2N(RA)RB;
J3 is H, halogen, CN, Ci-4 alkyl, OH, oxo, O-Ci-4 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, CO2RA SO2RA, or S02N(RA)RB;
L is N or N oxide; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
In an aspect of Embodiment E31, Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-C1.3 alkyl, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and J3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-Ci-3 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2.
A thirty-second embodiment of the present invention (Embodiment E32) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R6 is:
Figure imgf000021_0002
and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A thirty-third embodiment of the present invention (Embodiment E33) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R6 is:
Figure imgf000021_0003
and all other variables are as originally defined or as defined in any one of the foregoing embodiments. To the extent any of the preceding or subsequent embodiments refer back to and are incorporated into Embodiments E2 and E4 respectively, the provisos set forth therein apply. It is understood, however, that the definitions of variables in the provisos set forth in Embodiments E2 and E4 can be customized to reflect the definitions of variables in the embodiments being incorporated therein. For example, the provisos set forth in Embodiments E2 and E4 can be customized to reflect the definition of R.6 in Embodiments E30 to E33. As a particular example, when Embodiment E30 is incorporated into Embodiment E2, the proviso can be adjusted to read as follows — and provided that:
and HZ* is other than H, then R.6 is not
Figure imgf000022_0001
Figure imgf000022_0002
A thirty-fourth embodiment of the present invention (Embodiment E34) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is phenyl or naphthyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently C 1-6 alkyl, O-Ci-6 alkyl, CF3, OCF3, OH, halogen, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA, C(O)CF3, Cθ2RA, SO2RA, CH=CH-(CH2)θ-2CN, C=C- (CH2)1-2N(R )R 5 or C l 6 alkylene-N(RA)RB; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. In an aspect of this embodiment, AryA is as originally defined in Embodiment E34, except that the list of optional substituents excludes C≡ C-(CH2)i-2N(RA)RB .
A thirty-fifth embodiment of the present invention (Embodiment E35) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
Figure imgf000023_0001
; wherein Tl and T2 and T3 are each independently H, Ci_4 alkyl, halogen, CN,
CH=CH-CN, C(O)RA, Or (CH2)l-2N(RA)RB; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A thirty-sixth embodiment of the present invention (Embodiment E36) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
; wherein Tl is H or Cl; and all other variables are as originally defined or as defined in any one of the foregoing embodiments. In an aspect of this embodiment, Tl is H. A thirty-seventh embodiment of the present invention (Embodiment E37) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
Figure imgf000023_0003
; wherein Tl is H or Cl; T2 is CN, CH(O), CH2NH2, or CH2N(H)CH3 ; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A thirty-eighth embodiment of the present invention (Embodiment E38) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
Figure imgf000023_0004
; wherein Tl and T2 are each independently H, Cl .4 alkyl, halogen, CN, CH=CH- CN, or C=C-CH2N(R )R • Qn^ ail other variables are as originally defined or as defined in any one of the foregoing embodiments. In an aspect of this embodiment, AryA is as originally defined in Embodiment 38, except that Tl and T2 are each independently H, Cl .4 alkyl, halogen,
CN, or CH=CH-CN.
A thirty-ninth embodiment of the present invention (Embodiment E39) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryA is:
Figure imgf000023_0005
* ; and all other variables are as originally defined or as defined in any one of the foregoing embodiments.
A fortieth embodiment of the present invention (Embodiment E40) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetA is a heteroaryl selected from the group consisting of thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, isobenzofuranyl, benzisoxazolyl, benzoxazolyl, benzimidazolyl, benzopiperidinyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, quinazolinyl, and imidazopyridinyl, wherein the heteroaryl is optionally substituted with from 1 to 3 substituents each of which is independently C i _4 alkyl, CF3, O-C 1.4 alkyl, OCF3, OH, halogen, CN, NO2, N(RA)RB, C(O)N(RA)RB5
C(O)RA, C(0)CF3, CO2RA, Sθ2RA, or Sθ2N(RA)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments. In an aspect of Embodiment E40, HetA is as originally defined in Embodiment E40, except that each of the optional 1 to 3 substituents is independently Ci-4 alkyl, CF3, O-C1.4 alkyl, OCF3, OH, halogen, CN, NO2, N(RA)RB, C(O)N(RA)RB5 C(O)RA, C(0)CF3, CO2RA, or SO2RA.
A forty-first embodiment of the present invention (Embodiment E41) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RA and RB are each independently H or Cl -6 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments. A forty-second embodiment of the present invention (Embodiment E42) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RA and RB are each independently H or Cl .4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A forty-third embodiment of the present invention (Embodiment E43) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RA and RB are each independently H or CH3; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A forty-fourth embodiment of the present invention (Embodiment E44) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RC and RD are each independently H or Cl -6 alkyl; or alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(0)2; and wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Ci-4 alkyl, (2) CF3, (3) C(O)N(RA)RB5 (4) C(O)RA, (5) C(0)-CF3,
(6) C(O)ORA, or (7) S(O)2RA; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A forty-fifth embodiment of the present invention (Embodiment E45) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein RC and RD are each independently H or C 1.4 alkyl; or alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of ^ , Ss-^ , and ^ — ' ; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A forty-sixth embodiment of the present invention (Embodiment E46) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.C and RD are each independently H or C 1.4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A forty-seventh embodiment of the present invention (Embodiment E47) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.C and RP are each independently H or CH3; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A forty-eighth embodiment of the present invention (Embodiment E48) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R.9 is H or Ci .4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments. A forty-ninth embodiment of the present invention (Embodiment E49) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A fiftieth embodiment of the present invention (Embodiment E50) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each CycE is independently C3-7 cycloalkyl which is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, Ci .4 alkyl, OH, O-Ci-4 alkyl, Cl -4 fluoroalkyl, or O-C1-.4 fluoroalkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A fifty-first embodiment of the present invention (Embodiment E51) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each AryE is independently phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently Cl, Br, F, CN, NO2, Cl .4 alkyl, Cl .4 fluoroalkyl, OH, O-Ci-4 alkyl, O-Ci-4 fluoroalkyl, C(O)N(RA)RB, C(O)RA, Cθ2RA, SRA, S(O)RA, SO2RA, Sθ2N(RA)RB, Or Sθ2N(RA)C(O)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A fifty-second embodiment of the present invention (Embodiment E52) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, C 1.4 alkyl, Cl .4 fluoroalkyl, O-C1.4 alkyl, O-Ci-4 fluoroalkyl, OH, N(RA)RB5 N(RA)C(O)N(RA)RB, or N(RA)C02RB; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A fifty-third embodiment of the present invention (Embodiment E53) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 3 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono- unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 3 substituents, each of which is independently Cl, Br, F, CN, C 1-4 alkyl, OH, oxo, O-Ci-4 alkyl, Ci_4 fluoroalkyl, or O-Ci-4 fluoroalkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A fifty-fourth embodiment of the present invention (Embodiment E54) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein each AryB is independently phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently Cl, Br, F, CN, NO2, C 1.4 alkyl, C 1.4 fluoroalkyl, OH, O-C 1.4 alkyl, O-C 1.4 fluoroalkyl, C(O)N(RA)RB, C(O)RA, Cθ2RA, SRA, S(O)RA, SO2RA, Sθ2N(RA)RB, Or Sθ2N(R A)C(O)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments.
A fifty-fifth embodiment of the present invention (Embodiment E55) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein AryB is phenyl which is optionally substituted with from 1 to 2 substituents each of which is independently Cl, Br, F, CN, NO2, C 1-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB5 C(O)RA, CO2RA, SO2RA, or Sθ2N(RA)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments. A fifty-sixth embodiment of the present invention (Embodiment E56) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3,
N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02RB, C(O)N(RA)RB, C(O)RA, CO2RA, Sθ2RA, Sθ2N(RA)RB, or phenyl, with the proviso that no more than 1 of the optional substituents is phenyl; and all other variables are as originally defined or as defined in any of the preceding embodiments. In an aspect of this embodiment, HetB is as originally defined in Embodiment E56, except that the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, Cl .4 alkyl, Cl .4 fluoroalkyl, O-C 1.4 alkyl, O-C 1.4 fluoroalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02RB, 802N(RA)RB, OΓ phenyl, with the proviso that no more than 1 of the optional substituents is phenyl.
A fifty-seventh embodiment of the present invention (Embodiment E57) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetB is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, pyridyl and pyrimidinyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents, each of which is independently Cl, Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, Sθ2N(R A)RB, Or phenyl, with the proviso that no more than 1 of the optional substituents is phenyl; and all other variables are as originally defined or as defined in any of the preceding embodiments, hi an aspect of this embodiment, HetB is as originally defined in Embodiment E57, except that the heteroaromatic ring is optionally substituted with from 1 to 2 substituents, each of which is independently Cl, Br, F, Ci-4 alkyl, CF3, O-Ci-4 alkyl, OCF3, OH, N(RA)RB, or phenyl, with the proviso that no more than 1 of the optional substituents is phenyl. A fifty-eighth embodiment of the present invention (Embodiment E58) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetC is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 3 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(0)2, and wherein the saturated or mono- unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 3 substituents, each of which is independently Cl, Br, F, CN, Cl .4 alkyl, OH, oxo, O-Ci-4 alkyl, Ci .4 fluoroalkyl, O-C1.4 fluoroalkyl, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or Sθ2N(RA)RB; and all other variables are as originally defined or as defined in any of the preceding embodiments. A fifty-ninth embodiment of the present invention (Embodiment E59) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein HetC is a saturated heterocyclic ring selected from the group consisting of 1-pyrrolidinyl, 1 -piperidinyl, 4-morpholinyl, 4-thiomorpholinyl in which the S is optionally oxidized to S(O) or S(0)2, and
1-piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 2 substituents each of which is Cl, Br, F, CN, C 1.4 alkyl, OH, oxo, O-C1.4 alkyl, CF3, OCF3,
C(0)NH2, C(0)N(H)CH3, C(O)N(CH3)2, C(O)CH3, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined or as defined in any of the preceding embodiments. Additional embodiments of AryB, HetB, and HetC are incorporated into the definition of R6 in Embodiment E31 above. A first class of compounds of the present invention (alternatively referred to herein as Class Cl) includes compounds, and pharmaceutically acceptable salts thereof, selected from compounds of Formula VIII:
Figure imgf000028_0001
wherein all variables therein are as originally defined. A sub-class of Class Cl (i.e., Sub-class SCl-I) includes the compounds of Formula VIII in which X is O and pharmaceutically acceptable salts thereof. Other sub-classes of Class Cl include the compounds of Formula VIII and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
A second class of compounds of the present invention (alternatively referred to herein as Class C2) includes compounds and pharmaceutically acceptable salts thereof, selected from compounds of Formula:
Figure imgf000028_0002
(Ha), (lib), (Hc), (Hd),
Figure imgf000028_0003
Figure imgf000029_0001
(Via), and (Vila) ; wherein all variables therein are as originally defined. A sub-class of Class C2 (i.e., Sub-class SC2-1) includes the compounds in which X is O and pharmaceutically acceptable salts thereof. Other sub-classes of Class C2 include the compounds of Formulas Ha to Vila and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
A third class of compounds of the present invention (Class C3) is identical to Class C2 except that compounds of Formula IVc and Formula Vila and their salts are excluded. A sub-class of Class C3 (i.e., Sub-class SC3-1) includes the compounds in which X is O and pharmaceutically acceptable salts thereof. Other sub-classes of Class C3 include the compounds of the various formulas (excluding IVc and Vila) and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
A fourth class of compounds of the present invention (Class C4) includes compounds of Formula He as shown in Class C3 and pharmaceutically acceptable salts thereof, wherein all variables therein are as originally defined. A sub-class of Class C4 (i.e., Sub-class SC4-1) includes the compounds of Formula lie in which X is O and pharmaceutically acceptable salts thereof. Other sub-classes of Class C4 include the compounds of Formula lie and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
A fifth class of compounds of the present invention (Class C5) includes compounds of Formula Hi as shown in Class C3 and pharmaceutically acceptable salts thereof, wherein all variables therein are as originally defined. A sub-class of Class C5 (i.e., Sub-class SC5-1) includes the compounds of Formula Hi in which X is O and pharmaceutically acceptable salts thereof. Other sub-classes of Class C3 include the compounds of Formula IIi and their pharmaceutically acceptable salts, wherein the variables are as respectively defined in the preceding embodiments.
A sixth class of compounds of the present invention (Class C6) includes compounds of Formula I and pharmaceutically acceptable salts thereof, wherein: X is O;
Rl is AryA;
R.2, R3 and RlO are each independently selected from the group consisting of:
(1) H, (2) halogen, (3) N(RA)RB, (4) Ci_6 alkyl, (5) Ci -6 fluoroalkyl, (6) O-Ci-6 alkyl, and (7) O-Ci-6 fiuoroalkyl; Rl 1 and Rl 2 are each independently H or C\-β alkyl;
R4 and R5 are each independently selected from the group consisting of: (1) H,
(2) C 1-6 alkyl, (3) O-Ci-6 alkyl, (4) C 1-6 fluoroalkyl, (5) O-Ci-6 fluoroalkyl, and (6) halogen;
R6 is: (l)
Figure imgf000030_0001
, (2) , (3) *-CH2C(O)N(RA)-AryB,
(4) *-CH2C(O)N(RA)-HetB, (5) *-CH2C(O)N(RA)-Ci_3 alkylene-AryB, (6) *-CH2C(O)N(RA)-Ci-3 alkylene-HetB, (7) *-CH2C(O)O-Ci_3 alkylene-AryB,
(8) *-CH2-HetB, (9) *-CH2C(O)-HetB, (10) *-CH2C(O)-HetC, or (11) *-CH2CH2θH;
L is N or N oxide;
R7 and R8 are each independently selected from the group consisting of: (1) H, (2) OH, (3) halogen, (4) CN, (5) NO2, (6) Ci-6 alkyl, (7) O-Ci-6 alkyl, (8) O(CH2)2-3N(RA)RB, (9) 0(CH2) 1-3 C(O)RA (iθ) Ci-6 fluoroalkyl, (11) O-Ci-6 fluoroalkyl, (12) N(RC)RD5 (13) N(RA).(CH2)2-3 -N(RC)RD, (14) C(O)N(RA)RB, (15) C(O)RA (16) C(O)ORA, (17) SRA, (is) S(O)RA (19) S(O)2RA, and
Figure imgf000030_0002
R9 is H or C 1-4 alkyl; AryA is phenyl or naphthyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently Ci -6 alkyl, O-Ci-6 alkyl, CF3, OCF3, OH, halogen, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, C(O)CF3, CO2RA, SO2RA, CH=CH-(CH2)0-2CN, C≡C— (CH2)1-2N(RA)RB , Or Ci-6 alkylene-N(RA)RB.
AryB is phenyl which is optionally substituted with from 1 to 2 substituents each of which is independently Cl5 Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, S(0)2RA, or S(O)2N(RA)RB;
HetB is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, pyridyl and pyrimidinyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents, each of which is independently Cl, Br, F, CN, NC-2, C1-4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB5 C(O)RA, CO2RA, Sθ2RA, 802N(RA)RB, Or phenyl, with the proviso that no more than 1 of the optional substituents is phenyl;
HetC is a saturated heterocyclic ring selected from the group consisting of 1- pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl in which the S is optionally oxidized to S(O) or S(O)2, and 1-piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 2 substituents each of which is Cl, Br, F, CN, Cl -4 alkyl, OH, oxo, O-Ci-4 alkyl, CF3, OCF3, C(O)N(RA)RB5 C(O)RA, Cθ2RA, S(0)2RA, or S(0)2N(RA)RB; each RA is independently H or Ci-6 alkyl; each RB is independently H or Ci -6 alkyl; each RC is independently H or Cl -6 alkyl; each RD is independently H or Cl -6 alkyl; and alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(0)2; and wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Ci -.4 alkyl, (2) CF3, (3) C(O)N(RA)RB, (4) C(O)RA, (5) C(0)-CF3, (6) C(O)ORA, Or (7) S(O)2RA; and all other variables are as originally defined.
A sub-class of Class C6 (i.e., Sub-class SC6-1) includes the compounds of Formula I and their pharmaceutically acceptable salts, wherein V is CH; W is C(R3); either (i) Z and Y are both C and ring A is benzo, or (ii) Z is N and Y is C and ring A is pyrido or dihydropyrido; ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms; and all other variables are as originally defined in Class C6.
Another sub-class of Class C6 (Sub-class SC6-2) includes the compounds of Formula I and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C6; and provided that:
and R4 is other than H, then R6 is not
Figure imgf000031_0001
when ring B is
Figure imgf000032_0001
, then R.6 is not or
Figure imgf000032_0002
A seventh class of compounds of the present invention (Class C7) includes compounds of Formula I and pharmaceutically acceptable salts thereof, wherein:
Figure imgf000032_0003
and all other variables are as originally defined in Class C6.
A sub-class of Class C7 (Sub-class SC7-1) includes the compounds of Formula I and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C7; and provided that:
Figure imgf000032_0004
An eighth class of compounds of the present invention (Class C8) includes compounds of Formula I and pharmaceutically acceptable salts thereof, wherein: V and W are both CH; Z and Y are both C; ring A is benzo; ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms; and all other variables are as defined in Class C7.
A ninth class of compounds of the present invention (Class C9) includes compounds of Formula EX:
Figure imgf000032_0005
and pharmaceutically acceptable salts thereof, wherein: Tl and T2 and T3 are each independently H, C 1-4 alkyl, halogen, CN, CH=CH- CN, C(O)RA, or (CH2)1 -2N(RA)RB;
R2 and R3 are each independently selected from the group consisting of: (1) H, (2) halogen, (3) N(RA)RB, (4) Ci-4 alkyl, (5) CF3, (6) O-Cl-4 alkyl, and (7) OCF3;
Figure imgf000033_0001
Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-4 alkyl, CF3, OH, O-C 1.4 alkyl, OCF3 , C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or Sθ2N(RA)RB;
J3 is H, Cl, Br, F, CN, CM alkyl, OH, oxo, O-C1-4 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, Cθ2RA, SO2RA, or Sθ2N(RA)RB;
L is N or N oxide;
Q is: (1) -CH(R4)-, (2) -C(R4)=C(R5)-, (3) -CH(R4)-CH(R5)-, (4) -C(R4)=C(R5)-CH2-, (5) -CH(R4)-CH(R5)-CH2-, (6) -C(R4)=C(R5)-CH=CH-,
(7) -CH(R4)-CH(R5)-CH=CH-, (8) -C(R4)=C(R5)-CH2CH2-, (9) -CH(R4)-CH(R5)-CH2CH2-,
(10) -C(R4)=N-, (11) -N=C(R4)-, or (12) -N=N-; wherein the left-most atom in Q is the atom directly attached to the fused benzo;
R4 and R5 are each independently selected from the group consisting of: (1) H, (2) Ci-4 alkyl, (3) O-C1.4 alkyl, (4) CF3, (5) OCF3, and (6) halogen;
R7 and R8 are each independently selected from the group consisting of: (1) H, (2) OH, (3) halogen, (4) CN, (5) NO2, (6) Ci-4 alkyl, (7) O-C1.4 alkyl,
(8) O(CH2)2-3N(RA)RB, (9) 0(CH2) 1-3 C(O)RA, (I0) CF3, (11) OCF3, (12) O(CH2)l-2CF3, (12) N(RC)RD, (13) N(RA)-(CH2)2-3-N(RC)RD, and (14) C(O)N(RA)RB; each RA is independently H or Cl .4 alkyl; each RB is independently H or Cl .4 alkyl; each RC is independently H or Cl .4 alkyl; each RD is independently H or C 1-4 alkyl; and alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
— N^ — N I — N )
\/ , ^ , and W .
A sub-class of Class C9 (Sub-class SC9-1) includes the compounds of Formula DC and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C9; and provided that:
(A) when Q is -N=C(R4)- and R4 is other than H, then R6 is not
Figure imgf000034_0001
Another sub-class of Class C9 (Sub-class SC9-2) includes the compounds of
Formula IX and their pharmaceutically acceptable salts, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-C1.3 alkyl, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, C1-3 alkyl, OH, oxo, O-C1.3 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class C9 or Sub-class SC9-1.
Another sub-class of Class C9 (Sub-class SC9-3) includes the compounds of Formula DC and their pharmaceutically acceptable salts, wherein Q is -CH2CH2CH2-, -CH=N-,
-C(Cl)=N-, -N=CH-, or -N=N-; and all other variables are as originally defined in Class C9 or Sub-class SC9-2.
A tenth class of compounds of the present invention (Class ClO) includes compounds of Formula DCa:
Figure imgf000034_0002
and pharmaceutically acceptable salts thereof, wherein all the variables are as originally defined in Class C9.
A sub-class of Class ClO (Sub-class SClO-I) includes the compounds of Formula DCa and their pharmaceutically acceptable salts, wherein all the variables are as originally defined in Class C9; and provided that when Q is -N=C(R4)-, then R4 is H. Another sub-class of Class ClO (Sub-class SC 10-2) includes the compounds of Formula IXa and their pharmaceutically acceptable salts, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-C1.3 alkyl, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class ClO or Sub-class SClO-I.
An eleventh class of compounds of the present invention (Class CI l) includes compounds of Formula Kb:
Figure imgf000035_0001
and pharmaceutically acceptable salts thereof, wherein Q is: (1) -CH=CH-, (2) -CH=CH-CH2-, (3) -CH=CH-CH=CH-, (4) -CH2CH2-CH=CH-, (5) -CH=CH-CH2CH2-, (6) -C(R4)=N-, (7) -N=CH-, (8) -N=N-, or (9) CH2CH2CH2;
Tl is H or Cl; R.2 and R3 are each independently selected from the group consisting of H, Cl, Br,
F and C 1-4 alkyl;
R4 is H, C 1.4 alkyl, Cl, Br, or F;
L is N or N oxide; and one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other ofR7 and R8 is H.
A sub-class of Class Cl 1 (Sub-class SCl 1-1) includes the compounds of Formula IXb and their pharmaceutically acceptable salts, wherein all of the variables are as originally defined in Class Cl 1 ; and provided that when Q is -N=C(R4)-, then R4 is H. Another sub-class of Class CI l (Sub-class SCl 1-2) includes the compounds of
Formula IXb and their pharmaceutically acceptable salts, wherein Q is CH2CH2CH2, -CH=N-,
-C(Cl)=N-, -N=CH-, or -N=N-.; and all other variables are as originally defined in Class CI l.
A twelfth class of compounds of the present invention (Class C 12) includes compounds of Formula IXc:
Figure imgf000036_0001
and pharmaceutically acceptable salts thereof, wherein:
Tl is H or Cl;
T2 is CN, CH(O), CH2NH2, or CH2N(H)CH3;
R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(0)N(H)CH3, or C(O)N(CH3)2; and
Q, R2, R3, R4 and L are as defined in Class CI l.
A sub-class of Class Cl 2 (Sub-class SC 12-1) includes the compounds of Formula IXb and their pharmaceutically acceptable salts, wherein all of the variables are as originally defined in Class C 12; and provided that when Q is -N=C(R4)-, then R4 is H.
Another sub-class of Class C12 (Sub-class SC 12-2) includes the compounds of Formula IXc and their pharmaceutically acceptable salts, wherein Q is CH2CH2CH2, -CH=N-,
-C(Cl)=N-, -N=CH-, or -N=N-.; and all other variables are as originally defined in Class C 12. A thirteenth class of compounds of the present invention (Class C 13) includes compounds of Formula FXd:
Figure imgf000036_0002
and pharmaceutically acceptable salts thereof, wherein:
Q is: (1) -CH(R4)-, (2) -C(R4)=C(R5)-, (3) -CH(R4)-CH(R5)-, (4) -C(R4)=C(R5)-CH2-, (5) -CH(R4)-CH(R5)-CH2-, (6) -C(R4)=C(R5)-CH=CH-, (7) -CH(R4)-CH(R5)-CH=CH-, (8) -C(R4)=C(R5)-CH2CH2-, (9) -CH(R4)-CH(R5)-CH2CH2-, (10) -C(R4)=N-, (11) -N=C(R4)-; or (12) -N=N-; wherein the left-most atom in Q is the atom directly attached to the fused benzo;
Tl and T2 are each independently H, Cl .4 alkyl, halogen, CN, or CH=CH-CN;
R2 and R3 are each independently selected from the group consisting of: (1) H, (2) halogen, (3) CM alkyl, (4) CF3, (5) O-C1.4 alkyl, (6) OCF3, and (7) N(RA)RB;
R4 and R5 are each independently selected from the group consisting of: (1) H, (2) CM alkyl, (3) O-C1.4 alkyl, (4) CF3, (5) OCF3, and (6) halogen; R7 and R8 are each independently selected from the group consisting of: (1) H, (2) OH, (3) halogen, (4) CN, (5) NO2, (6) C 1.4 alkyl, (7) O-C1.4 alkyl, (8) O(CH2)2-3N(RA)RB, (9) 0(CH2)1.3C(O)RA5 (10) CF3, (11) OCF3, (12) O(CH2)l-2CF3, (12) N(RC)RD, (13) N(RA)-(CH2)2.3 -N(RC)RD, and (14) C(O)N(RA)RB; each RA is independently H or Cl .4 alkyl; each RB is independently H or Cl .4 alkyl; each RC is independently H or Cl .4 alkyl; each RD is independently H or Cl .4 alkyl; and alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
.-N 7N *-N I — N )
\/ , \^ , and ^V .
A sub-class of Class C13 (Sub-class SC 13-1) includes the compounds of Formula IXd and their pharmaceutically acceptable salts, wherein all of the variables are as originally defined in Class Cl 3; and provided that when Q is -N=C(R4)-, then R4 is H.
A fourteenth class of compounds of the present invention (Class C 14) includes compounds of Formula DCe:
Figure imgf000037_0001
and pharmaceutically acceptable salts thereof, wherein:
Q is: (1) -CH=CH-, (2) -CH=CH-CH2-, (3) -CH=CH-CH=CH-, (4) -CH2CH2-CH=CH-, (5) -CH=CH-CH2CH2-, (6) -C(R4)=N-, (7) -N=C(R4)S or (8) -N=N-;
R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl;
R4 is H, C 1-4 alkyl, Cl, Br, or F; and
R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2.3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2.
A sub-class of Class C 14 (Sub-class SC 14-1) includes the compounds of Formula DCe and their pharmaceutically acceptable salts, wherein all of the variables are as originally defined in Class C 14; and provided that when Q is -N=C(R4)-, then R4 is H. Another sub-class of Class C14 (Sub-class SC 14-2) includes the compounds of Formula IXe and their pharmaceutically acceptable salts, wherein Q is -CH=N-, -C(Cl)=N-, -N=CH-, or -N=N-; R2 is Br or Cl; R3 is H; and R.8 is H or NH2-
A fifteenth class of compounds of the present invention (Class C 15) includes compounds of Formula X:
Figure imgf000038_0001
and pharmaceutically acceptable salts thereof, wherein all of the variables are as originally defined in Class C9.
A sub-class of Class Cl 5 (Sub-class SCl 5-1) includes the compounds of Formula
X and their pharmaceutically acceptable salts, wherein R6 is
Figure imgf000038_0002
; and all other variables are as originally defined in Class C 15.
Another sub-class of Class Cl 5 (Sub-class SC 15-2) includes the compounds of Formula X and their pharmaceutically acceptable salts, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Ci-3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-C1.3 alkyl, CF3, OCF3, C(0)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class C 15. y
Another sub-class of Class C15 (Sub-class SC15-3) includes the compounds of Formula X and their pharmaceutically acceptable salts, wherein:
Tl and T2 and T3 are each independently H, Cl .4 alkyl, halogen, or CN;
Figure imgf000038_0003
R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl; one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(0)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other of R? and R8 is H. Another sub-class of Class Cl 5 (Sub-class SC 15-4) includes the compounds of Formula X and their pharmaceutically acceptable salts, wherein:
Tl and T2 and T^ are each independently H, CH3, Cl, or CN, with the proviso that at least one of Tl and T2 and T3 is Cl and at least one of Tl and T2 and T3 is CN;
R2 and R.3 are each independently selected from the group consisting of H, Cl, Br, F and C 1.4 alkyl;
Figure imgf000039_0001
one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, NH2, N(H)CH3, or N(CH3)2- A sixteenth class of compounds of the present invention (Class C 16) includes compounds of Formula XI :
Figure imgf000039_0002
and pharmaceutically acceptable salts thereof, wherein U is CH or N; all other variables are as originally defined in Class C9.
A sub-class of Class C16 (Sub-class SC 16-1) includes the compounds of Formula
XI and their pharmaceutically acceptable salts, wherein R6 is
Figure imgf000039_0003
~~NH ; and all other variables are as originally defined in Class C 16.
Another sub-class of Class C16 (Sub-class SC 16-2) includes the compounds of Formula XI and their pharmaceutically acceptable salts, wherein Jl and j2 are each independently H, Cl, Br, F, CN, NO2, C 1.3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, Ci-3 alkyl, OH, oxo, O-Ci-3 alkyl, CF3, OCF3, C(0)NH2, C(0)N(H)CH3, C(O)N(CH3)2, C(O)H, C(0)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as originally defined in Class C 15.
Another sub-class of Class C16 (Sub-class SC 16-3) includes the compounds of Formula XI and their pharmaceutically acceptable salts, wherein: Tl and T2 and T3 are each independently H, C 1-4 alkyl, halogen, or CN;
Figure imgf000040_0001
R2 and R.3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl; one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other of R7 and R8 is H.
Another sub-class of Class Cl 6 (Sub-class SC 16-4) includes the compounds of Formula XI and their pharmaceutically acceptable salts, wherein:
Tl and T2 and T3 are each independently H, CH3, Cl, or CN, with the proviso that at least one of Tl and T2 and T3 is Cl and at least one of Tl and T2 and T3 is CN;
R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1-4 alkyl;
Figure imgf000040_0002
one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, NH2, N(H)CH3, or N(CH3)2- A seventeenth class of the present invention (Class C 17) includes compounds selected from the group consisting of the compounds set forth in Examples 1-7, 9-13 and 15-29 and their pharmaceutically acceptable salts. A sub-class of Class Cl 7 (Sub-class SC 17-1) includes compounds selected from the group consisting of the compounds set forth in Examples 1 to 4 and their pharmaceutically acceptable salts. Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as originally defined or as defined in any of the foregoing embodiments, aspects, classes or sub-classes, wherein the compound or its salt is in a substantially pure form. As used herein "substantially pure" means suitably at least about 60 wt.%, typically at least about 70 wt.%, preferably at least about 80 wt.%, more preferably at least about 90 wt.% (e.g., from about 90 wt.% to about 99 wt.%), even more preferably at least about 95 wt.% (e.g., from about 95 wt.% to about 99 wt.%, or from about 98 wt.% to 100 wt.%), and most preferably at least about 99 wt.% (e.g., 100 wt.%) of a product containing a compound of Formula I or its salt (e.g., the product isolated from a reaction mixture affording the compound or salt) consists of the compound or salt. The level of purity of the compounds and salts can be determined using a standard method of analysis such as thin layer chromatography, gel electrophoresis, high performance liquid chromatography, and/or mass spectrometry. If more than one method of analysis is employed and the methods provide experimentally significant differences in the level of purity determined, then the method providing the highest purity level governs. A compound or salt of 100% purity is one which is free of detectable impurities as determined by a standard method of analysis. With respect to a compound of the invention which has one or more asymmetric centers and can occur as mixtures of stereoisomers, a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer.
The present invention also includes prodrugs of the compounds of Formula I. The term "prodrug" refers to a derivative of a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is converted in vivo into Compound I. Prodrugs of compounds of Formula I can exhibit enhanced solubility, absorption, and/or lipophilicity compared to the compounds per se, thereby resulting in increased bioavailability and efficacy. The in vivo conversion of the prodrug can be the result of an enzyme-catalyzed chemical reaction, a metabolic chemical reaction, and/or a spontaneous chemical reaction (e.g., solvolysis). When the compound contains, for example, a hydroxy group, the prodrug can be a derivative of the hydroxy group such as an ester (-OC(O)R), a carbonate ester (-OC(O)OR), a phosphate ester (-O-P(=O)(OH)2), or an ether (-OR). Other examples include the following: When the compound of Formula I contains a carboxylic acid group, the prodrug can be an ester or an amide, and when the compound of Formula I contains a primary amino group or another suitable nitrogen that can be derivatized, the prodrug can be an amide, carbamate, urea, imine, or a
Mannich base. One or more functional groups in Compound I can be derivatized to provide a prodrug thereof. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, edited by H. Bundgaard, Elsevier, 1985; ; J. J. Hale et al., J. Med. Chem. 2000, vol. 43, pp.1234-1241; C. S. Larsen and J. Ostergaard, "Design and application of prodrugs" in: Textbook of Drug Design and Discovery, 3rd edition, edited by C. S. Larsen, 2002, pp. 410-458; and Beaumont et al., Current Drug Metabolism 2003, vol. 4, pp. 461-458; the disclosures of each of which are incorporated herein by reference in their entireties.
Another embodiment of the present invention (alternatively referred to as "Embodiment PDl ") is a prodrug of a compound of Formula I as originally defined above.
Another embodiment of the present invention (Embodiment PD2) is a compound of Formula I -P:
Figure imgf000041_0001
wherein:
R.6P is attached to the ring atom in B which is adjacent to shared atom Z or which is adjacent to
the ring atom that is adjacent to Z, and is
Figure imgf000042_0001
, wherein each ring N is optionally an N-oxide;
R9P is PO(OH)O- -M+; PO(O-)2 -2M+; PO(O-)2 -M2+; or an acid salt of:
Figure imgf000042_0002
M+ is a pharmaceutically acceptable monovalent counterion; M2+ is a pharmaceutically acceptable divalent counterion;
Rl5 is H, Ci-6 alkyl, (CH2)2-3CF3, AryA, or HetA;
Rl6a and Rl6b are each independently H, C\-β alkyl, (CH2)2-3CF3, AryA, or HetA; each Rl 7 is independently H or Ci -6 alkyl; each Rl 8 is independently H or C\.β alkyl; alternatively, Rl 5 together with an Rl 7 or Rl 8 and the atoms to which each is attached and any carbons in a chain therebetween form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 5 is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S (0)2; alternatively, Rl 6a together with an Rl 7 or Rl 8 and the atoms to which each is attached and any carbons in a chain therebetween form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 6a is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, an Rl 7 together with the Rl 8 attached to the same carbon atom form a 5- or 6-membered, saturated monocyclic ring optionally containing a heteroatom, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) Or S(O)2;
Rl9 is H or C 1-6 alkyl; R20 is H or C 1-6 alkyl;
R21 is H or C 1-6 alkyl; R22a and R22b are each independently H, C 1-6 alkyl, (CH2)2-3CF3, AryA, or HetA;
R23 is H or Ci_6 alkyl;
R24 is H or C 1-6 alkyl; alternatively, Rl 9 together with R23 or R24 and the atoms to which each is attached form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 9 is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, R20 and R21 together with the carbon atom to which both are attached form a 5- or
6-membered, saturated monocyclic ring optionally containing a heteroatom, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, R22a together with an R20 or R21 and the atoms to which each is attached form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which R22a is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, R23 and R24 together with the carbon atom to which both are attached form a 5- or 6-membered, saturated monocyclic ring optionally containing a heteroatom, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; wherein the monocyclic ring formed by combining Rl 5 together with an Rl^ or RlS, the monocyclic ring formed by combining Rl 6a together with an Rl 7 or Rl 8, the monocyclic ring formed by combining Rl 7 together with an Rl 8, the monocyclic ring formed by combining Rl 9 together with an R23 or R24 , the monocyclic ring formed by combining R20 together with an R21, the monocyclic ring formed by combining R22a together with an R20 or R21, and the monocyclic ring formed by combining R23 together with an R24, are each independently and optionally substituted with from 1 to 3 substituents each of which is independently: (1) Ci-6 alkyl, (2) Ci-6 haloalkyl, (3) Ci_6 alkyl substituted with OH, O-Ci- 6 alkyl, O-Ci-6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA, CO2RA, SRA, S(O)RA, SO2RA, or S02N(RA)RB, (4) O-Ci-6 alkyl, (5) O-Ci-6 haloalkyl, (6) OH, (7) oxo, (8) halogen, (9) CN, (10) NO2, (11) N(RA)RB5 (12) C(O)N(RA)RB5 (13) C(O)RA, (14)
C(O)-Ci-6 haloalkyl, (15) C(O)ORA (16) OC(O)N(RA)RB, (17) SRA (18) S(O)RA (19) S(O)2RA, (20) S(O)2N(RA)RB5 (21) N(RA)CORB, or (22) N(RA)S02RB;
d is an integer equal to 2, 3, or 4; and
all other variables are as originally defined above for a compound of Formula I. In the definition of the monocyclic ring formed by combining Rl 5 together with an Rl 7 or Rl 8, the phrase "any carbons in a chain therebetween" refers to the carbon chain [C(Rl 7)Rl8)]2_4. If the ring is formed by combining Rl 5 with the Rl 7 or Rl 8 on the adjacent carbon, there are no carbons therebetween as exemplified by structure A below, wherein the arrow symbolizes the joining of Rl 5 and Rl 7 to form a ring. If the ring is formed by combining Rl 5 with the Rl 7 or Rl 8 on a non-adjacent carbon, there is at least one carbon therebetween as exemplified by structure B below. Analogous considerations apply with respect to the monocyclic ring formed by combining Rl 6a together with an Rl7 or Rl8.
Figure imgf000044_0001
Another embodiment of the present invention (Embodiment PD3) is a compound of Formula I-P as defined in Embodiment PD2; and provided that
Figure imgf000044_0002
on ring B denote the points of attachment to ring A. Another embodiment of the present invention (Embodiment PD4) is a compound of Formula I-P as defined in Embodiment PD2, wherein R6P is attached to the ring atom in B which is adjacent to shared atom Z; HetE and HetF are as defined in Embodiment E2; and all other variables are as defined in Embodiment PD2.
Another embodiment of the present invention (Embodiment PD5) is a compound of Formula I-P as defined in Embodiment PD4; and provided that
(A) when ring B is
Figure imgf000044_0003
, then R4 is H; and (B) ring B is not
Figure imgf000045_0001
; wherein the asterisks on ring B denote the points of attachment to ring A.
Another embodiment of the present invention (Embodiment PD6) is a compound of Formula I -P, wherein the compound is selected from the group consisting of:
Figure imgf000045_0002
(H-P), (iii-p), (IV-P),
Figure imgf000045_0003
(V-P), (VI-P), and (VII-P);
wherein all of the variables are as defined in Embodiment PD2 or Embodiment PD3.
Another embodiment of the present invention (Embodiment PD7) is a compound of Formula I -P, wherein the compound is selected from the group consisting of compounds of Formula H-P, III-P, IV-P, V-P, and VI-P as defined in Embodiment PD6 wherein all of the variables are as defined in Embodiment PD4 or Embodiment PD5.
Another embodiment of the present invention (Embodiment PD8) is a compound of Formula I -P, wherein the compound is selected from the group consisting of compounds of Formula Ha-P, 1Ib-P, Hc-P, Hd-P, 1Ie-P, Hf-P, Hg-P, Hh-P, 1Ii-P, Hj-P, Hk-P, IH-P, 1Im-P, Hn-P, Ho-P, Hp-P, Hq-P, Hr-P, IHa-P, IVa-P, IVb-P, IVc-P, Va-P, VIa-P, and VIIa-P wherein these formulas are identical to Formulas Ha, Hb, He, Hd, He, Hf, πg, Hh, Hi, Hj, Ilk, III, Hm, Hn, Ho, Hp, Hq, Hr, Ilia, FVa, FVb, FVc, Va, Via and Vila respectively as set forth above in Class C2, except that Ra is replaced with R.6P; and wherein all of the variables are as defined in Embodiment PD2 or Embodiment PD3. Another embodiment of the present invention (Embodiment PD9) is a compound of Formula I -P, wherein the compound is selected from the group consisting of compounds of Formula Ha-P, Hb-P, Hc-P, Hd-P, πe-P, Hf-P, πg-P, IHi-P, Hi-P, Hj-P, 1Ik-P, πi-P, Hm-P, Hn-P, Ho-P, Hp-P, Hq-P, 1Ir-P, HIa-P, IVa-P, FVb-P, Va-P and VIa-P wherein these formulas are identical to Formulas Ha, πb, He, Hd, πe, Hf, Hg, Hh, m, πj, Hk, III, Hm, Hn, no, Up, Hq, Hr, Ilia, IVa, IVb, Va and Via respectively as set forth above in Class C2, except that R.6 is replaced with R.6P; and wherein all of the variables are as defined in Embodiment PD4 or Embodiment PD5.
Another embodiment of the present invention (Embodiment PDlO) is a compound
of Formula I-P, wherein R6P is
Figure imgf000046_0001
or ; and X, Rl, R2, R3, R4,
R5, R7, R8, RlO, Rl I5 Rl2, AryA, RA, RB5 RC and RD are each as defined in Class C6 set forth above; and all other variables (including R9P) are as defined in Embodiment PD2.
Another embodiment of the present invention (Embodiment PDl 1) is a compound of Formula I -P, or a pharmaceutically acceptable salt thereof, wherein all the variables are as originally defined in Embodiment PD
(A) when ring B is
Figure imgf000046_0002
Another embodiment of the present invention (Embodiment PD 12) is a compound of Formula I -P, wherein V and W are both CH; Z and Y are both C; ring A is benzo; ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms; and all other variables are as defined in Embodiment PDlO or Embodiment PDl 1.
Another embodiment of the present invention (Embodiment PD 13) is a compound of Formula VIII-P:
Figure imgf000046_0003
wherein all of the variables are as defined in any one of Embodiments PD2, PD3, PD4 and PD5. Compounds of Formula VIII-P as defined in Embodiments PD2, PD3, PD4 and PD5 respectively and wherein X is O form classes of compounds of interest.
Another embodiment of the present invention (Embodiment PD 14) is a compound of Formula DC-P:
Figure imgf000047_0001
wherein L, Q, Tl, T2, R2, R3, R4, R5, R7, R8; RA, RB, RC and RD are as defined in Class C9; and R9P is as defined in Embodiment PD2.
Another embodiment of the present invention (Embodiment PD 15) is a compound of Formula DC-P as defined in Embodiment PD 14; and provided that (A) when Q is -N=C(R4)- , then R4 is H.
Another embodiment of the present invention (Embodiment PD 16) is a compound of Formula DC-P, wherein Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Cl .3 alkyl, CF3, OH, O-Ci-3 alkyl, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; J3 is H, Cl, Br, F, CN, Cl -3 alkyl, OH, oxo, O-Ci-3 alkyl, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(CH3)2, C(O)H, C(O)CH3, CO2H, CO2CH3, SO2CH3, or SO2NH2; and all other variables are as defined in Embodiment PD14 or
Embodiment PD 15.
Another embodiment of the present invention (Embodiment PD 17) is a compound of Formula DC-P, wherein Q is -CH2CH2CH2-, -CH=N-, -C(Cl)=N-, -N=CH-, or -N=N-; and all other variables are as originally defined in Embodiment PD 14 or Embodiment PD 16.
Another embodiment of the present invention (Embodiment PD 18) is a compound of Formula DCa-P:
Figure imgf000047_0002
wherein Q, Tl, T2, R2, R3, R4, R5, R7, R8, RA, RB, RC and RD are as defined in Class C13; and R9P is as defined in Embodiment PD2.
Another embodiment of the present invention (Embodiment PD 19) is a compound of Formula DCa-P as defined in Embodiment PDl 8; and provided that when Q is -N=C(R4)-, then R4 is H. Another embodiment of the present invention (Embodiment PD20) is a compound of Formula DCb-P:
Figure imgf000048_0001
wherein Q, R2, R35 R4 and R& are as defined in Class C 14 set forth above; and R9P is as defined in Embodiment PD2.
Another embodiment of the present invention (Embodiment PD21) is a compound of Formula DCb-P as defined in Embodiment PD20; and provided that when Q is -N=C(R4)-, then R4 is H.
Another embodiment of the present invention (Embodiment PD22) is a compound selected from the group consisting of:
Figure imgf000048_0002
Figure imgf000049_0001
wherein R.9P is as defined in Embodiment PD2.
Another embodiment of the present invention (Embodiment PD23) is a compound as defined in any one of Embodiments PD2 to PD22, wherein R.9P is PO(OH)O- -M+; P0(0")2 •2M+; P0(0-)2 -M2+; or an acid salt of:
Figure imgf000050_0001
M+ is a pharmaceutically acceptable monovalent counterion;
M2+ is a pharmaceutically acceptable divalent counterion;
Rl5 is H or Ci_4 alkyl;
Rl 6a and Rl 6b are each independently H or C 1-4 alkyl;
Rl9 is H or Ci_4 alkyl;
R20 is H or C 1-4 alkyl;
R22a and R22b are each independently H or C 1-4 alkyl; and d is an integer equal to 2, 3, or 4.
Another embodiment of the present invention (Embodiment PD24) is a compound as defined in any one of Embodiments PD2 to PD22, wherein R9P is an acid salt of:
Figure imgf000050_0002
A class of the preceding embodiment (Class C1-PD24) includes compounds as defined in Embodiment PD24, wherein the acid salt in the definition of R9P is a hydrochloride salt.
Another embodiment of the present invention (Embodiment PD25) is a compound selected from the group consisting of:
Figure imgf000050_0003
Pharmaceutically acceptable monovalent counterions (M+) suitable for use in the prodrugs of the invention described in the foregoing embodiments include NH4+, alkali metal cations (e.g., Na+ or K+), and cations from alkylamines, hydroxyalkylamines (e.g., tris(hydroxymethyl)methylamine), choline, lysine, arginine, histidine, and N-methyl-D- glucamine. Suitable divalent counterions (M2+) include the cations of alkaline earth metals such as Mg2+ and Ca2+. Additional pharmaceutically acceptable salts of basic drugs (pharmaceutically acceptable monovalent and divalent counterions) are described in P. L. Gould, Int. J. Pharm. 1986, vol. 33 pp. 201-217 and S. M. Berge et al., J Pharm. ScI, 1977, vol. 66, pp. 1-19.
Acid salts suitable for use in the prodrugs of the invention described in the foregoing embodiments include the salts of organic and inorganic acids. Suitable salts of inorganic acids include the salts of hydrochloric acid, sulfuric acid, alkali metal bisulfates (e.g., KHSO4), and the like. Suitable salts of organic acids include the salts of carboxylic acids and sulfonic acids, such as alkylcarboxylic acids (e.g., acetic acid, propanoic acid, butyric acid, etc.), fluoroalkylcarboxlic acids (e.g., trifluoroacetic acid), arylcarboxylic acids (benzoic acid), alkylsulfonic acids (e.g., ethylsulfonic acid), fluoroalkylsulfonic acids (e.g., trifiuoromethylsulfonic acid), and arylsulfonic acids (e.g., benzenesulfonic acid or toluenesulfonic acid).
While not wishing to be bound by any particular theory, it is believed that the compounds set forth in Embodiments PD2 to PD25 act as prodrugs, wherein the compound is relatively stable at low pH (e.g., pH = 1 to 3) but will convert by hydrolysis or cyclization to its free base at physiological pH (e.g., a pH of greater than about 7), thereby releasing the active substance in vivo. This reaction is exemplified as follows for a hydrochloride salt:
Figure imgf000051_0001
Other embodiments of the present invention include the following: (a) A pharmaceutical composition comprising an effective amount of a compound of Formula I as defined above, or a prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
(b) A pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula I as defined above, or a prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
(c) The pharmaceutical composition of (a) or (b), further comprising an effective amount of an anti-HIV agent selected from the group consisting of HTV antiviral agents, immunomodulators, and anti-infective agents.
(d) The pharmaceutical composition of (c), wherein the anti-HIV agent is an antiviral selected from the group consisting of HIV protease inhibitors, HTV reverse transcriptase inhibitors other than a compound of Formula I, HTV integrase inhibitors,HTV fusion inhibitors, and HIV entry inhibitors. (e) A combination which is (i) a compound of Formula I as defined above, or a prodrug or pharmaceutically acceptable salt thereof, and (ii) an anti-HTV agent selected from the group consisting of HIV antiviral agents, immunomodulators, and anti-infective agents; wherein Compound I and the anti-HF/ agent are each employed in an amount that renders the combination effective for inhibition of HTV reverse transcriptase, for treatment or prophylaxis of infection by HIV, or for treatment, prophylaxis of, or delay in the onset or progression of AIDS.
(f) The combination of (e), wherein the anti-HIV agent is an antiviral selected from the group consisting of HIV protease inhibitors, HIV reverse transcriptase inhibitors other than a compound of Formula I, HIV integrase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.
(g) A method for the inhibition of HIV reverse transcriptase in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I or a prodrug or pharmaceutically acceptable salt thereof.
(h) A method of the prophylaxis or treatment of infection by HIV (e.g., HTV- 1) in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I or a prodrug or pharmaceutically acceptable salt thereof.
(i) The method of (h), wherein the compound of Formula I is administered in combination with an effective amount of at least one other HTV antiviral selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.
(j) A method for the prophylaxis, treatment or delay in the onset or progression of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I or a prodrug or pharmaceutically acceptable salt thereof.
(k) The method of (j), wherein the compound is administered in combination with an effective amount of at least one other HIV antiviral other than a compound of Formula I, selected from the group consisting of HIV protease inhibitors, HTV integrase inhibitors, non- nucleoside HTV reverse transcriptase inhibitors, nucleoside HFV reverse transcriptase inhibitors, HTV fusion inhibitors, and HIV entry inhibitors.
(1) A method for the inhibition of HIV reverse transcriptase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
(m) A method for the prophylaxis or treatment of infection by HIV (e.g., HIV- 1) in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f). (n) A method for the prophylaxis, treatment, or delay in the onset or progression of AIDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
The present invention also includes a compound of Formula I, or a prodrug or pharmaceutically acceptable salt thereof, (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) therapy (e.g., of the human body), (b) medicine, (c) inhibition of HTV reverse transcriptase, (d) treatment or prophylaxis of infection by HIV, or (e) treatment, prophylaxis of, or delay in the onset or progression of AIDS. In these uses, the compounds of the present invention can optionally be employed in combination with one or more anti-HFV agents selected from HTV antiviral agents, anti-infective agents, and immunomodulators.
Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses (i)(a)-(e) through (iii)(a)-(e) set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes or sub-classes described above. Ln all of these embodiments etc., the compound may optionally be used in the form of a prodrug or pharmaceutically acceptable salt.
Additional embodiments of the present invention include each of the pharmaceutical compositions, combinations, methods and uses set forth in the preceding paragraphs, wherein the compound of the present invention or its salt employed therein is substantially pure. With respect to a pharmaceutical composition comprising a compound of Formula I or its prodrug or salt and a pharmaceutically acceptable carrier and optionally one or more excipients, it is understood that the term "substantially pure" is in reference to a compound of Formula I or its prodrug or salt per se. Still additional embodiments of the present invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses (i)(a)-(e) through (iii)(a)-(e) set forth above, wherein the HIV of interest is HIV-I. Thus, for example, in the pharmaceutical composition (d), the compound of Formula I is employed in an amount effective against HIV-I and the anti-HIV agent is an HIV-I antiviral selected from the group consisting of HIV-I protease inhibitors, HTV-I reverse transcriptase inhibitors other than a compound of Formula I, HIV-I integrase inhibitors, HIV-I fusion inhibitors and HIV-I entry inhibitors.
As used herein, the term "alkyl" refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example, "C 1-6 alkyl" (or "C1-C6 alkyl") refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso- propyl, ethyl and methyl. As another example, "C 1-4 alkyl" refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. The term "alkenyl" refers to a monovalent straight or branched chain aliphatic hydrocarbon radical containing one carbon-carbon double bond and having a number of carbon atoms in the specified range. Thus, for example, "C2-C6 alkenyl" (or "C2-6 alkenyl") refers to all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1 -propenyl, 2-propenyl, and ethenyl (or vinyl). A class of alkenyls of interest with respect to the invention are alkenyls of formula -CH=CH-(CF^) I-3CH3.
The term "alkynyl" refers to a monovalent straight or branched chain aliphatic hydrocarbon radical containing one carbon-carbon triple bond and having a number of carbon atoms in the specified range. Thus, for example, "C2-C6 alkynyl" (or "C2-6 alkynyl") refers to all of the hexynyl and pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-butynyl, 1-propynyl, 2-propynyl, and ethynyl.
The term "alkylene" refers to any divalent linear or branched chain aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example, "-Ci -6 alkylene-" refers to any of the Ci to Ce linear or branched alkylenes, and "-Ci .4 alkylene-" refers to any of the Ci to C4 linear or branched alkylenes. A class of alkylenes of interest with respect to the invention is -(CH2)l-6-> and sub-classes of particular interest include -(CH2)l-4-, -(CH2)2-4-, -(CH2)l-3-, -(CH2)2-3-, -(CH2)l-2-, and -CH2-. Another sub-class of interest is an alkylene selected from the group consisting of -CH2-, -CH(CH3)-, and -C(CH3)2-.
The term "cycloalkyl" refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range. Thus, for example, "C3-8 cycloalkyl" (or "C3-C8 cycloalkyl") refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo). The term "haloalkyl" refers to an alkyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen (i.e., F, Cl, Br and/or I). Thus, for example, "Ci -6 haloalkyl" (or "C1-C6 haloalkyl") refers to a Cl to Ce linear or branched alkyl group as defined above with one or more halogen substituents. The term "fluoroalkyl" has an analogous meaning except that the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH2)θ-4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3- trifluoro-n-propyl, etc.). A fluoroalkyl of particular interest is CF3.
The term "C(O)" refers to carbonyl. The terms "S(O)2" and "SO2" each refer to sulfonyl. The term "S(O)" refers to sulfinyl.
The term "contain" in the proviso that "no more than two of V, W, Y and Z contain N" means that no more than two of V, W, Y and Z provide a ring nitrogen in ring A. It is understood that the substituents Rl 1 in N(Rl 1) and Rl2 in N(Rl2) can contain N. An asterisk ("*") as the end of an open bond in a chemical group denotes the point of attachment of the group to the rest of the compound.
The term "aryl" refers to (i) phenyl, (ii) 9- or 10-membered bicyclic, fused carbocylic ring systems in which at least one ring is aromatic, and (iii) 11- to 14-membered tricyclic, fused carbocyclic ring systems in which at least one ring is aromatic. Suitable aryls include, for example, phenyl, naphthyl, tetrahydronaphthyl (tetralinyl), indenyl, anthracenyl, and fluorenyl. A class of aryls of interest with respect to the invention is phenyl and napthyl. An aryl of particular interest is phenyl.
The term "heteroaryl" refers to (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, (ii) a 9- or 10-membered bicyclic fused ring system, or (iii) an 11- to 16-membered tricyclic fused ring system, wherein the fused ring system of (ii) or (iii) contains from 1 to 6 heteroatoms independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatom, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2- Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Suitable 9- and 10-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolyl, benzodioxolyl (e.g.,
Figure imgf000055_0001
isochromanyl, benzothienyl, benzofuranyl, imidazo[l,2-a]pyridinyl, benzotriazolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl,
2,3-dihydrobenzofuranyl, and 2,3-dihydrobenzo-l,4-dioxinyl (i.e., ° ). Suitable tricyclic heteroaryls include, for example, xanthyl and carbazolyl.
Examples of 4- to 7-membered, saturated heterocyclic rings within the scope of this invention (see HetF) include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl. Examples of 4- to 7-membered, mono-unsaturated heterocyclic rings within the scope of this invention (see HetF) include mono-unsaturated heterocyclic rings corresponding to the saturated heterocyclic rings listed in the preceding sentence in which a single bond is replaced with a double bond (e.g., a carbon-carbon single bond is replaced with a carbon-carbon double bond).
It is understood that the specific rings and ring systems suitable for use in the present invention are not limited to those listed in the preceding paragraphs. These rings and ring systems are merely representative.
Unless expressly stated to the contrary in a particular context, any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results.
Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaromatic ring described as containing from "1 to 4 heteroatoms" means the ring can contain 1 , 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from "1 to 4 heteroatoms" is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms. As another example, an aryl or heteroaryl described as optionally substituted with "from 1 to 6 substituents" is intended to include as aspects thereof, an aryl or heteroaryl substituted with 1 to 6 substituents, 2 to 6 substituents, 3 to 6 substituents, 4 to 6 substituents, 5 to 6 substituents, 6 substituents, 1 to 5 substituents, 2 to 5 substituents, 3 to 5 substiuents, 4 to 5 substituents, 5 substituents, 1 to 4 substituents, 2 to 4 substituents, 3 to 4 substituents, 4 substituents, 1 to 3 substituents, 2 to 3 substituents, 3 substituents, 1 to 2 substituents, 2 substituents, and 1 substituent.
When any variable (e.g., RA or R.B) occurs more than one time in any constituent or in Formula I or in any other formula depicting and describing compounds of the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
Unless expressly stated to the contrary, substitution by a named substituent is permitted on any atom in a ring (e.g., cycloalkyl, aryl, or heteroaryl) provided such ring substitution is chemically allowed and results in a stable compound.
As a result of the selection of substituents and substituent patterns, certain compounds of the present invention can exhibit tautomerism such as keto-enol tautomerism. All tautomeric forms of these compounds, whether present individually or in mixtures, are within the scope of the present invention. For example, in compounds of the present invention where a hydroxy (-OH) substituent is permitted on a heteroaromatic ring and keto-enol tautomerism is possible, it is understood that the substituent might in fact be present, in whole or in part, in the keto form. A "stable" compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject). The compounds of the present invention are limited to stable compounds embraced by Formula I.
As a result of the selection of substituents and substituent patterns, certain compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether individually or in mixtures, are within the scope of the present invention. The methods of the present invention involve the use of compounds of the present invention in the inhibition of HIV reverse transcriptase (e.g., wild type HIV-I and/or mutant strains thereof), the prophylaxis or treatment of infection by human immunodeficiency virus (HIV) and the prophylaxis, treatment or delay in the onset or progression of consequent pathological conditions such as AIDS. Prophylaxis of AIDS, treating AIDS, delaying the onset or progression of AIDS, or treating or prophylaxis of infection by HIV is defined as including, but not limited to, treatment of a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the present invention can be employed to treat infection by HFV after suspected past exposure to HIV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery. As another example, the present invention can also be employed to prevent transmission of HIV from a pregnant female infected with HIV to her unborn child or from an HIV-infected female who is nursing (i.e., breast feeding) a child to the child via administration of an effective amount of Compound I or a pharmaceutically acceptable salt thereof. The compounds can be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. When compounds employed in the present invention carry an acidic moiety (e.g., -COOH or a phenolic group), suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound. The term "administration" and variants thereof (e.g., "administering" a compound) in reference to a compound of Formula I mean providing the compound or a prodrug of the compound to the individual in need of treatment or prophylaxis. When a compound or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating or prophylaxis of HIV infection or AIDS), "administration" and its variants are each understood to include provision of the compound or prodrug and other agents at the same time or at different times. When the agents of a combination are administered at the same time, they can be administered together in a single composition or they can be administered separately. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
By "pharmaceutically acceptable" is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof. The term "subject" as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. In one embodiment, the effective amount is a "therapeutically effective amount" for the alleviation of the symptoms of the disease or condition being treated. In another embodiment, the effective amount is a "prophylactically effective amount" for prophylaxis of the symptoms of the disease or condition being prevented. The term also includes herein the amount of active compound sufficient to inhibit HIV reverse transcriptase (wild type and/or mutant strains thereof) and thereby elicit the response being sought (i.e., an "inhibition effective amount"). When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free form (i.e., the non-salt form) of the compound.
In the method of the present invention (i.e., inhibiting HIV reverse transcriptase, treating or prophylaxis of HTV infection or treating, prophylaxis of, or delaying the onset or progression of AIDS), the compounds of Formula I, optionally in the form of a salt or a prodrug, can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The compounds of the invention can, for example, be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Liquid preparations suitable for oral administration (e.g., suspensions, syrups, elixirs and the like) can be prepared according to techniques known in the art and can employ any of the usual media such as water, glycols, oils, alcohols and the like. Solid preparations suitable for oral administration (e.g., powders, pills, capsules and tablets) can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like. Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as a solubility aid. Injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions for use in the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences, 18th edition, edited by A. R. Gennaro, Mack Publishing Co., 1990 and in Remington - The Science and Practice of Pharmacy, 21st edition, Lippincott Williams & Wilkins, 2005.
The compounds of Formula I can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses. One preferred dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses. Another preferred dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
In one embodiment, a compound of Formula I such as the compound of Example 1 can be administered to adult humans orally in the form of a tablet or capsule containing the compound in an amount in a range of from about 40 mg to about 900 mg, wherein the tablet or capsule is administered once per day or twice per day. In another embodiment, a compound of Formula I such as the compound of Example 1 can be administered to adult humans orally in the form of a tablet or capsule containing the compound in an amount in a range of from about 40 mg to about 320 mg, wherein the tablet or capsule is administered once per day or twice per day.
As noted above, the present invention is also directed to use of a compound of Formula I with one or more anti-HIV agents. An "anti-HIV agent" is any agent which is directly or indirectly effective in the inhibition of HIV reverse transcriptase or another enzyme required for HIV replication or infection, the treatment or prophylaxis of HTV infection, and/or the treatment, prophylaxis or delay in the onset or progression of AIDS. It is understood that an anti- HIV agent is effective in treating, preventing, or delaying the onset or progression of HIV infection or AIDS and/or diseases or conditions arising therefrom or associated therewith. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more anti- HIV agents selected from HIV antiviral agents, imunomodulators, antiinfectives, or vaccines useful for treating HFV infection or AIDS, such as those disclosed in Table 1 of WO 01/38332 or in the Table in WO 02/30930. Suitable HFV antivirals for use in combination with the compounds of the present invention include, for example, those listed in Table A as follows:
Table A
Figure imgf000060_0001
Figure imgf000061_0001
EI = entry inhibitor; FI = fusion inhibitor; InI = integrase inhibitor; PI = protease inhibitor; nRTI = nucleoside reverse transcriptase inhibitor; nnRTI = non-nucleoside reverse transcriptase inhibitor. Some of the drugs listed in the table are used in a salt form; e.g., abacavir sulfate, indinavir sulfate, atazanavir sulfate, nelfinavir mesylate.
It is understood that the scope of combinations of the compounds of this invention with anti-HP/ agents is not limited to the HIV antivirals listed in Table A and/or listed in the above-referenced Tables in WO 01/38332 and WO 02/30930, but includes in principle any combination with any pharmaceutical composition useful for the treatment or prophylaxis of AIDS. The HIV antiviral agents and other agents will typically be employed in these combinations in their conventional dosage ranges and regimens as reported in the art, including, for example, the dosages described in the Physicians' Desk Reference, Thomson PDR, Thomson PDR, 57th edition (2003), the 58th edition (2004), the 59th edition (2005), and subsequent editions thereof. The dosage ranges for a compound of the invention in these combinations are the same as those set forth above.
Abbreviations employed herein include the following:
ACN = acetonitrile; AIDS = acquired immunodeficiency syndrome; BOC or Boc = t- butyloxycarbonyl; (BOC)2θ (or BOC2O) = di-t-butyl carbonate; Bn-p-OMe = p-methoxybenzyl;
BrdUTP = bromodeoxyuridine triphosphate; n-Bu = n-butyl; t-Bu = t-butyl; CHAPS = 3-[(3- cholamidopropyl)-dimethylammonio]-l-propane-sulfonate; DCE = 1 ,2-dichloroethane; DCM = dichloromethane; DMAP =4-dimethylaminopyridine; DMF = dimethylformamide; DMPU = 1,3- dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (or N,N'-dimethylpropyleneurea); DMSO = dimethylsulfoxide; dNTP = deoxynucleoside triphosphate; DPPA = diphenylphosphoryl azide; EDC = l-ethyl-3-(3-dimethylaminopropyl) carbodiimide; EGTA = ethylene glycol bis(2- aminoethyl ether)-N,N,N',N'-tetraacetic acid; Et = ethyl; EtOAc = ethyl acetate; EtOH = ethanol; HOAT = l-hydroxy-7-azabenzotriazole; HPMCAS-LF = hydroxypropylmethylcellulose acetate succinate - low fine (powder); HPLC = high-performance liquid chromatography; HRMS = high resolution mass spectroscopy; IPA = isopropyl alcohol; LAH = lithium aluminum hydride; LC = liquid chromatography; LDA = lithium diisopropylamide; LRMS = low resolution mass spectroscopy; mCPBA = meta-chloroperbenzoic acid; MeOH = methanol; NBS =
N-bromosuccinimide; NMP = N-methyl pyrrolidinone; NMR = nuclear magnetic resonance; Ph = phenyl; PMB = para-methoxybenzyl; TEA = triethylamine; TFA = trifluoroacetic acid; THF = tetrahydrofuran; Tos = tosyl.
The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily obtainable starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above.
Scheme A depicts a general method suitable for the preparation of compounds of the invention with a nitrogen atom in ring B adjacent to a carbon shared with ring A, wherein the fused bicyclic A-I is coupled with l-Boc-lH-pyrazolo[3,4-b]pyridin-3-yl methylene bromide A-2 in the presence of a base (e.g., an alkali metal carbonate such as CsCO3) and then the Boc protective group is removed by treating the coupled product with a suitable acid (e.g., TFA) to afford A-3. An alkyl group can be introduced at the 1 -position of the pyrazolopyridinyl group by reaction of A-3 with an alkyl halide. Scheme A
Figure imgf000062_0001
Representative examples of starting substrate A-I include the following:
Figure imgf000062_0002
Substrates of Formula A-Ia can be prepared in accordance with Scheme B:
Figure imgf000063_0001
Substrates of Formula A-Ib can be prepared in accordance with Scheme B1:
Figure imgf000063_0002
Representative methods for preparing reactants of formula A-I and A-2 are further described in the examples below.
Scheme C depicts the preparation of benzotriazolyl compounds of the present invention, wherein the nitro group on the 2-amino-nitrobenzene derivative C-I can be reduced to the corresponding dianiline C-2 through catalytic hydrogenation or by the action of tin II chloride. The dianiline can undergo cyclization to the corresponding triazole C-3 upon diazotization. Alkylation of the triazole can be accomplished through reaction with a suitable electrophile such as R.6 (which may require protection) in the presence of a base to afford either C-4 or C-6.
Scheme C
Figure imgf000063_0003
Scheme D depicts the preparation of pyrazolopyridine and imidazopyridine compounds of the invention, wherein a hydrazino or aminomethyl pyridine D-I can be acylated with the requisite carboxylic acid to provide acylate D-2, which can be cyclized dehydratively using phosphorous oxychloride to afford D-3. Scheme D
Figure imgf000064_0001
D = CH2 Or NH E = CH or N
Scheme E depicts the preparation of benzopyrazolyl and indazolyl compounds of the invention wherein the arylboronic acid E-I can be coupled with a suitable phenol or aniline (i.e., RlXH) in the presence of a copper carboxylate (e.g., copper acetate) to provide the aryl ether or aryl amine E-2, which can be deprotonated and acylated to provide aldehyde or ketone E-3. The aldehyde or ketone can be further reacted with hydrazine to afford the corresponding benzopyrazole or indazole penultimate E-4, which can be alkylated with a suitable R.6 halide (R.6 may require protection) to provide the compound of the invention E-5. Scheme E
Figure imgf000064_0002
NHoNH,
Figure imgf000064_0003
Scheme F depicts another route for preparing compounds of the invention, wherein the aryl ether or aryl amine E-2 can be deprotonated and quenched with methylchloroformate to provide the ester IM. Nucleophilic displacement of the fluorine in FA with a suitably protected amine (exemplified by PMB in Scheme F) can provide £^2, which can be converted to the corresponding diamine Fjθ through a Curtius rearrangement. Following deprotection (e.g., treatment of the PMB with acid), the diamine can be converted to a variety of heterocycles including, for example, the triazole F-4 shown in Scheme F. Scheme F
Figure imgf000065_0001
Scheme G depicts a representative preparation of a pro-drug of the present invention, wherein the benzotriazolyl compound of the present invention G-I can be treated with a Boc-protected amine in the presence of a phosgene to afford acylated amine G-2, which can then be deprotected by treatment with a suitable acid (e.g., HCl or TFA) to provide desired prodrug Gθ. Scheme G
Figure imgf000065_0002
In the methods for preparing compounds of the present invention set forth in the foregoing schemes, functional groups in various moieties and substituents (e.g., R.6 in Scheme C, Ho in Scheme E, R6 in Scheme F, as well as other groups explicitly or implicitly referred to in the foregoing schemes) may be sensitive or reactive under the reaction conditions employed and/or in the presence of the reagents employed. Such sensitivity/reactivity can interfere with the progress of the desired reaction to reduce the yield of the desired product, or possibly even preclude its formation. Accordingly, it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. Protection can be achieved by means of conventional protective groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 and in T. W. Greene & P.G.M. Wuts,
Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999, and 2nd edition, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. Alternatively the interfering group can be introduced into the molecule subsequent to the reaction step of concern. The following examples serve only to illustrate the invention and its practice. The examples are not to be construed as limitations on the scope or spirit of the invention. References in the following examples to "room temperature" means a temperature of from about 2O0C to about 25°C.
INTERMEDIATE 1
1 -(tert-Butyl)-3 -(bromomethyl)- 1 H-pyrazolo [3 ,4-b]pyridine- 1 -carboxylate
Figure imgf000066_0001
Intermediate I was prepared in accordance with the procedure described in Henke et al., J. Med. Chem. 1997, 40: p. 2706. More particularly:
Step 1: l-(2-fluoropyridine-3-yl)ethanone
A solution of 3.13 mL (30.90 mmol) of freshly distilled diisopropylamine in 10 mL of anhydrous THF under nitrogen cooled to -78°C was treated dropwise with 19.31 mL (30.90 mmol) of a 1.6 M solution of n-BuLi in hexanes. The resulting solution was stirred at - 780C for approximately 20 minutes, and was briefly (5-10 minutes) warmed to -400C, then recooled to -78°C. At 30 minutes post addition, 3.0Og (30.90 mmol) of 2-fluoropyridine was added dropwise to the reaction. The resulting solution was stirred at -780C for 30 minutes. The reaction was treated dropwise with a solution of 3.16 mL (30.90 mmol) of the Weinreb amide (i.e., N-methoxy-n-methylacetamide) in 30 mL of THF. The resulting solution was stirred 18 hours, allowing the bath to slowly evaporate and the reaction temperature to rise to room temperature. The reaction was treated with 5 mL of IN HCl, and was concentrated to remove most of the THF. The residue was extracted twice with EtOAc, and the combined extracts were washed with IN HCl, saturated aqueous NaHCO3 solution, and brine, and were dried over anhydrous MgSθ4. Filtration and concentration of the filtrate provided a crude orange oil, which was purified by flash chromatography over silica gel with 3:1 hexanes/EtOAc to provide 1.10 g of the title product as an orange oil. lH NMR (CDCI3): δ 2.72(s,3H), 7.33(m,lH), 8.34(m,lH), 8.41(m,lH).
Step 2: 3-methyl-lH-pyrazolo[3,4-b]pyridine (36-2)
Figure imgf000067_0001
A stirred solution of 1.1 Og (7.91 mmol) of l-(2-fluoropyridine-3-yl)ethanone in 5 mL of ethylene glycol under nitrogen was treated with 265 μL (8.31 mmol) of hydrazine. This solution was stirred for 2 hours at room temperature and then heated at 165°C for 1.5 hours. The solution was cooled to room temperature, poured into CH2CI2 (25 mL), and extracted with H2O (2x50 mL). The organic portions were combined, dried (MgSO4), filtered and concentrated in vacuo to give the title product as a fluffy off-white solid. lH NMR (CDCI3): δ 2.6 l(s, 3H), 7.14(m,lH), 8.06(dd,lH), 8.58(dd,lH), 11.18(br s, IH).
Step 3 : tert-butyl 3 -methyl- 1 H-pyrazolo [3 ,4-b]pyridine- 1 -carboxylate
Figure imgf000067_0002
A stirred solution of 692 mg (5.20 mmol) of 3-methyl-lH-pyrazolo[3,4-b]pyridine in 25 mL of acetonitrile under nitrogen was cooled to O0C in an ice bath, and was treated with 635 mg (5.20 mmol) of DMAP and 761 μL (5.46 mmol) of triethylamine. A solution of 1.36 g (6.24 mmol) of (BOC)2θ in 5 mL acetonitrile was then added dropwise using an addition funnel.
Upon completion of addition, the ice bath was removed and the mixture was stirred for an additional 18 hours at room temperature. Solvent was removed in vacuo, and the residue was partitioned between EtOAc and H2O. The organic layer was separated, dried (MgSO4), filtered and concentrated in vacuo to an orange oil. This crude material was purified by flash chromatography over silica gel with 1 : 1 ethyl acetate/hexanes to give the title product as a clear oil. IH NMR (CDCIS): δ 1.74(s,9H), 2.60(s,3H), 7.29(m,lH), 8.02(dd,lH), 8.74(dd,lH).
Step 4 : 1 -(tert-butyl)-3 -(bromomethyl)- 1 H-pyrazolo [3 ,4-b]pyridine- 1 -carboxylate
A stirred solution of 934 mg (4.00 mmol) of tert-butyl 3 -methyl- 1 H-pyrazolo [3 ,4- b]pyridine-l -carboxylate in 10 mL of CCI4 was heated to reflux, and then a mixture of 783 mg
(4.40 mmol) of NBS and 97 mg (0.40 mmol) of benzoyl peroxide was added portion- wise over 5 minutes as a solid. The resulting solution was heated at reflux for 5 hours and then allowed to cool to room temperature. The reaction mixture was filtered through a pad of Celite to remove precipitated succinimide, and the filtrate was concentrated in vacuo. The crude residue was purified by flash chromatography over silica gel with 1 :2 ethyl acetate/hexanes to the title product as a solid. lH NMR (CDCI3): δ 1.76(s,9H), 4.78(s,2H), 7.35(q,lH), 8.24(dd,lH), 8.77(dd,lH).
INTERMEDIATE 2 3 -(Chloromethyl)-N, 1 -bis(4-methoxybenzyl)- 1 H-pyrazolo [3 ,4-b]pyridin-6-amine
Figure imgf000068_0001
Step 1 : tert-Butyl 6-fluoro-l-(4-methoxybenzyl)-lH-pyrazolo[3,4-b]pyridine-3- carboxylate
Figure imgf000068_0002
To a solution of tert-butyl 6-fluoro-lH-pyrazolo[3,4-b]pyridine-3-carboxylate (29.55 g, 125 mmol) in THF (300 mL) cooled in an ice bath was added KOtBu (13.98g, 125 mmol) at such a rate as to maintain the temperature between 5-10°C, and then 4-methoxybenzyl bromide (18.2 mL, 125 mmol) was added. The resulting mixture was stirred in an ice bath for 1 hour and then stirred at room temperature for 18 hours. The resulting suspension was quenched with saturated aqueous NH4CI (200 mL) and then extracted with EtOAc (2x300 mL). The combined organic extracts were washed with brine, dried with MgSθ4 and the solvent removed in vacuo. The resulting residue was purified on a silica gel (100Og) column (0-11% EtOAc/hexanes) to give the title compound. LRMS (M+l)=380.1
Step 2: tert-Butyl l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH-pyrazolo[3,4- b]pyridine-3 -carboxylate
Figure imgf000069_0001
To a solution of tert-butyl 6-fluoro-l-(4-methoxybenzyl)-lH-pyrazolo[3,4- b]pyridine-3 -carboxylate (2.55g, 7.14 mmol) in NMP (30 mL) was added 4-methoxybenzylamine (2.80 mL, 21.41 mmol). The resulting mixture was then heated to 80°C for 2 hours, after which the mixture was diluted with water (200 mL) and extracted with EtOAc (2x200 mL). The combined extracts were washed with water (100 mL), dried with MgSθ4, filtered, absorbed onto silica gel (17 g) and removed the solvent in vacuo. This solid was purified on silica gel (80 g) column (0-100% EtOAc/CH2Cl2 to give the title compound. LRMS (M+l)=474.0
Step 3: { l-(4-Methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH-pyrazolo[3,4-b]pyridin-
3 -yl} methanol
Figure imgf000069_0002
To a solution of tert-butyl l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH- pyrazolo[3,4-b]pyridine-3-carboxylate (2.65 g, 5.58 mmol) in 30 mL THF cooled in an ice bath was added a 2M solution of LiAlH4 in THF (3.49 mL, 6.98 mmol). The resulting mixture was stirred cold for 20 minutes and then warmed to room temperature and then left at room temperature for 2.5 hours. The mixture was then diluted with THF (50 mL) and then treated sequentially with water (265 μL), 15% NaOH (265 μL) and water (795 μL) and then stirred for 30 minutes. The resulting suspension was filtered through diatomaceous earth and the resulting cake was rinsed with THF (50 mL). The combined filtrates were preabsorbed onto silica gel (15) and the solvent removed in vacuo. This solid was purified on silica gel (80g) column (0-20% MeOH/CH2Cl2) to give the title compound. LRMS (M+l)=404.9
Step 4 : 3 -(Chloromethyl)-N, 1 -bis(4-methoxybenzyl)- 1 H-pyrazolo [3 ,4-b]pyridin-6-amine
To a slurry of { l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH- pyrazolo[3,4-b]pyridin-3-yl}methanol (1.49g, 3.68 mmol) in chloroform (15 mL) cooled in an ice bath was added thionyl chloride (538 μL, 7.37 mmol). The resulting mixture was then allowed to warm to room temperature and left at room temperature for 30 minutes. The reaction was determined by LCMS monitoring not to be completenot complete, so the reaction mixture was re-cooled in an ice bath, treated with additional thionyl chloride (100 μL), and then stirred at room temperature for 30 minutes. The reaction mixture was then poured into aqueous NaHCθ3, extracted into CHCI3 and the solvent removed in vacuo. This residue was purified on a silica gel (12Og) column (0-60% EtOAc/CHCl3 to give the title compound. LRMS (M+l )=422.9
EXAMPLE 1
3 -Chloro-5- { [5-chloro- 1 -( 1 H-pyrazolo[3 ,4-6]pyridin-3 -ylmethyl)- 1 H-indazol-4- yl]oxy}benzonitrile
Figure imgf000070_0001
Step 1: 3-Bromo-5-chlorophenyl 2-chloro-5-fluorophenyl ether
Figure imgf000070_0002
To a solution of 2-chloro-5-fluorophenol ( 82.3 g, 562 mmol) and l-bromo-3- chloro-5-fluorobenzene (124g, 590 mmol) in NMP (200 mL) was added potassium carbonate (155g, 1.123mol). The resulting mixture was then heated to 140°C and maintained at 1400C for 30 hours, after which the mixture was poured into water (1500 mL) and extracted with EtOAc (2500 + 1500 mL). The combined extracts were washed with water and brine. This solution was concentrated on the rotary evaporator and the residue was distilled at high vacuum at 135-19O0C to give the title compound as a clear, colorless liquid. lH NMR (CDCI3) δ 7.45 (dd, IH, J=9.0 and 4.5 hz), 7.28(dd, IH, J=UHz), 7.26(s, IH), 7.00(dd, Ih, J=I.95Hz), 6.92(ddd, IH, J=10.5, 7.6 and 2.7Hz), 6.89(dd, IH, J=I.95Hz).
Step 2: 2-(3-Bromo-5-chlorophenoxy)-3-chloro-6-fluorobenzaldehyde
Figure imgf000071_0001
To a solution of 3-bromo-5-chlorophenyl 2-chloro-5-fluorophenyl ether (10Og, 298 mmol) in THF (300 mL) cooled to -78°C over a dry ice/acetone bath was added 1.8M lithium diisopropylamide in hexanes/THF/ethylbenzene (174 mL, 313 mmol) over lOmin. The resulting mixture was stirred for 20 minutes and then treated with DMF (46.1 mL, 595 mmol). The DMF-treated mixture was then removed from the cooling bath and allowed to warm to room temperature and then left at room temperature for 1 hour. The reaction mixture was then quenched with water (1000 mL) and extracted with EtOAc (3x500 mL). The combined extracts were washed with water (500 mL), dried over MgSθ4, and concentrated in vacuo. This residue was purified on a silica gel column (0-40% CH2C12/hexanes) to give the title product. LRMS (M-18+1) =346.7
Step 3: 4-(3-Bromo-5-chlorophenoxy)-5-chloro-lH-indazole
Figure imgf000071_0002
To a suspension of 2-(3-bromo-5-chlorophenoxy)-3-chloro-6-fluorobenzaldehyde (77.5g, 213 mmol) in ethanol (120 mL) was added hydrazine hydrate (31 mL, 639 mmol). The resulting mixture was then heated at reflux for 4 days, after which the mixture was cooled to room temperature, diluted with water (100 mL) and the resulting solid was filtered. The solid was absorbed onto silica gel (30Og) and purified on a silica gel (1500g) column (0-40% EtOAc/CH2Cl2) to give the title product as a white solid. LRMS (M+l)=358.8
Step 4: 3-Chloro-5-[(5-chloro-lH-indazol-4-yl)oxy]benzonitrile
Figure imgf000072_0001
To a suspension of 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-indazole (4Og, 112 mmol) and zinc cyanide (15.74g, 134 mmol) in DMF (400 mL) was added palladium tetrakis triphenylphosphine (38.7g, 33.5 mmol) and heated to 90°C for 1 hour. After this time, the reaction was cooled to room temperature and partitioned between saturated aq. NH4CI (500 mL), water (500 mL) and EtOAc (2x1000 mL). The combined extracts were dried over MgSθ4, absorbed onto silica gel (200 g) and the solvent removed in vacuo. This solid was purified on a silica gel (1000 g) column (0-10% EtOAc/CH2Cl2) to give the title compound as a white solid.
LRMS (M+l)=303.9
Step 5: 3-Chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-ό]pyridin-3-ylmethyl)-lH-indazol-4- yl] oxy } benzonitrile
To a suspension of 3-chloro-5-[(5-chloro-lΗ-indazol-4-yl)oxy]benzonitrile (24g, 79 mmol) and tert-butyl 3-(bromomethyl)-lH-pyrazolo[3,4-b]pyridine-l-carboxylate (= Intermediate 1; 24.63g, 79 mmol) in DMF (150 mL) at O0C was added cesium carbonate (51.4g, 158 mmol). The resulting mixture was allowed to warm to room temperature and then stirred at room temperature for 2 hours, after which the mixture was partitioned between water (1000 mL) and EtOAc (1000 mL). The organic extract was washed with water (1000 mL) and then with brine (200 mL), dried over MgSθ4 and the solvent removed in vacuo. This residue was purified on a silica gel (500 g) column (0-10% acetonitrile/CH2Cl2) to give the the Boc-protected form of the title compound. This material was dissolved in TFA (50 mL) and allowed to stand at room temperature for 10 minutres, after which the solvent was removed in vacuo. The resulting solid was then preabsorbed onto silica gel (50 g) and purified on silica gel (330 g) column (10-30% acetonitrile/CH2Cl2) to give the title compound as a white solid. lH NMR (DMSO- d6): δ 13.65 (s, IH)5 8.49 (d, J=4.6Hz, IH), 7.91 (d, J=8.3Hz, IH). 7.89 (s, IH), 7.82 (d, J= 8.8Hz, IH), 7.62 (d, J= 8.6Hz, IH), 7.47 (m, IH), 7.39 (m, IH), 7.13 (dd, J= 7.7 and 4.6Hz, IH), 6.05 (s, 2H) ppm. LRMS (M+l)= 434.7
EXAMPLE IA Alternative preparation of 3-chloro-5-{[5-chloro-l-(l//-pyrazolo[3,4-6]pyridin-3-ylmethyl)-lH- indazol-4-yl] oxy } benzonitrile
Step 1: 3-Bromo-5-chlorophenyl 2-chloro-5-fluorophenyl ether A round bottom flask (100 L) was charged with K2CO3 (11.410 kg; 82.56 moles; 3.00 eqs.), DMSO (40 L), and l-bromo-3-chloro-5-fluorobenzene (5.82 kg, 27.79 moles; 1.00 eq.). The resulting white slurry was degassed for 10 minutes using a subsurface stream of nitrogen, after which 2-chloro-5-fluorophenol (1.2 kg) was added through a dropping funnel. The reaction mixture was then heated to 150°C, and a second portion 2-chloro-5-fluorophenol (4.56 kg) was added in batches of about 0.5-0.6 kg batch over 7 hours. The mixture was then aged at 150°C for 12 hours, and cooled to room temperature. About half of the mixture was transferred to an extractor (100 L) filled with water (30 L), extracted with heptane (45 L), and then washed with water (18 L). The other half of the mixture was worked up in the same manner. The combined organic layers were filtered through a silica pad (22 kg), washed with heptane (50 L), and concentrated on a rotavap with a bath temperature of 50°C-60°C to provide a clear colorless viscous oil that solidified after cooling to room temperature.
Step 2: 2-(3-Bromo-5-chlorophenoxy)-3-chloro-6-fluorobenzaldehyde A round bottom flask was charged with diisopropylamine (1.336 kg, 13.20 moles;
1.2 eqs.) and THF (25 L), and the mixture cooled to -16°C in a dry ice/acetone bath. A solution of n-butyl lithium (2.5 M; 12.65 moles; 1.17 eqs.) in hexane was added over 25 minutes, while keeping the temperature below 10C, after which the mixture was aged 20 minutes and then cooled to below -70°C. 3-Bromo-5-chlorophenyl 2-chloro-5-fluorophenyl ether (3.638 kg; 10.8 moles; 1.0 eq.) in THF (4 L) was then added over 35 minutes. The reaction mixture was kept below -6O0C and aged for 1.5 hours, after which DMF (3.683 kg; 50.4 moles; 1.2 eq.) was added over 15 minutes. After aging the mixture a further 50 minutes, the reaction mixture was warmed to -20°C and quenched with water (5 L). The mixture was then warmed to 15°C, transferred to an extractor (100 L) filled with water (20 L), and extracted with EtOAc (28 L). The organic layer was washed with water (22 L), IN HCl (25 L), and brine (18 L), and then concentrated to 15L. Heptane (25 L) was added to the concentrate, and the resulting solution was heated to 6O0C and then concentrated to 18 L as it was cooled to 11°C. The dark yellow suspension was filtered and washed with heptane (5 L), and dried overnight to provide the title product as a solid.
Step 3: 4-(3-Bromo-5-chlorophenoxy)-5-chloro-lH-indazole
A suspension of 2-(3-bromo-5-chlorophenoxy)-3-chloro-6-fluorobenzaldehyde fluorobenzaldehyde (4.5 kg; 12.36 moles; 1.0 eq.) in DMSO (18 L) was degassed, after which hydrazine monohydrate (6.192 kg; 123.7 moles; 10.0 eqs.) was added over 20 minutes at room temperature. The reaction solution was degassed again, stirred at room temperature for 15 minutes, heated to 73°C, and then aged for 16 hours. After the mixture was cooled to room temperature, isopropanol (15 L) and then water (40 L) were added, and the resulting mixture cooled to room temperature, filtered under pressure, and washed with isopropanol:water (1 :2; 10 L), water (12 L), and heptane (12 L). The title product as a solid was obtained after drying at 30°C-35°C under vacuum for four days.
Step 4: 3-Chloro-5-[(5-chloro-lH-indazol-4-yl)oxy]benzonitrile Bromine (154 g; 0.964 mole; 0.10 eq.) was added to a slurry of zinc (particle size
< 10 microns; 192 g; 2.940 moles; 0.30 eq.) in DMF (10 L) at room temperature. The resulting mixture was then stirred fast for 30 minutes while 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH- indazole (3.508 kg; 9.798 moles; 1.00 eq., zinc cyanide (690 g; 5.879 moles; 0.60 eq.), triphenylphosphine (308 g; 1.176 moles; 0.12 eq.), palladium acetate (66 g; 0.294 mole; 0.03 eq.) and DMF (11 L) were added at room temperature. The reaction mixture was then degassed for 15 minutes using a subsurface stream of nitrogen, heated to 85°C, and then aged for 4.5 hours. The reaction mixture was then cooled to room temperature and stirred overnight. The reaction mixture was then diluted with THF (18 L) and heated to 500C, after which aqueous EDTA 3Na (0.5M, 20L) was added and the mixture aged at 50°C-60°C for 1 hour. The mixture was then filtered through solka floe and washed with THF (20L), and the filtrate transferred to an extractor (100 L) filled with brine (15L) and separated. The aqueous layer was extracted with EtOAc (15 L), and the combined organic layers were washed with a second portion of EDTA 3Na (0.5M, 20L), then water (20 L), and then brine (15 L). The solution was treated with activated carbon (Darko KB), filtered through solka floe, concentrated to a slurry of less than 10 L, switched to toluene (6 L), concentrated to half volume, heated to 40°C, added heptane (6 L), and cooled below 25°C. The resulting slurry was filtered, washed with extra toleuene:heptane (1 :3; 4 L), heptane (4 L), and dried to provide the title product as a solid.
Step 5: 3-chloro-5-{[5-chloro-l-(l-t-butyloxycarbonyl-lH-pyrazolo[3,4-6]pyridin-3- ylmethyl)-lH-indazol-4-yl]oxy}benzonitrile
A 4-necked round bottom flask (75 L) under nitrogen and equipped with a mechanical stirrer, a thermocouple and an addition funnel was placed on a steam bath. 3-Chloro- 5-[(5-chloro-lH-indazol-4-yl)oxy]benzonitrile (2.07 kg; 6.12 moles; 1.0 eq.), l-(tert-butyl)-3- (bromomethyl)-lH-pyrazolo[3,4-b]pyridine-l-carboxylate (2.48 kg; 7.95 moles; 1.30 eqs.) were charged to the flask, followed by the addition of DMF (11.2 L). The mixture was cooled to 3.1°C with ice-water, after which DBU (1.46 L; 9.79 moles; 1.60 eqs.) was added over 30 minutes while keeping the internal temperature below about 21°C. The reaction mixture was then cooled to 60C and aged at that temperature until complete conversion of the indazole as determined by HPLC. MTBE (10 L), AcOEt (5 L), H2O (10 L) were then added and the mixture transferred to an extractor (100 L). The flask was rinsed with MTBE (1.2 L), EtOAc (1.2 L) and H2O (1.2 L), the rinse was stirred for 10 minutes, and then allowed to settle. The aqueous layer was cut away, and the organic layer was drummed off. The aqueous layer was transferred to the extractor, after which MTBE (7.4 L) and EtOAc (3.7 L) were added, and the mixture stirred for 10 minutes, and then allowed to settle. The aqueous layer was cut away. The first organic layer was transferred to the extractor, and the drum was rinsed with MTBEiEtOAc (2:1; 1.5 L). Water (11.2 L) was added to the extractor, and the mixture was stirred for 10 minutes, then allowed to settle. The aqueous layer was cut away, the organic layer was drummed off, and the extractor was rinsed with AcOEt (I L x 2). The combined organic layers were concentrated in vacuo with rotavap at a bath temperature of 30°C-35 °C to 4.775 kg (with solvent). The concentrate was then separated via a silica gel column (40 kg) using heptane-EtOH. The desired fractions were concentrated in a round bottom flask (75 L) using a batch concentrator to about 15 L. EtOAc (4 L) was added to the concentrate and the mixture stirred at room temperature overnight. The resulting crystalline slurry was then heated to 45 °C, stirred for 40 minutes at 45 °C and then allowed to cool to room temperature. The crystals were then separated by filtration using a filter pot, and the resulting wet cake was rinsed with EtO Ac-heptane (1 :2; 6 L) and then dried with a nitrogen stream to afford the desired title product as crystals.
Step 6 : 3 -Chloro-5- { [5-chloro- 1 -( 1 H-pyrazolo [3 ,4-ό]pyridin-3 -ylmethyl)- 1 H-indazol-4- yl] oxy } benzonitrile
A jacketed reaction vessel (30 L) equipped with a thermocouple was charged with 3 -chloro-5- { [5-chloro- 1 -( 1 -t-butyloxycarbonyl- 1 Η-pyrazolo [3 ,4-6]pyridin-3 -ylmethyl)- 1 Η- indazol-4-yl]oxy}benzonitrile (1.338 kg; 2.499 moles; 1.0 eq.) and then with DMF (10.7 L) and IPA (2.68 L). Concentrated HCl (2.68 L) was then charged to the veseel during which time the internal temperature rose from 16°C to 44°C. The mixture was then heated to 60 °C. After 1 hour at 600C, the suspension became a clear solution. Conversion was complete after 1.75 hours as determined by ΗPLC, at which point the reaction mixture was transferred into a 4-necked round bottom flask (75 L) at 55°C-60°C via an in-line filter. The reaction vessel was rinsed with IPA (2 L x 2), and the rinse transferred to the flask via the in-line filter. Filtered water (16 L) was then added to the mixture via an additional funnel while maintaining the temperature at 55°C-60°C, during which crystallization of the title product began. Upon completion of the water addition, the mixture was stirred at 55°C for 40 minutes, then cooled to room temperature and filtered with a filter pot. The wet cake was rinsed with filtered IPA: water (3:7, 10 L), and then with filtered water (7 L x 6), and then dried in a vacuum oven at 40°C for two days to afford the title product.
EXAMPLE 2 3 -Chloro-5 - { [3 ,5-dichloro- 1 -( 1 Η-pyrazolo[3 ,4-b]pyridin-3 -ylmethyl)- 1 H-indazol-4- yl]oxy} benzonitrile
Figure imgf000076_0001
Step 1 : 3-Chloro-5-[(3,5-dichloro-lH-indazol-4-yl)oxy]benzonitrile
Figure imgf000076_0002
To a solution of 3-chloro-5-[(5-chloro-lH-indazol-4-yl)oxy]benzonitrile (lOOmg, 0.329 mmol) in DMF (1 mL) was added 1.0M KOtBu in THF (329 μL, 0.329 mmol) and then N- chlorosuccinimide (44mg, 0.329 mmol). The resulting reaction mixture was then stirred for 10 minutes, after which the mixture was purified on a LUNA column (10 μ, Cl 8, 250x21.2 cm) eluting with 5-95% ACN/water with 0.1% TFA) to give the title compound. LRMS (M+l)=337.9
Step 2 : 3-Chloro-5- { [3 ,5 -dichloro- 1 -( 1 H-pyrazolo [3 ,4-b]pyridin-3-ylmethyl)- 1 H-indazol-
4-yl]oxy}benzonitrile
To a solution of 3-chloro-5-[(3,5-dichloro-lH-indazol-4-yl)oxy]benzonitrile (42 mg, 0.124 mmol) in DMF (1 mL) was added tert-butyl 3-(bromomethyi)-lH-pyrazolo[3,4- b]pyridine-l-carboxylate (38.7mg, 0.124 mmol) and cesium carbonate (81mg, 0.248 mmol). The resulting mixture was stirred at room temperature for 2 hours, after which the reaction mixture was partitioned between water (2 x 5 mL) and EtOAc (10 mL). The organic extract was dried over MgSθ4, and the solvent removed in vacuo. This residue was purified on a silica gel (12 g) column (0-20% EtOAc/CH2Cl2) to give the Boc protected compound. This material was dissolved in TFA (2 mL) and allowed to stand for 10 minutes, after which the reaction mixture was concentrated in vacuo and the resulting residue was azeotroped from acetonitrile (2x3 mL) to give the title compound.. lH NMR (CDCl3): δ 8.71 (dd, J= 1.71 and 4.64Hz, IH), 8.01 (dd, J= 1.7 and 7.9Hz, IH), 7.53
(d, J=9.0Hz, IH), 7.48 (d, J= 9.0Hz, IH), 7.33 (m, IH), 7.25 (m, IH), 7.10 (m, IH), 6.91 (m, IH) and 5.89 (s, 2H) ppm. EXAMPLE 3
3 - { [5-Chloro-4-(3 -chloro-5-cyanophenoxy)- 1 H-indazol- 1 -yl]methyl } - 1 H-pyrazolo [3 ,4- 6]pyridin-6-aminium chloride. (Alternative name: 3-({l-[(6-Amino-lH-pyrazolo[3,4-b]pyridine- 3-yl)methyl]-5-chloro-lH-inda2;ol-4-yl}oxy)-5-chlorobenzonitrile, HCl salt)
Figure imgf000077_0001
Step 1: 3-Chloro-5-{[5-chloro-l-({l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-
1 H-pyrazolo [3 ,4-b]pyridin-3 -yl } methyl)- 1 H-indazol-4-yl]oxy } benzonitrile
Figure imgf000077_0002
3-chloro-5-[(5-chloro-lH-indazol-4-yl)oxy]benzonitrile (0.677 g, 2.225 mmol) and lithium tert-butoxide (0.178 g, 2.225 mmol) were dissolved in DMF (5 mL) and allowed to stir for 5 minutes. To this mixture at O0C was added 3-(chloromethyl)-N,l-bis(4- methoxybenzyl)-lΗ-pyrazolo[3,4-b]pyridin-6-amine ( Intermediate 2; 0.896 g, 2.119 mmol) as a solution in DMF (5 mL). The mixture was then allowed to warm to room temperature overnight, after which aqueous ammonium chloride (20 mL) was added and the mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic fractions were washed with water (5 x 50 mL), dried over MgSθ4, filtered and concentrated under reduced pressure. The resulting residue was subjected to automated silica gel chromatography eluting with a gradient of 0-10% ethyl acetate in dichloromethane to yield the title product. LRMS (M+l) = 691.8
Step 2: 3-({ l-[(6-Amino-lH-pyrazolo[3,4-b]pyridin-3-yl)methyl]-5-chloro-lH-indazol-4- yl} oxy)-5 -chlorobenzonitrile
Figure imgf000078_0001
3 -chloro-5- { [5 -chloro- 1 -( { 1 -(4-methoxybenzyl)-6- [(4-methoxybenzyl)amino] - 1 H- pyrazolo[3,4-b]pyridin-3-yl}methyl)-lH-indazol-4-yl]oxy}benzonitrile (0.848 g, 1.228 mmol) was dissolved in TFA (10 mL) and placed in an oil bath at 750C. After 2.5 hours, the reaction mixture was allowed to cool to room temperature and was concentrated under reduced pressure. The resulting residue was suspended in a chloroform and ethyl acetate mixture (4:1, 200 mL) and aqueous sodium bicarbonate (50 mL) was added. Ethyl acetate was then added until both phases had become solutions. The organic phase was separated and the aqueous phase was washed with chloroform (2 x 100 mL). The combined organic fractions were dried over MgSθ4, filtered and concentrated under reduced pressure. The resulting residue was subjected to automated silica gel chromatography eluting with a gradient of 0-10% methanol in chloroform to yield the title product. lΗ NMR (DMSO- do): δ 12.60 (s, 1Η), 7.86 (s, 1Η), 7.81-7.78 (m, 1Η), 7.73 (d, J=
9.0 Hz, IH), 7.58 (d, J= 9.0 Hz, IH), 7.49-7.47 (m, IH), 7.38-7.34 (m, 2H), 6.30 (s, 2H), 6.21 (d, J= 8.8 Hz, IH), 5.82 (s, 2H). LRMS (M+ 1) = 449.7
Step 3 : 3 - { [5 -Chloro-4-(3 -chloro-5 -cyanophenoxy)- 1 H-indazol- 1 -yl] methyl } - 1 H- pyrazolo [3 ,4-ό]pyridin-6-aminium chloride
To 3-({ l-[(6-amino-lH- pyrazolo[3,4-b]pyridin-3-yl)methyl]-5-chloro-lH- indazol-4-yl}oxy)-5-chlorobenzonitrile (0.936 g, 2.079 mmol) as a solution in 20% methanol in chloroform (300 mL) was added IN HCl (2.079 mL, 2.079 mmol), and the resulting mixture was then concentrated under reduced pressure. The resulting white paste was diluted with acetonitrile (100 mL) and the solvent evaporated in vacuo. The dilution-evaporation was repeated twice more for a total of three times. The resulting residue was placed under vacuum overnight to give product. lΗ NMR (DMSO-d6): δ. 7.91 (s, 1Η), 7.81 (s, 3Η), 7.68-7.60 (m, 2H), 7.48 (s, IH), 7.37 (s, IH), 6.50-6.30 (m, 2H), 6.00-5.86 (m, 2H). HRMS (M+ 1) = 450.06
EXAMPLE 4
3 -chloro-5- { [5-chloro- 1 -( 1 //-pyrazolo[3 ,4-6]pyridin-3 -ylmethyl)- IH-1 ,2,3 -benzotriazol-4- yl]oxy} benzonitrile
Figure imgf000079_0001
Step 1 : l-(4-methoxybenzyl)-lH-l,2,3-benzotriazol-4-ol
Figure imgf000079_0002
4-Methoxy-benzylbromide (2.976 g, 14.80 mmol) was added to a stirred suspension of 4-hydroxy-benztriazole (2.0 g, 14.80 mmol) and cesium carbonate (9.645 g, 29.6 mmol) in DMF (30 mL) at room temperature and the reaction mixture was stirred for 1 hour. Aqueous ammonium chloride (30 mL) was then added to quench the reaction and the mixture was then extracted with ethyl acetate (2 x 100 mL). The organic fractions were combined and concentrated under reduced pressure. The resulting residue was subjected to reverse phase chromatography (5-95% MeCN/H2θ, 0.1% TFA). The product fractions were combined and extracted with dichloromethane (2 x 100 mL). The combined extracts were dried over MgSθ4, filtered and concentrated under reduced pressure to yield the title product. ^H NMR (DMSO d6) δ 10.67 (s, 1, H), 7.29-7.27 (m, 3H), 7.15(d, J=8.3 Hz, IH), 6.88-6.84(m, 2H), 6.63(d, J=7.6Hz, IH), 5.80(s, 2H), 3.71(s, 3H).
Step 2: 5-Ctøoro-l-(4-methoxybenzyl)-lH-l,2,3-benzotriazol-4-ol
Figure imgf000079_0003
To a stirred solution of l-(4-methoxybenzyl)-l//-l,2,3-benzotriazol-4-ol (0.984 g, 3.85 mmol) at O0C in THF (15 mL) was added IN NaOH (3.85 mL, 3.85 mmol). The resulting mixture was then stirred for several minutes, after which N-chloro-succinimide (0.515 g, 3.85 mmol) was added in one portion. The stirred reaction mixture was quenched after 5 minutes at O0C with aqueous ammonium chloride (25 mL) and extracted with dichloromethane (2 x 100 mL). The combined extracts were concentrated under reduced pressure. The resulting residue was subjected to reverse phase chromatography (5-95% MeCN/H2θ, 0.1% TFA). The product fractions were combined and extracted with dichloromethane (2 x 100 mL). The combined extracts were dried over MgSθ4, filtered and concentrated under reduced pressure to afford the title product. lH NMR (DMSO dβ) δ 11.61(s, IH), 7.44(d, J=8.5Hz, IH), 7.30 (d, J=8.5Hz, 2H), 7.23 (d, J=8.6Hz, IH), 6.90(d, J=8.8Hz, 2H), 5.84(s, 2H), 3.71(s, 3H).
Step 3: 3-Chloro-5-{[5-chloro-l-(4-methoxybenzyl)-l//-l,2,3-benzotriazol-4- yl] oxy } benzonitrile
Figure imgf000080_0001
A stirred suspension of 5-chloro-l-(4-methoxybenzyl)-l//-l,2,3-benzotriazol-4-ol (0.050 g, 0.173 mmol), 3-fluoro-5-chloro-benzonitrile (0.081 g, 0.518 mmol) and cesium carbonate (0.068 g, 0.207 mmol) in NMP (1.5 mL) was heated at 14O0C for 72 hours. The reaction mixture was then quenched with aqueous ammonium chloride (25 mL) and extracted with dichloromethane (2 x 100 mL). The combined extracts were concentrated under reduced pressure. The resulting residue was subjected to reverse phase chromatography (5-95% MeCN/H2θ, 0.1% TFA). The product fractions were combined and extracted with dichloromethane (2 x 100 mL). The combined extracts were dried over MgSO-J., filtered and concentrated under reduced pressure to yield the title product. lH NMR (DMSO d6) δ 7.90- 7.88(m, IH), 7.80(s, IH), 7.79-7.75(m, IH), 7.60-7.55(m, 2H), 7.40-7.35(d, J=6.9Hz, 2H), 6.95- 6.88 (m, 2H), 5.80(s, 2H), 3.71 (s, 3H).
Step 4: 3-Chloro-5-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile
Figure imgf000080_0002
3-chloro-5- { [5-chloro- 1 -(4-methoxybenzyl)- IH- 1 ,2,3-benzotriazol-4- yl]oxy}benzonitrile (0.0097 g, 0.023 mmol) was dissolved in TFA (2 mL) and heated at 750C for 2 hours. The reaction mixture was then allowed to cool to room temperature and then concentrated under reduced pressure. The resulting residue was subjected to automated silica gel chromatography eluting with 0-25% ethyl acetate in hexanes to give the title product. LRMS (M+l) = 304.8 Step 5: ter/-Butyl 3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl] methyl } - 1 H-pyrazolo [3 ,4-6] pyridine- 1 -carboxylate
Figure imgf000081_0001
To 3-cWoro-5-[(5-cMoro-lH-l,2,3-ber^otriazol-4-yl)oxy]benzonitrile (0.006 g,
0.020 mmol) and cesium carbonate (0.0077 g, 0.024 mmol) suspended in DMF (1 mL) at room temperature was added tert-butyl 3 -(bromomethyl)-l//-pyrazolo [3 ,4-ό]pyridine-l -carboxylate (= Intermediate 1; 0.0068 g, 0.022 mmol) as a solution in DMF (0.5 mL). After stirring for 1 hour at room temperature, the reaction mixture was quenched with aqueous ammonium chloride (2 mL), and the quenched mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic fractions were washed with water (3 x 10 mL), dried over MgSθ4, filtered and concentrated under reduced pressure. The resulting residue was subjected to automated silica gel chromatography eluting with a gradient of 25-50% ethyl acetate in hexanes to afford the title product. LRMS (M+l) = 435.7
Step 6: 3-Chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-ό]pyridin-3-ylmethyl)-l//-l,2,3- benzotriazol-4-yl]oxy } benzonitrile tert-Butyl 3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl]methyl}-lH-pyrazolo[3,4-ό]pyridine-l-carboxylate (0.001 g, 1.86 μmol) was dissolved in TFA (2 mL) at room temperature. After 5 minutes, the solvent was evaporated in vacuo to afford the title product. lΗ NMR (CDCI3): δ 8.52-8.46 (m, 1Η), 8.35 (d, J= 4.15 Hz, IH), 7.59 (d, J= 8.79 Hz, IH),
7.57 (d, J= 8.78 Hz, IH), 7.36 (s, IH), 7.33-7.27 (m, IH), 6.98 (s, IH), 6.25 (s, 2H). HRMS
(M+l) = 436.05.
EXAMPLE 4A
Alternative preparation of 3 -chloro-5- { [5-chloro- 1 -( 1 H-pyrazolo [3 ,4-2>]pyridin-3 -ylmethyl)- 1 H- l,2,3-benzotriazol-4-yl]oxy}benzonitrile
Step 1 : 2-(3-bromo-5-chlorophenoxy)-l-chloro-3-nitrobenzene 2,3-dichloronitrobenzene (764 mg, 3.99 mmol), 3-bromo-5-chlorophenol (1.65 g,
7.98 mmol) and potassium carbonate (661 mg, 4.79 mmol) were suspended in NMP (5mL) and placed in an oil bath at 12O0C. After 2 hours, the reaction was allowed to cool to room temperature, saturated aqueous ammonium chloride (1OmL) was added and the mixture was extracted with ethyl acetate (2x50mL). The combined organic fractions were washed with dilute brine (4x50 mL), dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by automated column chromatography on silica gel (8Og), eluting with 0-100% CH2Cl2/hexanes to yield the title compound. *H NMR (CD3CN) δ 8.02 (dd, J=8.3Hz, J=I.5 Hz, IH), 7.88 (dd, J=8.2Hz,, J=I.6Hz, IH), 7.52 (dd, J=8.2Hz, J=8.3Hz, IH), 7.38 (m, IH), 7.07 (m, IH), 6.97 (m, IH).
Step 2: 3-(3-bromo-5-chlorophenoxy)-4-chloro-2-nitroaniline
To copper (I) chloride (5.45 mg, 0.055 mmol) and potassium tert-butoxide (247 mg, 2.204 mmol) suspended in DMF (3mL) at 00C was added 1,1,1-trimethylhydrazinium iodide (139 mg, 0.689 mmol). This mixture was allowed to stir for several minutes at which point the mixture was cooled to -4O0C and 2-(3-bromo-5-chlorophenoxy)-l-chloro-3-nitrobenzene (200 mg, 0.551 mmol) as a solution in DMF (1 mL) was added dropwise. The reaction was maintained at -4O0C for 15 minutes and was then quenched at -4O0C with saturated aqueous ammonium chloride (10 mL). Water (1 OmL) was added and the mixture was allowed to warm to room temperature. The mixture was extracted with ethyl acetate (2x50 mL). The combined organic fractions were washed with water (3x50mL), dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by automated column chromatography on silica gel (4Og) eluting with 0-25%EtOAc/hexanes to give the title product. LRMS (M+l) = 378.7.
Step 3: 3-(3-bromo-5-chlorophenoxy)-4-chlorobenzene-l,2-diamine
3-(3-bromo-5-chlorophenoxy)-4-chloro-2-nitroaniline (5.7 g, 15 mmol) and tin(II) chloride dihydrate (17 g, 75 mmol) were suspended in MeOH (10OmL) and heated to 750C under a reflux condenser and N2. After 10 hours, the reaction was allowed to cool to room temperature. The reaction was concentrated under reduced pressure, diluted with ethyl acetate (15OmL) and 10% aqueous sodium carbonate (25OmL) was added with vigorous stirring until the pH was 10. The mixture was filtered through celite. The resulting biphasic filtrate was separated and the aqueous extracted again with ethyl acetate (15OmL). The combined organic fractions were dried (MgSθ4), filtered and the solvent was evaporated under reduced pressure to yield the title product. LRMS (M+l) = 348.7.
Step 4: 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole
3-(3-bromo-5-chlorophenoxy)-4-chlorobenzene-l,2-diamine (4.97 g, 14.3 mmol) in acetic acid (25 mL) was cooled to 15°C under N2 and sodium nitrite (1.08g, 15.7 mmol) in water (39.3 mL) was added dropwise. After 1.5 hours, the reaction was diluted with EtOAc (300 mL), and the organic phase was separated and washed with water (3x100 mL). The organic phase was then dried (MgSO4), filtered, concentrated to afford the title product. LRMS (M+ 1) = 359.7.
Step 5 : 3 -chloro- 5 - [(5 -chloro- 1 H- 1 ,2,3 -benzotriazol-4-yl)oxy] benzonitrile 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole (5.0 g, 14 mmol), tetrakis triphenylphosphine palladium (0) (4.83 g, 4.83 mmol) and zinc cyanide (1.96 g, 16.7 mmol) were suspended in dry DMF (50 mL) under N2 and placed in an oil bath at 9O0C. After 2.5 hours, the reaction was allowed to cool to room temperature. The mixture was diluted with EtOAc (30OmL) and washed with water (4x100 mL), dried (MgSO4), filtered and concentrated with silica gel (20 g). This was purified by automated column chromatography on silica gel (120 g), eluting with 0-30%EtOAc/hexanes to deliver the title compound. LRMS (M+l) = 304.8.
Step 6: te/t-Butyl 3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yljmethyl } - 1 H-pyrazolo [3 ,4-6]pyridine- 1 -carboxylate
Figure imgf000083_0001
To 3-chloro-5-[(5-chloro-l//-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (0.006 g, 0.020 mmol) and cesium carbonate (0.0077 g, 0.024 mmol) suspended in DMF (1 mL) at room temperature was added tert-butyl 3 -(bromomethyl)-l//-pyrazolo [3 ,4-6]pyridine-l -carboxylate (= Intermediate 1; 0.0068 g, 0.022 mmol) as a solution in DMF (0.5 mL). After stirring for 1 hour at room temperature, the reaction mixture was quenched with aqueous ammonium chloride
(2 mL), and the quenched mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic fractions were washed with water (3 x 10 mL), dried over MgSθ4, filtered and concentrated under reduced pressure. The resulting residue was subjected to automated silica gel chromatography eluting with a gradient of 25-50% ethyl acetate in hexanes to afford the title product. LRMS (M+l) = 435.7
Step 7: 3-Chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-6]pyridin-3-ylmethyl)-lH-l,2,3- benzotriazol-4-yl]oxy} benzonitrile tert-Butyl 3 - { [5-chloro-4-(3 -chloro-5 -cyanophenoxy)- IH-1 ,2,3 -benzotriazol- 1 - yl]methyl}-lH-pyrazolo[3,4-6]pyridine-l-carboxylate (0.001 g, 1.86 μmol) was dissolved in
TFA (2 mL) at room temperature. After 5 minutes, the solvent was evaporated in vacuo to afford the title product. IH NMR (CDCIS): δ 8.52-8.46 (m, IH), 8.35 (d, J= 4.15 Hz, IH), 7.59 (d, J= 8.79 Hz, IH), 7.57 (d, J= 8.78 Hz, IH), 7.36 (s, IH), 7.33-7.27 (m, IH), 6.98 (s, IH), 6.25 (s, 2H). HRMS (M+l) = 436.05.
EXAMPLE 5
3 -chloro- 5 -( { 5 -chloro- l-[(7-oxido-l H-pyrazolo [3 ,4-b]pyridin-3 -yl)methyl] - 1 H-indazol-4- yl } oxy)benzonitrile
Figure imgf000084_0001
To a suspension of 3-chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-b]pyridin-3- ylmethyl)- 1 H-indazol-4-yl]oxy}benzonitrile (96mg, 0.22 lmmol) was added mCPBA (59.8mg, 0.243mmol) and stirred at room temperature for 18 hours. The suspension was concentrated in vacuo and then resuspended in DMF (5mL). This suspension was filtered and then purified by reverse phase HPLC (Luna column, lOμ, C 18, 250x21.2 cm) eluting with 5-95% ACN/water with 0.1%TFA). The desired fractions were concentrated to dryness and the resulting solid was suspended in MeOH (ImL) and filtered to give the title compound.
1H NMR (DMSO-d6): δ 8.35 (d, IH, J=6.1Hz), 7.90 (s, IH), 7.82 (d, IH, J=9Hz), 7.80 (dd, IH,
J=1.5Hz), 7.63 (d, IH, J=9Hz), 7.51 (d, IH, J=8.3Hz), 7.47 (m, IH), 7.40 (dd, IH, J=2Hz), 7.12 (dd, IH, J=6 and 8Hz) and 6.06 (s, lH)ppm. LRMS (M+l)=450.8.
EXAMPLE 6
3-({l-[(6-amino-lH-pyrazolo[3,4-6]pyridin-3-yl)methyl]-5-chloro-l//-l,2,3-benzotriazol-4- yl } oxy)- 5 -chlorobenzonitrile
Figure imgf000084_0002
Step 1 : 3 -chloro-5 - { [5 -chloro- 1 -( { 1 -(4-methoxybenzyl)-6- [(4-methoxybenzyl)amino] - 1 H- pyrazolo [3 ,4-6]pyridin-3 -yl } methyl)- IH-1 ,2,3-benzotriazol-4-yl]oxy } benzonitrile
Figure imgf000085_0001
3-chloro-5-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (140 mg, 0.459 mmol) and lithium tert-butoxide (37 mg, 0.459 mmol) were dissolved in DMF (ImL) under N2 and allowed to stir for 20 minutes. After this time, the reaction was cooled to O0C and 3- (chloromethyl)-N, 1 -bis(4-methoxybenzyl)- 1 Η-pyrazolo [3 ,4-b]pyridin-6-amine as a solution in DMF (ImL) was added dropwise. After 1 hour, the reaction was quenched with saturated aqueous ammonium chloride (3mL), diluted with water (3mL) and the mixture was extracted with ethyl acetate (2x25mL). The combined organic fractions were washed with dilute brine (4x1 OmL), dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by automated column chromatography on silica gel (12g), eluting with 0-100% EtOAc/hexanes to give the title compound. LRMS (M+ 1) = 690.5.
Step 2: 3-({ l-[(6-amino-lH-pyrazolo[3,4-ό]pyridin-3-yl)methyl]-5-chloro-l//-l,2,3- benzotriazol-4-yl } oxy)-5 -chlorobenzonitrile 3-chloro-5-{[5-chloro-l-({l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH- pyrazolo [3 ,4-δ]pyridin-3-yl} methyl)- IH-I ,2,3-benzotriazol-4-yl]oxy}benzonitrile (135 mg, 0.195 mmol) was dissolved in TFA (10 mL) and placed in an oil bath at 750C. After 2 hours, the reaction was allowed to cool to room temperature and was concentrated under reduced pressure. The resulting residue was diluted with CΗCl3/EtOAc (4:1, 50 mL) and methanol was added until a solution was achieved. 50% Aqueous sodium bicarbonate (1O mL) was then added. The organic phase was removed and the aqueous was extracted with CHCI3 (25 mL). The combined organic fractions were, dried (MgSO4), filtered and concentrated. The resulting residue was adsorbed onto silica gel with CHCl3/MeOH and purified by automated column chromatography on silica gel (12g), eluting with 0-5%MeOH/CH2Cl2 to afford the title compound. lH NMR (DMSO d-6) δ 7.82 (d, J=9.0Hz, IH), 7.81 (m, IH), 7.75 (d, J=9.0Hz, IH), 7.58 (m, IH), 7.55 (d, J=8.8Hz, IH), 7.52 (m, IH), 6.36 (m, IH), 6.30 (d, J=8.8Hz, IH), 6.16 (s, IH).
EXAMPLE 7
3-chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-b]pyridin-3-ylmethyl)-lH-benzimidazol-4- yl]oxy}benzonitrile dihydrochloride Dihydrocloride salt of:
Figure imgf000086_0001
Step 1 : 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-benzimidazole
A solution of 3-(3-bromo-5-chlorophenoxy)-4-chlorobenzene-l,2-diamine (400 mg, 1.149 mmol) in 90% formic acid (5mL) was heated to 100°C for 1 hour. This mixture was comcentrated in vacuo and then partitioned between ethyl acetate (4OmL) and sat. aq. NaHCθ3 (4OmL). The organic extract was dried over MgSθ4, filtered and concentrated in vacuo to give the desired compound. LRMS (M+l>=358.7.
Step 2: 3-chloro-5-[(5-chloro-lH-benzimidazol-4-yl)oxy]benzonitrile To a solution of 4-(3-bromo-5-chlorophenoxy)-5-chloro-lH-benzimidazole 430 mg, 1.201 mmol) in DMF (5mL) was added palladium tetrakistriphenylphosphine (416 mg, 0.360 mmol) and zinc cyanide (141 mg, 1.201 mmol) and the mixture heated to 90°C for 1 hour. This mixture was partitioned between ethyl acetate (5OmL) and water (2OmL). The organic extract was washed with water (10 mL), dried over MgSO-J., filtered and the solvent removed in vacuo. This residue was purified on silica gel eluting with 0-20% ethyl acetate/methylene chloride to give the title compound. LRMS (M+l)=303.8.
Step 3 : 3 -chloro-5 - { [5-chloro- 1 -( 1 H-pyrazolo[3 ,4-b]pyridin-3 -ylmethyl)- 1 H- benzimidazol-4-yl] oxy } benzonitrile dihydrochloride To a suspension of 3-chloro-5-[(5-chloro-lH-benzimidazol-4-yl)oxy]benzonitrile
(101 mg, 0.332 mmol) and tert-butyl 3-(bromomethyl)-lH-pyrazolo[3,4-b]pyridine-l-carboxylate (104 mg, 0.332 mmol) in DMF (ImL) was added cesium carbonate (216 mg, 0.664 mmol) and the suspension was stirred at room temperature for 2.25 hours. This mixture was diluted with water (1OmL) ans extracted with ethyl acetate (2xl2mL). The combined extracts were washed with water, dried over MgSθ4, filtered and evaporated in vacuo. This residue was purified on silica gel (4Og) column eluting with 0-100% ethyl acetate/methylene chloride. The fractions corresponding to the desired Boc protected product were combined and the solvent removed in vacuo. This residue was redissolved in TFA (3mL) and allowed to stand at room temperature for 10 minutes. The solvent was removed in vacuo and the residue was purified on silica gel (4g) column eluting with 0-10% methanol/methylene chloride gradient. The pure fractions were combined, treated with IN hydrochloric acid and the solvent removed in vacuo to provide title compound. lH NMR (DMSO- do): δ 13.7 (s, IH), 8.58 (s, IH), 8.52 (d, IH, J=4.4Hz), 8.16 (d,
IH, 8.0Hz), 7.74 (dd, IH, J=I .5Hz), 7.63 (d, IH, J=8.8Hz), 7.47 (d, IH, J=8.5Hz), 7.39 (dd, IH, J=1.5Hz), 7.29 (dd, IH, J=2Hz), 7.19 (dd, IH, J=4.5 and 8.1Hz) and 5.92 (s, 2H) ppm. LRMS (M+l)=434.7
EXAMPLE 8 2- [[(3 - { [5 -chloro-4-(3 -chloro-5-cyanophenoxy)- 1 H- 1 ,2,3 -benzotriazol- 1 -yl]methyl } - 1 H- pyrazolo[3,4-&]pyridin- 1 -yl)carbonyl](methyl)amino]-iV-methylethanaminium chloride
Figure imgf000087_0001
Step 1: tert-butyl {2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-
1 -yl] methyl } - 1 H-pyrazolo [3 ,4-ό]pyridin- 1 - yl)carbonyl](methyl)amino] ethyl} methyl carbamate
Figure imgf000087_0002
To a suspension of 3-chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-6]pyridin-3- ylmethyl)-lH-l,2,3-benzotriazol-4-yl]oxy}benzonitrile (117 mg, 0.268 mmol) in dichloromethane (5mL) at O0C was added pyridine (0.043 mL, 0.536 mmol). To this suspension was then added triphosgene (32 mg, 0.107 mmol) as a solid, in one addition, followed by addition of diisopropyl ethylamine (0.198 mL, 1.135 mmol). This suspension was allowed to stir at O0C until a solution was achieved. At this point, 2-[(tert-butoxycarbonyl)amino]-./V- methylethanaminium chloride (120 mg, 0.567 mmol) was added as a solid followed by diisopropyl ethylamine (0.047 mL, 0.268 mmol). The reaction was allowed to warm to room temperature and after 10 minutes, the reaction was diluted with dichloromethane (25mL), washed with water (15mL) and the aqueous layer was re-extracted with dichloromethane (25mL). The combined organic fractions were dried (MgSO4), filtered and concentrated. The resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/Η2O + 0.1% TFA. LRMS (M+ 1) = 549.6.
Step 2: 2-[[(3-{[5-chloro-4-(3-cMoro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl] methyl } - 1 H-pyrazolo [3 ,A-b\ pyridin- 1 -yl)carbonyl] (methyl)amino] -JV- methylethanaminium chloride tert-butyl { 2- [[(3 - { [5-chloro-4-(3 -chloro-5 -cyanophenoxy)- 1 H- 1 ,2,3 -benzotriazol- 1 -yl] methyl } - 1 H-pyrazolo [3,4-6] pyridin- 1 -yl)carbonyl] (methyl)amino] ethyl } methylcarbamate (125 mg, 0.192 mmol) was dissolved in TFA (5mL). After 20 minutes, the reaction was concentrated and the resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/Η2θ + 0.1% TFA. Product fractions were concentrated under reduced pressure and the resulting solid was dissolved in MeCN (3mL), cooled to -780C and IN HCl (5mL) added. This froze and was lyophilized to yield the title compound. lH NMR (DMSO-dβ) δ 8.68 (dd, J=4.5Hz, J=I.5Hz, IH), 8.57 (s, IH), 8.26 (d, J=8.0Hz, IH), 8.11 (s, IH), 7.96 (m, IH), 7.83 (d, J=9.0Hz, IH), 7.72 (m, IH), 7.58 (m, IH), 7.44 (dd, J=4.6Hz, J=8.0Hz, IH), 7.35 (m, IH), 7.28 (m, IH), 6.50 (s, 2H), 3.70 (s, 3H), 3.20 (s, 2H), 3.00 (s, 2H), 2.20 (m, 3H).
EXAMPLE 9
N-(2-chlorobenzyl)-2- [5-chloro-4-(3 -chloro-5 -cyanophenoxy)- IH-1 ,2,3 -benzotriazol- 1 -yl]-N- methylacetamide
Figure imgf000088_0001
3-chloro-5-[(5-chloro-l//-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (25 mg, 0.082 mmol) and lithium tert-butoxide (6.9 mg, 0.089 mmol) were dissolved in DMF (0.5mL) and allowed to stir for 5 minutes. After this time, the reaction was cooled to O0C and 2-chloro-N-(2- chlorobenzyl)-N-methylacetamide as a solution in DMF (0.5mL) was added dropwise. This was allowed to warm to room temperature and after 16 hours, the reaction was quenched with TFA, diluted with MeCN and purified by reverse phase chromatography eluting with 30-95% MeCN/H2θ + 0.1% TFA. Product fractions were lyophilized to yield the title compound. lH NMR (DMSO-d6) δ 7.84 (m, IH), 7.83 (d, J=9.0Hz, IH), 7.79 (d, J=9.0Hz, IH), 7.58 (m, IH), 7.51 (m, IH), 7.47 (m, IH), 7.35 (m, 3H), 6.05 (s, 2H), 4.62 (s, 2H), 3.20 (s, 3H).
EXAMPLE 10
3 -( { 1 -[(6-amino- 1 H-pyrazolo [3 ,4-b]pyridin-3 -yl)methyl]-5-chloro- 1 H-benzimidazol-4-yl } oxy)- 5-chlorobenzonitrile bis(trifluoroacetate)
Figure imgf000089_0001
Step 1 : 3-chloro-5-{[5-chloro-l-({ l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-lH- pyrazolo [3 ,4-b]pyridin-3 -yl } methyl)- 1 H-benzimidazol-4-yl]oxy jbenzonitrile bis(trifluoroacetate)
Figure imgf000089_0002
To an ice bath cooled solution of 3-chloro-5-[(5-chloro-lH-benzimidazol-4- yl)oxy]benzonitrile (48mg, 0.158 mmol) in DMF (ImL) was added lithium t-butoxide (12mg, 0.158 mmol) and stirred for 5 minutes. After this time, 3-(chloromethyl)-N,l-bis(4- methoxybenzyl)-lH-pyrazolo[3,4-b]pyridin-6-amine (44mg, 0.104 mmol) was added and the mixture stirred for 10 minutes over an ice bath. After this time, the reaction mixture was allowed to stir overnight at room temperature. The reaction mixture was then purified by reverse phase HPLC (Luna column, lOμ, Cl 8, 250x21.2 cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the desired compound. LRMS (M+l)=689.5.
Step 2: 3-({l-[(6-amino-lH-pyrazolo[3,4-b]pyridin-3-yl)methyl]-5-chloro-lH- benzimidazol-4-yl}oxy)-5-chlorobenzonitrile bis(trifluoroacetate) A solution of 3-chloro-5-{[5-chloro-l-({l-(4-methoxybenzyl)-6-[(4- methoxybenzyl)amino] - 1 H-pyrazolo [3 ,4-b]pyridin-3 -yl } methyl)- 1 H-benzimidazol-4- yl]oxy}benzonitrile bis(trifluoroacetate) (39 mg, 0.042 mmol) in trifluoroacetic acid (2 mL) was heated to 70°C for 4 hours. After this time, the solvent was removed in vacuo and the residue was purified on a Luna column (lOμ, C 18, 250X21.2cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the desired compound. 1H NMR (DMSO- (tø): δ 12.73 (s, IH), 8.50 (s, IH), 7.74 (dd, IH, J=I .5Hz), 7.62 (br s, IH),
7.59 (s, IH, J=8.8Hz), 7.46 (d, IH, J=8.5Hz), 7.41 (dd, IH, J=I.5Hz), 7.27 (br m, IH), 6.40 (br, 3H) and 5.70 (s, 2H) ppm. LRMS (M+l)=448.8.
EXAMPLE 11 3-chloro-5-{ [5-chloro-l -(2-oxo-2-pyridin-3-ylethyl)- 1 H- 1 ,2,3-benzotriazol-4-yl]oxy}benzonitrile
Figure imgf000090_0001
3-chloro-5-[(5-chloro-l//-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (50 mg, 0.164 mmol) and cesium carbonate (160 mg, 0.492 mmol) were suspended in DMF (1 mL) at room temperature under N2- To this was added 2-bromo-l-pyridin-3-ylethanone (48.3 mg, 0.172 mmol) as a solid. The resulting mixtture was stirred under N2 for 16 hours. The reaction mixture was then diluted with water (2 mL) and extracted with EtOAc (2x15 mL). The combined organic fractions were washed with water (3x10 mL), dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/H2θ + 0.1% TFA. The product was lyophilized to afford the title compound. lH NMR (DMSO-d6) δ 9.30 (s, IH), 8.90 (m, IH),
8.44 (d, J=7.8Hz, IH), 7.88 (d, J=8.8Hz, IH), 7.85 (m, IH), 7.79 (d, J=8.8Hz, IH), 7.68 (m, IH), 7.60 (m, IH), 7.57 (m, IH), 6.68 (s, 2H). HRMS (M+l) = 424.0395
EXAMPLE 12 2-[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l-yl]-N-(2- chlorophenyl)acetamide
Figure imgf000090_0002
To a suspension of [5-chloro-4-(3-chloro-5-cyanophenoxy)-l//-l,2,3- benzotriazol-1-yl] acetic acid (15 mg, 0.041 mmol) (see step 2 in Example 16) in DCM (0.5 mL) was added oxalyl chloride (58 mg, 0.454 mmol). This was followed by addition of DMF (1 drop) and then, following bubbling cessation, by addition of 2-chloroaniline (158 mg, 1.239 mmol). After 10 minutes, the reaction mixture was concentrated, taken up in DMF/MeOH and purified by reverse phase chromatography, eluting with 30-95% MeCN/H2O + 0.1% TFA. The product fraction was lyophilized to yield the title compound. lH NMR (DMSO-d6) δ 10.2 (s, IH), 7.90 (d, J=9.0Hz, IH), 7.83 (m, 2H), 7.75 (d, J=8.3Hz, IH), 7.55 (m, 3H), 7.34 (m, IH), 7.24 (m, IH), 5.85 (s, 2H). HRMS (M+l) = 472.0152. EXAMPLE 13
2-[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l-yl]-N-[3- (trifluoromethyl)pyridin-4-yl]acetamide
Figure imgf000091_0001
To a suspension of [5-chloro-4-(3-chloro-5-cyanophenoxy)-l//-l,2,3- benzotriazol-1-yl] acetic acid (15 mg, 0.041 mmol) (see step 2 in Example 16) in DCM (0.5 mL) was added oxalyl chloride (58 mg, 0.454 mmol), followed by addition of DMF (1 drop) and then, following bubbling cessation, by addition of 3-(trifluoromethyl)pyridin-4-amine (201 mg, 1.239 mmol). After 10 minutes, the reaction mixture was concentrated, taken up in MeOH/DMSO, and purified by reverse phase chromatography eluting with 30-95% MeCN/H2O + 0.1% TFA.
Product fractions were lyophilized to yield the title compound. lH NMR (CDCI3) δ 8.1 (m, 3H),
8.50 (s, IH), 7.75 (d, J=8.8Hz, IH), 7.49 (d, J=8.8Hz, IH), 7.55 (m, 2H), 7.41 (m, IH), 7.27 (m, IH), 7.07 (s, IH), 5.60 (s, 2H). HRMS (M+l) = 507.0363
EXAMPLE 14
2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l-yl]methyl}-lH- pyrazolo[3,4-6]pyridin-l-yl)carbonyl](methyl)amino]ethanaminium chloride (Alternative name: JV-(2-aminoethyl)-3 -{ [5 -chloro-4-(3 -chloro-5 -cyanophenoxy)- 1 H-indazol- 1 -yl] methyl } -JV- methyl-lH-pyrazolo[3,4-ό]pyridine-l-carboxamide, HCl salt)
Figure imgf000091_0002
Step 1 tert-butyl {2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-
1 -yl] methyl } - 1 H-pyrazolo [3 ,4-&]pyridin- 1 - yl)carbonyl] (methyl)amino] ethyl } carbamate
Pyridine (0.061 mL, 0.756 mmol) was added to a suspension of 3-chloro-5-{[5- chloro- 1 -( 1 H-pyrazolo[3 ,4-ό]pyridin-3 -ylmethyl)- 1 H- 1 ,2,3 -benzotriazol-4-yl]oxy } benzonitrile (165 mg, 0.378 mmol) in DCM (10 mL) at O0C, followed by the addition in a single charge of triphosgene (45 mg, 0.151 mmol) as a solid, and then by the addition of diisopropyl ethylamine (0.198 mL, 1.135 mmol). This suspension was allowed to stir at O0C until a solution was achieved. 2-[(tert-Butoxycarbonyl)amino]-N-methylethanaminiuni chloride (120 mg, 0.567 mmol) was then added as a solid followed by diisopropyl ethylamine (0.198 mL, 1.135 mmol). The reaction mixture was allowed to warm to room temperature and after 10 minutes, the reaction mixture was diluted with dichloromethane (25 mL), washed with water (15 mL), and the aqueous layer was extracted with dichloromethane (25 mL). The combined organic fractions were dried (MgSO-O, filtered and concentrated. The resulting residue was purified by automated column chromatography on silica gel (12g), eluting with 50-100% EtOAc/hexanes to afford the title compound. LRMS (M+l) = 635.6.
Step 2: 2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl]methyl } - 1 H-pyrazolo[3 ,4-6]pyridin- 1 - yl)carbonyl] (methyl)amino] ethanaminium chloride
Hydrochloric acid in dioxane (4 M, 5 mL) was added to tert-butyl {2-[[(3-{[5- chloro-4-(3-chloro-5-cyanophenoxy)-l//-l,2,3-benzotriazol-l-yl]methyl}-lH-pyrazolo[3,4- 6]pyridin-l-yl)carbonyl](methyl)amino]ethyl}carbamate (620 mg, 974 mmol) at O0C. After 2 hours, the reaction mixture was concentrated under reduced pressure and the residue crystallized from ethanol. lH NMR (DMSO-dό) δ 8.68 (d, J=4.5Hz, IH), 8.28 (d, J=8.0Hz, IH), 7.97 (d,
J=9.1Hz, IH), 7.90 (s, IH), 7.82 (m, IH), 7.55 (m, IH), 7.43 (m, IH), 6.50 (s, 2H), 3.65 (m, 2H), 3.1 (m, 5H).
EXAMPLE 15 Benzyl [5 -chloro-4-(3 -chloro-5-cyanophenoxy)- IH-1 ,2,3 -benzotriazol- 1 -yl] acetate
Figure imgf000092_0001
Lithium tørt-butoxide (57.7 mg, 0.721 mmol) was added to 3-chloro-5-[(5-chloro- IH-1 ,2,3-benzotriazol-4-yl)oxy]benzonitrile (200 mg, 0.655 mmol) in DMF (2 mL). This reaction mixture was allowed to stir for 5 minutes, after which the mixture was cooled to O0C and benzyl bromoacetate was added dropwise and the mixture immediately allowed to warm to room temperature. After 30 minutes, the reaction was quenched with saturated aqueous ammonium chloride (2 mL) at O0C, and the mixture was extracted with ethyl acetate (2x25 mL). The organic fractions were concentrated to 25 mL and washed with water (3x10 mL), dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by automated column chromatography on silica gel (12g) eluting with 0-25% EtOAc/hexanes to afford the title compound. lH NMR (DMSO-d6) δ 7.92 (d, J=8.9Hz, IH), 7.84 (m, IH), 7.82 (d, J=8.9Hz, IH), 7.58 (m, IH), 7.52 (m, IH), 7.37 (m, 5H), 5.90 (s, 2H), 5.20 (s, 2H). HRMS (M+l) = 453.0516.
EXAMPLE 16
1 -{ [5-chloro-4-(3-chloro-5-cyanophenoxy)-lH-l ,2,3-benzotriazol-l -yl] acetyl }piperidine-3- carboxamide
Figure imgf000093_0001
Step 1: fert-butyl [5-Chloro-4-(3-chloro-5-cyanophenoxy)-lH-l,2,3-benzotriazol-l- yl] acetate
Figure imgf000093_0002
3-chloro-5-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (500 mg, 1.64 mmol) and cesium carbonate (534 mg, 1.64 mmol) were suspended in DMF (5mL) under N2- To this was added tert-butyl bromoacetate (336mg, 1.72 mmol) After 1 hour, the reaction was quenched with saturated aqueous ammonium chloride (5 mL), diluted with water and the mixture extracted with ethyl acetate (2x25 mL). The combined organic fractions were washed with water (3x 25mL) and dried (MgSO4), filtered and the solvent was evaporated under reduced pressure.
The resulting residue was purified by automated column chromatography on silica gel (40 g) eluting with 0-15%EtOAc/hexanes to give the title product. LRMS (M+l) = 418.9.
Step 2: [5-Chloro-4-(3-chloro-5-cyanophenoxy)-l//-l,2,3-benzotriazol-l-yl]acetic acid
Figure imgf000093_0003
tert-Butyl [5-chloro-4-(3-chloro-5-cyanophenoxy)- 1 H- 1 ,2,3-benzotriazol- 1 - yl]acetate (50 mg, 0.12 mmol) was dissolved in TFA (3mL). After 1 hour, the reaction mixture was concentrated under reduced pressure to yield the title compound. lH NMR (DMSO-dό) δ 7.90 (d, J=8.9Hz, IH), 7.84 (m, IH), 7.80 (d, J=8.9Hz, IH), 7.52 (m, IH), 7.58 (m, IH), 5.70 (s, IH).
Step 3 : 1 - { [5-chloro-4-(3-chloro-5-cyanophenoxy)- IH- 1 ,2,3-benzotriazol- 1 - yl]acetyl}piperidine-3-carboxamide [5 -chloro-4-(3 -chloro-5 -cyanophenoxy)- IH-1 ,2 ,3 -benzotriazol- 1 -yl] acetic acid (13 mg, 0.036 mmol) (see step 2 in Example 16), piperidine-3-carboxamide (4.6 mg, 0.036 mmol), 3-{[(ethylimino)methylene]amino}-iV,jV-dimethylpropan-l-aminium chloride (6.9 mg, 0.036 mmol), 3H-[l,2,3]triazolo[4,5-6]pyridin-3-ol (4.9 mg, 0.036 mmol), and triethylamine (0.005 mL, 0.036 mmol) were dissolved in DMF (0.5 mL). After 1 hour, the reaction mixture was diluted with aqueous MeOH (1 mL) and purified by reverse phase chromatography eluting with 30-95% MeCN/Η2θ + 0.1% TFA. Product fractions were lyophilized to yield the title product. lH NMR (DMSO-dό) δ 7.84 (m, IH), 7.77 (d, J=4.4Hz, IH), 7.76 (s, 2H), 7.58 (m ,1H), 7.51 (m, IH), 7.44 (m, IH), 7.36 (m, IH), 7.02 (m, IH), 6.84 (m, IH), 5.97 (m, 2H), 5.93 (m, IH), 5.87 (m, 0.5H), 5.83 (m, 0.25H), 4.29 (m, 2H), 3.80 (m, 4H), 3.40 (m, IH), 3.10 (m, IH), 2.95 (m, IH), 2.65 (m, IH), 2.20 (m, IH), 1.90 (m, 2H), 1.70 (m, 4H), 1.40 (m, IH). HRMS (M+l) = 473.0867.
EXAMPLE 17
(3-chloro-5-{[5-chloro-l-(lH-pyrazolo[3,4-ό]pyridin-3-ylmethyl)-lH-l,2,3-benzotriazol-4- yl]oxy}phenyl)methanaminium trifluoroacetate (Alternative name: l-(3-chloro-5-{[5-chloro-l- (lH-pyrazolo[3,4-ό]pyridin-3-ylmethyl)-lH-l,2,3-benzotriazol-4-yl]oxy}phenyl)methanamine, TFA salt)
Figure imgf000094_0001
To 3 -chloro-5 - { [5-chloro- 1 -( 1 H-pyrazolo[3 ,4-6]pyridin-3-ylmethyl)- 1 H- 1 ,2,3 - benzotriazol-4-yl]oxy}benzonitrile (10 mg, 0.023 mmol) dissolved in dry TΗF (0.5 mL) at 00C was added LAΗ solution IM in TΗF (0.046 mL, 0.046 mmol). After 30 minutes, the reaction mixture was quenched with EtOAc (2 mL) at O0C. To this was added saturated aqueous Na2SO4
(0.25 mL). After 5 minutes, water (0.5 mL) was added. This mixture was allowed to stir for 5 minutes after which time solid excess Na2SO4 was added to the reaction mixture. This mixture was filtered and solvent removed under reduced pressure. The resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/H2θ + 0.1% TFA. Product fractions were lyophilized to afford the title compound. lH NMR (DMSO-d6) δ 8.54 (dd, J=4.5 Hz, J=I .4 Hz, IH), 8.15 (dd, J=8.0Hz, J=1.5Hz, IH), 8.15 (s, 3H), 7.90 (d, J=8.9Hz, IH), 7.80 (d, J=8.9Hz, IH), 7.32 (m, IH), 7.22 (dd, J=8.0Hz, 4.5Hz, IH), 7.17 (s, 2H), 6.38 (s, 2H), 4.00 (dd, J=I 1.4Hz, J=5.6Hz, IH),
EXAMPLE 18
3 -chloro-5 - { [5-chloro- 1 -( 1 H-pyrazolo [3 ,4-%yridin-3 -ylmethyl)- 1 H- 1 ,2,3-benzotriazol-4- yl]oxy}benzaldehyde
Figure imgf000095_0001
To S-chloro-S-ICS-chloro-l^lH-pyrazoloP^-δJpyridin-S-ylmethyO-lH-l^^- benzotriazol-4-yl]oxy}benzonitrile (10 mg, 0.023 mmol) dissolved in dry TΗF (0.5 mL) at 0°C was added LAΗ solution IM in TΗF (0.046 mL, 0.046 mmol). After 30 minutes, the reaction was quenched with EtOAc (2 mL) at 00C, followed by addition of saturated aqueous Na2SO4
(0.25 mL), and then after 5 minutes by addition of water (0.5 mL). This mixture was allowed to stir for 5 minutes after which time solid Na2SO4 was added to the reaction mixture. The dried mixture was then filtered and solvent removed under reduced pressure. The resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/Η2O + 0.1% TFA. Product fractions were lyophilized to afford the title compound. lH NMR (DMSO- d6) δ 9.90
(s, IH), 8.52 (d, J=3.5Hz), 8.10 (d, J=7.5Hz), 7.90 (d, J=8.9Hz, IH), 7.80 (d, J=8.9Hz, IH), 7.72 (m, IH), 7.30 (m, IH), 7.20 (dd, J=8.1Hz, J=4.6Hz, IH), 6.40 (s, 2H).
EXAMPLE 19 2,5-dichloro-3-{[5-chloro-l-(lH-pyrazolo[3,4-δ]pyridin-3-ylmethyl)-lH-l,2,3-benzotriazol-4- yl]oxy}benzonitrile
Figure imgf000095_0002
Step 1 : l-bromo-2,5-dichloro-3-methoxybenzene Methanol (5 mL) was added to potassium tert-butoxide (3.94 g, 123 mmol) suspended in toluene/DMPU (3:1, 240 mL), and the mixture was placed in an oil bath at 8O0C under N2 with a reflux condenser for 25 minutes to obtain a solution. The solution was then allowed to cool to room temperature under N2, after which l-bromo-2,5-dichloro-3- fluorobenzene (10 g, 41 mmol) was added dropwise to the solution and the resulting suspension was placed in an oil bath at 8O0C under N2- After 4 hours, the reaction mixture was allowed to cool to room temperature and was then diluted with hexanes (200 mL) and water (100 mL). The layers were separated and the aqueous layer was extracted with hexanes (200 mL). The combined organic portions were washed with water (3x300 mL), dried (MgSO4), filtered and concentrated to give the title compound. lH NMR (CDCI3) δ 7.20 (m, IH), 6.80 (m, IH), 3.90 (s, 3H).
Step 2: 3-bromo-2,5-dichlorophenol
Boron tribromide as a 1 M solution in dichloromethane (41 mL, 41 mmol) was added to l-bromo-2,5-dichloro-3-methoxybenzene (10.5 g, 41 mmol) in dichloromethane
(100 mL) at -780C under N2. The reaction mixture was allowed to warm to room temperature, and after 21 hours, the mixture was poured into 100 g of ice, diluted with 100 g of water, and the organic layer separated. The aqueous layer was extracted with dichloromethane (200 mL) and the combined organic extracts were dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. lH NMR (CDCI3) δ 7.20 (m, IH), 7.00 (m, IH), 5.70 (s, IH).
Step 3: l-bromo-2,5-dichloro-3-(2-chloro-6-nitrophenoxy)benzene
3-bromo-2,5-dichlorophenol (8.0 g, 33 mmol) and 2,3-dichloronitrobenzene (6.4 g, 33 mmol) were dissolved in NMP (30 mL), followed by the additon of potassium carbonate (5.5 g, 40 mmol). The resulting suspension was placed in an oil bath at 1200C for 7 hours, after which the reaction mixture was diluted with water (150 mL) and extracted with ethyl acetate (2x100 mL). The combined organic fractions were washed with water (3x100 mL), dried (MgSθ4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (330g) eluting with 0-20%CH2Cl2/hexanes to afford the title compound. lH NMR (CDCI3) δ 7.98 (dd, J=8.2Hz, J=I .6Hz, IH), 7.79 (dd, J=8.2Hz, J=I.6Hz, IH), 7.44 (dd, J=8.2Hz, J=8.2Hz, IH), 7.40 (d, J=2.2Hz, IH), 6.54 (d, J=2.2Hz, IH).
Step 4: 3-(3-bromo-2,5-dichlorophenoxy)-4-chloro-2-nitroaniline 1,1,1 -trimethylhydrazinium iodide (14.7 g, 72.7 mmol) was added to potassium tert-butoxide (8.20 g, 72.7 mmol) and copper (I) chloride (0.180 g, 1.82 mmol) in DMF (50 mL) at O0C. The resulting mixture was allowed to stir for several minutes at which point the mixture was cooled to -4O0C and l-bromo-2,5-dichloro-3-(2-chloro-6-nitrophenoxy)benzene (7.23 g, 18.2 mmol) as a solution in DMF (50 mL) was added dropwise. The reaction mixture was then maintained at -4O0C for 20 minutes, at which point the reaction was quenched at -4O0C with saturated aqueous ammonium chloride (10 mL). Water (10 mL) was then added and the mixture was allowed to warm to room temperature. The mixture was extracted with ethyl acetate (2x200 mL). The combined organic fractions were washed with water (3x200 mL), dried (MgSθ4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by automated column chromatography on silica gel (1.5 kg) eluting with 25%EtOAc/hexanes to give the title compound. LRMS (M+ 1) = 412.4.
Step 5: 3-(3-bromo-2,5-dichlorophenoxy)-4-chlorobenzene-l,2-diamine
3-(3-bromo-2,5-dichlorophenoxy)-4-chloro-2-nitroaniline (2.68 g, 6.50 mmol) and tin(II) chloride dihydrate (7.33 g, 32.5 mmol) were suspended in MeOH (50 mL) and heated to 750C under a reflux condenser and N2- After 11 hours, the reaction mixture was allowed to cool to room temperature, and concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate (150 mL), after which 10% aqueous sodium carbonate (250 mL) was added with vigorous stirring until the pH was 10. The resulting suspension was filtered through celite, the filtrate was extracted with ethyl acetate. The combined organic fractions were dried (MgSO4), filtered and the solvent was evaporated under reduced pressure to yield the title compound. LRMS (M+l) = 382.5.
Step 6: 4-(3-bromo-2,5-dichlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole
3-(3-bromo-2,5-dichlorophenoxy)-4-chlorobenzene-l,2-diamine (2.48 g, 6.47 mmol) in acetic acid (20 mL) was cooled to 15°C, after which sodium nitrite (0.446 g, 6.47 mmol) in water (6.47 mL) was added dropwise under N2- After 1.5 hours, the reaction mixture was diluted with EtOAc (200 mL), and the organic phase was separated and washed with water (3x75 mL). The organic phase was dried (MgSO4), filtered, concentrated and placed under vacuum to yield the title compound. LRMS (M+l) = 393.4.
Step 7: 2,5-dichloro-3-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile
4-(3-bromo-2,5-dichlorophenoxy)-5-chloro-lH-l,2,3-benzotriazole (2.55 g, 6.49 mmol), tetrakis triphenylphosphine palladium(O) (2.25 g, 1.95 mmol) and zinc cyanide (0.915 g, 7.79 mmol) were suspended in dry DMF (50 mL) under N2 and placed in an oil bath at 900C for
24 hours, after which the reaction mixture was allowed to cool to room temperature. The cooled mixture was then diluted with EtOAc (200 mL) and washed with water (4x100 mL), the aqueous layer was extracted with EtOAc (100 mL) and then washed with water (4x50 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated with silica gel. The concentrate was purified by automated column chromatography on silica gel (4Og) eluting with 0-30% EtOAc/hexanes to afford the title compound. LRMS (M+ 1) = 340.16.
Step 8: tert-buty\ 3-{[5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-lH-l,2,3-benzotriazol-
1 -yljmethyl } - 1 H-pyrazolo [3 ,4-ό]pyridine- 1 -carboxylate
Figure imgf000098_0001
2,5-dichloro-3-[(5-chloro-lH-l ,2,3-benzotriazol-4-yl)oxy]benzonitrile (1.00 g, 2.94 mmol) and cesium carbonate (1.15 g, 3.53 mmol) were suspended in dry DMF (10 mL) under N2 and tert-butyl 3-(bromomethyl)-lH-pyrazolo[3,4-&]pyridine-l-carboxylate (0.965 g, 3.09 mmol) was added as a solution in DMF (5 mL) at room temperature. After 1 hour, the reaction mixture was quenched with saturated aqueous ammonium chloride (20 mL) and diluted with water (50 mL). The mixture was then extracted with ethyl acetate (2x100 mL). The combined organic fractions were washed with water (3x100 mL), dried (MgSO-O, filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by automated column chromatography on silica gel (120 g) eluting with 25-50% EtOAc/hexanes. LRMS (M+ 1) = 569.6.
Step 9: 2,5-dichloro-3-{[5-chloro-l-(lH-pyrazolo[3,4-ό]pyridin-3-ylmethyl)-lH-l,2,3- benzotriazol-4-yl]oxy}benzonitrile tert-Butyl 3 - { [5-chloro-4-(2,5 -dichloro-3 -cyanophenoxy)- IH-1 ,2,3 -benzotriazol- l-yl]methyl}-lH-pyrazolo[3,4-&]pyridine-l-carboxylate (569 mg, 0.997 mmol) was dissolved in TFA (5 mL). After 20 minutes, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/Η2θ + 0.1% TFA. Product fractions concentrated under reduced pressure to yield the title compound. lH NMR (DMSO-d6) δ 8.53 (dd, J=4.4Hz, J=1.6Hz, IH), 8.14 (dd, J=8.0Hz, J=I.5Hz, IH), 8.04 (d, J=0.6Hz, IH), 7.89 (d, J=8.9Hz, IH), 7.79 (d, J=8.9Hz, IH), 7.44 (d, J=0.6Hz, IH), 7.21 (dd, J=8.0Hz, J=4.5Hz, IH)3 6.38 (d, 2H). HRMS (M+l) = 470.0076
EXAMPLE 20 2,5-dichloro-3-{[5-chloro-2-(lH-pyrazolo[3,4-ό]pyridin-3-yhnethyl)-2H-l,2,3-benzotriazol-4- yl]oxy}benzonitrile
Figure imgf000099_0001
Step 1 : tert-butyl 3- { [5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-2//-l ,2,3-benzotriazol-
2-yl]methyl } - 1 H-pyrazolo [3 ,4-&]pyridine- 1 -carboxylate 2,5-dichloro-3-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (1.00 g, 2.94 mmol) and cesium carbonate (1.15 g, 3.53 mmol) were suspended in dry DMF (10 mL) under N2, and tert-butyl 3-(bromomethyl)-lH-pyrazolo[3,4-ό]pyridine-l-carboxylate (0.965 g,
3.09 mmol) was added as a solution in DMF (5 mL) at room temperature. After 1 hour, the reaction mixture was quenched with saturated aqueous ammonium chloride (20 mL), diluted with water (50 mL), and the mixture extracted with EtOAc (2x100 mL). The combined organic fractions were washed with water (3x100 mL), dried (MgSC"4), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by automated column chromatography on silica gel (12Og) eluting with 25-50% EtOAc/hexanes. LRMS (M+ 1) = 569.6.
Step 2: 2,5-dichloro-3-{[5-chloro-2-(lH-pyrazolo[3,4-έ]pyridin-3-ylmethyl)-2//-l,2,3- benzotriazol-4-yl]oxy} benzonitrile tert-butyl 3-{[5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-2H-l,2,3-benzotriazol- 2-yl]methyl}-lH-pyrazolo[3,4-6]pyridine-l-carboxylate (100 mg, 0.175 mmol) was dissolved in TFA (5 mL) at room temperature. After 20 minutes, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/Η2O + 0.1% TFA. The product fractions were concentrated under reduced pressure to yield the title compound. lH NMR (DMSO-dό) δ 13.80 (s, IH), 8.44 (d, J=2.9Hz,
IH), 7.99 (d, J=2.2Hz), 7.95 (m, IH), 7.93 (d, J=9.2Hz, IH), 7.62 (d, J=9.2Hz, IH), 7.35 (d, J=2.3Hz, IH), 7.16 (dd, J=8.0Hz, J=4.6Hz, IH), 6.30 (s, 2H). HRMS (M+l) = 470.0076.
EXAMPLE 21
1 -(2,5-dichloro-3 - { [5 -chloro- 1 -( 1 H-pyrazolo [3 ,4-ό]pyridin-3 -ylmethyl)- IH-1 ,2,3 -benzotriazol-4- yl] oxy } phenyl)methanamine
Figure imgf000099_0002
2,5-dichloro-3-{[5-chloro-l-(lH-pyrazolo[3,4-ό]pyridin-3-ylmethyl)-lH-l,2,3- benzotriazol-4-yl]oxy}benzonitrile (283 mg, 0.601 mmol) was dissolved in dry THF (30 mL), cooled to O0C, and LAH solution (1.20 mL, 1.20 mmol) in THF (1.2 mL) was added. The reaction mixture was allowed to warm to room temperature, and after 2 hours the mixture was cooled to O0C and quenched with EtOAc (50 mL). To this mixture was added saturated aqueous Na2SC"4 (3 mL), followed 5 minutes later by the addition of water (5 mL). This mixture was stirred for 5 minutes after which excess solid Na2SO4 was added. The mixture was then filtered and solvent removed under reduced pressure. The resulting residue was purified by reverse phase chromatography eluting with 5-95% MeCN/H2θ + 0.1% TFA to yield the title compound. lH NMR (DMSO-d6) δ 8.53 (d, J=4.5Hz, IH), 8.12 (d, J=8.0Hz, IH), 7.98 (s, 2H), 7.89 (d, J=9.0Hz, IH), 7.79 (d, J=9.0Hz, IH), 7.48 (s, IH), 7.20 (dd, J=8.0Hz, J=4.5Hz, IH), 6.91 (s, IH), 6.38 (s, 2H), 4.21 (s, 2H). HRMS (M+l) = 476.0363.
EXAMPLE 22 3 -( { 1 - [(6-amino- 1 H-pyrazolo[3 ,4-ό]pyridin-3 -yl)methyl] -5 -chloro- IH-1 ,2,3 -benzotriazol-4- y 1 } oxy)-2 , 5 -dichlorobenzonitrile
Figure imgf000100_0001
Step 1 : 2,5-dichloro-3-{[5-chloro-l-({ l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]-
1 H-pyrazolo [3 ,4-6]pyridin-3 -yl } methyl)- IH-1 ,2 ,3 -benzotriazol-4- yl]oxy}benzonitrile
Figure imgf000100_0002
2,5-dichloro-3-[(5-chloro-lH-l ,2,3-benzotriazol-4-yl)oxy]benzonitrile (90 mg, 0.265 mmol) and lithium tert-butoxide (22 mg, 0.278 mmol) were dissolved in DMF (1 mL) and the solution stirred for 5 minutes at room temperature. The reaction mixture was cooled to 00C and 3-(chloromethyl)-iV,l-bis(4-methoxybenzyl)-lH-pyrazolo[3,4-6]pyridin-6-amine (112 mg, 0.265 mmol) in DMF (1.5 mL) was added. After the addition, the solution was allowed to warm to room temperature and stirred for 16 hours, after which saturated aqueous ammonium chloride (1 mL) was added and the mixture was extracted with ethyl acetate (2x15 mL). The combined organic fractions were washed with water (3x15 mL). The combined aqueous layers were back- extracted with EtOAc (25 mL) and the extracts subsequently washed with water (3x15 mL). The combined organic fractions were dried (MgSCH), filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (12g) eluting with 0-40% EtOAc/hexanes to afford the title compound. LRMS (M+ 1) = 726.3.
Step 2: 3-({l-[(6-amino-lH-pyrazolo[3,4-ό]pyridin-3-yl)methyl]-5-chloro-lH-l,2,3- benzotriazol-4-yl}oxy)-2,5-dichlorobenzonitrile
2,5-dichloro-3-{[5-chloro-l-({l-(4-methoxybenzyl)-6-[(4-methoxybenzyl)amino]- 1 H-pyrazolo [3 ,4-ό]pyridin-3-yl } methyl)- 1 H- 1 ,2,3-benzotriazol-4-yl]oxy } benzonitrile (60 mg, 0.083 mmol) was dissolved in TFA and heated to 75°C. After 1 hour, the reaction mixture was concentrated under reduced pressure and re-constituted in EtOAc (15 mL). The reconstituted mixture was then washed with saturated aqueous sodium carbonate (5 mL) and then with water (5 mL). The combined aqueous layers were back-extracted with EtOAc (15 mL). The combined organic fractions were dried (MgSO4), filtered and solvent removed under reduced pressure. The resulting residue was purified by column chromatography on silica gel (4 g) eluting with 0- 10% MeOΗ/CΗ2Cl2 to yield the title compound. lH NMR (DMSO-d6) δ 12.70 (s, IH), 8.04 (d,
J=2.3Hz, IH), 7.81 (d, J=8.9Hz, IH), 7.76 (d, J=8.9Hz, IH), 7.53 (d, J=8.6Hz, IH), 7.41 (d, J=2.3Hz, IH), 6.36 (s, 2H), 6.29 (d, J=8.7Hz, IH), 6.15 (s, 2H), 5.75 (s, IH). HRMS (M+ 1) = 485.0193.
EXAMPLE 23
3-chloro-5-({5-chloro-l-[(5-phenyl-l,3,4-oxadiazol-2-yl)methyl]-l//-l,2,3-benzotriazol-4- yl } oxy)benzonitrile
Figure imgf000101_0001
3-chloro-5-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (lOOmg, 0.328 mmol), cesium carbonate (107 mg, 0.328 mmol) and 2-(chloromethyl)-5-phenyl-l,3,4-oxadiazole (64 mg, 0.328 mmol) were combined and suspended in DMF (2 mL). After 16 hours at room temperature, the reaction mixture was quenched with saturated aqueous ammonium chloride (1 mL) and extracted with EtOAc (2x25 mL). The combined organic fractions were evaporated under reduced pressure, and the resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/Η2θ + 0.1% TFA. The product fractions were concentrated to yield the title compound. lH NMR (DMSO-d6) δ 8.01 (d, J=8.9Hz, IH), 7.96 (d, J=8.3Hz, 2H), 7.88 (d, J=8.9Hz, IH), 7.83 (m, IH), 7.61 (m, 5H), 6.54 (s, 2H). HRMS (M+ 1) = 463.0465. EXAMPLE 24
3-chloro-5-({5-chloro-2-[(5-phenyl-l,3,4-oxadiazol-2-yl)methyl]-2H-l,2,3-benzotriazol-4- yl } oxy)benzonitrile
Figure imgf000102_0001
3-chloro-5-[(5-chloro-lH-l,2,3-benzotriazol-4-yl)oxy]benzonitrile (lOOmg, 0.328 mmol), cesium carbonate (107 mg, 0.328 mmol) and 2-(chloromethyl)-5 -phenyl- 1, 3, 4-oxadiazole (64 mg, 0.328 mmol) were combined and suspended in DMF (2 mL). After 16 hours, the reaction mixture was quenched with saturated aqueous ammonium chloride (1 mL) and extracted with EtOAc (2x25 mL). The combined organic fractions were evaporated under reduced pressure. The resulting residue was purified by reverse phase chromatography eluting with 30- 95% MeCN/H2θ + 0.1% TFA. The product fractions were concentrated to yield the title compound. lH NMR (DMSO-d6) δ 8.01 (d, J=9.1Hz, IH) 7.92 (d, J=8.6Hz, 2H), 7.72 (m, IH), 7.68 (m, IH), 7.60 (m, 5H), 6.50 (s, IH). HRMS (M+l) = 463.0464.
EXAMPLE 25
3-chloro-5- { [7-methyl-3-( 1 H-pyrazolo [3 ,4-b]pyridin-3-ylmethyl)imidazo[ 1 ,5-a]pyridin-8- yl]oxy}benzonitrile trifluoroacetate (Alternative name: 3-chloro-5-{[7-chloro-3-(lH- pyrazolo[3,4-Zj]pyridin-3-ylmethyl)imidazo[l ,5-α]pyridin-8-yl]oxy}benzonitrile, TFA salt)
TFA salt of:
Figure imgf000102_0002
Step 1 : 3-fluoro-4-methylpyridine-2-carbonitrile
To a mixture of 2-bromo-3-bromo-4-methylpyridine (4.89g, 25.7 mmol) and zinc cyanide (3.02g, 25.7 mmol) in DMF (45mL) was added palladium tetra(triphenylphosphine) (2.97g, 2.57 mmol). The mixture was degassed and then heated at 90°C for 18 hours, after which the mixture was diluted with water (50OmL) and EtOAc (50OmL), filtered, and the resulting layers were separated. The aqueous layer was further extracted with EtOAc (2x500mL), and the combined extracts were washed with water (30OmL), dried over MgSθ4, filtered, and the solvent removed in vacuo. The resulting residue was chromatographed using RediSep column (330 g) and eluting with a gradient of 0-100% EtOAc/CH2Cl2- The pure fractions were combined and the solvent removed in vacuo to give title compound. lH NMR (CDCI3): δ 8.39 (d, IH, J=4.7Hz), 7.41 (m, IH) and 2.41 (s, 3H) ppm.
Step 2: 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carbonitrile
A mixture of 3-fluoro-4-methylpyridine-2-carbonitrile (2.1g, 15.43 mmol), 3- bromo-5-chlorophenol (3.68g, 17.74 mmol) and cesium carbonate (5.03g, 15.43 mmol) in DMF (3OmL) was heated at 70°C for 1 hour and then at 8O0C for another hour, after which the mixture was partitioned between water (300 mL) and ethyl acetate (2x500 mL). The combined extracts were washed with water (100 mL) and then brine (100 mL), dried over MgSθ4, filtered, and the solvent removed in vacuo. The residue was chromatographed using RediSep column (330 g) and eluted with a gradient of 0-10% EtOAc/CH2Cl2 and the pure fractions combined and concentrated on the rotary evaporator to give the title compound. LRMS (M+l)=324.9.
Step 3 : 1 -[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-yl]methanamine
To a solution of 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carbonitrile (570 mg, 1.762 mmol) in tetrahydrofuran (7 mL) cooled over dry ice/acetone bath was added 2M LAH in THF (1.233mL, 2.466 mmol) and the mixture stirred over dry ice-acetone bath for 40 minutes. After this time, the dry ice-acetone bath was replaced with a wet ice bath and mixture stirred for 5 minutes. The mixture was then treated with water (94 μL), 1.0N NaOH (94 μL) and more water (280 μL), and then stirred at room temperature for 30 minutes. After this time, the mixture was diluted with THF (7mL) and filtered through celite. The solids were washed with additional THF (1OmL). The filtrates were combined, the solvent removed under vacuum, and the residue purified using Waters PrepPak and eluting with a gradient of 5-95% ACN/H2O with
0.1% TFA. The desired fractions were combined and the solvent removed in vacuo to give the title compound. LRMS (M+l)=328.9.
Step 4 : { [3 -(3 -bromo-5-chlorophenoxy)-4-methylpyridin-2-yl]methyl } -2-( 1 H- pyrazolo [3 ,4-b]pyridin-3-yl)acetamide
Figure imgf000103_0001
To a solution of l-[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2- yljmethanamine (125mg, 0.382 mmol), lH-pyrazolo[3,4-b]pyridin-3-ylacetic acid compound with ammonium chloride (1 :1), (102mg, 0.443 mmol), HOAT (5.2mg, 0.038 mmol) and TEA (53 μL, 0.382 mmol) in DMF (2mL) was added EDC (80mg, 0.42 mmol), and the mixture was stirred for 2.2 hours. The mixture was then filtered and purified using Waters PrepPak column and eluting with a gradient of 5-95% ACN/H2O with 0.1% TFA. The desired fractions were lyophilized to give title compound. LRMS (M+l)=487.7.
Step 5: 3-{[8-(3-bromo-5-chlorophenoxy)-7-methylimidazo[l,5-a]pyridin-3-yl]methyl}-
1 H-pyrazolo[3,4-b]pyridine
Figure imgf000104_0001
To a suspension of N-{[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2- yl]methyl}-2-(lH-pyrazolo[3,4-b]pyridin-3-yl)acetamide (77mg, 0.158 mmol) in toluene (2mL) was added phosphorus oxychloride (120 μL, 0.79 mmol). The resulting mixture was then heated at 100°C for 1 hour, after which the solvent was removed in vacuo and the residue was stirred with CH2CI2 (5OmL) and saturated aqueous Na2CO3 (3OmL) for 30 minutes. The layers were partitioned and the organic extract was dried over MgSθ4, filtered and the solvent removed in vacuo. This residue was purified using RediSep column (12g) eluting with a gradient of 0-10% MeOH/CH2Cl2 . The pure fractions were combined and the solvent removed in vacuo to give the title compound. LRMS (M+l)=469.7.
Step 6: 3-chloro-5-{ [7-methyl-3-(lH-pyrazolo[3,4-b]pyridin-3-ylmethyl)imidazo[l ,5- a]pyridin-8-yl]oxy} benzonitrile trifluoroacetate To a suspension of 3-{ [8-(3-bromo-5-chlorophenoxy)-7-methylimidazo[l ,5- a]pyridin-3-yl]methyl}-lH-pyrazolo[3,4-b]pyridine (44 mg, 0.094 mmol) and zinc cyanide (12.12 mg, 0.103 mmol) in DMF (1 mL) was added palladium tetratriphenylphosphine (21.7mg, 0.019 mmol), and the resulting mixture was heated at 900C for 2 hours. The mixture was then cooled to room temperature and purified on a Luna column (10 μ, C 18, 250X21.2cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the title compound. lH NMR (CD3OD): δ 8.54
(d, IH, J=4Hz), 8.25 (d, IH, J=7Hz), 8.19 (d, IH, J=8Hz), 7.56 (dd, IH, J=1.5Hz), 7.50 (s, IH), 7.38 (dd, IH, J=I.5Hz), 7.30 (dd, IH, J=I.5Hz), 7.24 (dd, IH, J=4 and 8Hz), 6.96 (d, IH, J=7Hz), 5.01 (s, 2H)and 2.20 (s,3H) ppm. LRMS (M+l)=414.9. EXAMPLE 26
3 -chloro-5- { [7-methyl-3 -( 1 H-pyrazolo [3 ,4-b]pyridin-3 -ylmethyl)[ 1 ,2,4] triazolo [4,3 -a]pyridin-8- yl]oxy}benzonitrile trifluoroacetate (Alternative name: 3 -chloro-5 -{[7-methyl-3 -(I H- pyrazolo[3,4-b]pyridin-3-ylmethyl)[l,2,4]triazolo[4,3-a]pyridin-8-yl]oxy}benzonitrile, TFA salt)
TFA salt of:
Figure imgf000105_0001
Step 1 : 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carboxylic acid
A suspension of 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carbonitrile (5 g, 15.45 mmol) in concentrated HCl (30 niL) was heated at 100°C for 3 hours and then at 120°C for an additional 1.5 hours. This suspension was cooled to 50°C and the resulting white solid was filtered, washed with water (10 mL), and dried under high vacuum to give the title compound. LRMS (M+l)=343.8.
Step 2: 3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-amine To a suspension of 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carboxylic acid (2g, 5.84 mmol) in THF (12mL) was added TEA (1.627mL, 11.68 mmol), pyridine (944ul, 11.68 mmol), t-butanol (2.79mL, 29.2 mmol) and diphenylphosphoryl azide (1.89mL, 8.76 mmol). The resulting mixture was heated to 65 °C for 35 minutes, after which the mixture was diluted with CH2CI2 (2xl00mL) and washed with water (10OmL). The combined organic extracts were concentrated in vacuo, and the resulting residue was dissolved in TFA (20 mL) and allowed to stand for 15 minutes. After this time, the solvent was removed in vacuo and the residue was partitioned between saturated aqueous NaHCθ3 (5OmL) and CH2CI2 (100 mL).
The organic extract was concentrated on the rotary evaporator and the residue was purified using a RediSep column (33Og) eluting with a gradient of 0-30% EtOAc/CH2Cl2 to give the title compound. LRMS (M+l)=314.9.
Step 3: 3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-ol
To an ice cooled suspension of 3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2- amine (600mg, 1.913 mmol) in 5% aqueous H2SO4 (1OmL) was added a solution of sodium nitrite (198mg, 2.87 mmol) in water (ImL). The suspension was stirred in an ice bath for 30 minutes, after which it was added to a solution of 5% aqueous H2SO4 (1OmL), and the mixture was warmed to 1000C and maintained at 100°C for 1.5 hours. After this time, the mixture was cooled to 0°C and treated with additional sodium nitrite (60mg, 0.86 mmol) and then heated at 100°C for 20 minutes. After this time, the mixture was cooled to 25°C, the resulting solid was collected by filtration, washed with water (10 mL), and dried under high vacuum to give the title compound. HRMS (M+l)=313.9577.
Step 4: 3-(3-bromo-5-chlorophenoxy)-2-chloro-4-methylpyridine
A suspension of 3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-ol (340mg, 1.081 mmol) in phosphorus oxychloride (10 mL, 107 mmol) was heated at 100°C for 24 hours, after which the solvent was removed in vacuo. The resulting oil was quenched with saturated aqueous NaHCθ3 (5OmL) and extracted with EtOAc (10OmL). The organic extract was washed with water (2OmL), dried over MgSθ4, filtered, and the solvent removed on a rotary evaporator. This residue was purified using Waters PrepPak and eluting with a gradient of 5-95% ACN/H2O with 0.1% TFA. The desired fractions were combined and the solvent removed in vacuo to give the title compound. LRMS (M+l)=333.8.
Step 5: 3-(3-bromo-5-chlorophenoxy)-2-hydrazino-4-methylpyridine
Figure imgf000106_0001
To a solution of 3-(3-bromo-5-chlorophenoxy)-2-chloro-4-methylpyridine (121mg, 0.363 mmol) in DMSO (1 mL) was added hydrazine hydrate (177 μL, 3.63 mmol) and the mixture was heated at 100°C for 18 hours. The mixture was then purified on a Luna column (lOμ, C 18, 250X21.2cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the title compound. LRMS (M+l)=329.8.
Step 6: N'-[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2-yl]-2-(lH-pyrazolo[3,4- b]pyridin-3-yl)acetohydrazide
Figure imgf000106_0002
To a solution of 3-(3-bromo-5-chlorophenoxy)-2-hydrazino-4-methylpyridine trifluoroacetate (112mg, 0.253 mmol), lH-pyrazolo[3,4-b]pyridin-3-ylacetic acid compound with ammonium chloride (1 :1), (67.6mg, 0.253 mmol), HOAT (6.89mg, 0.051 mmol) and TEA (106 μL, 0.759 mmol) in DMF (ImL) was added EDC (58.2mg, 0.304 mmol) and the resulting mixture was stirred for 2 hours. The mixture was then filtered and purified on a Luna column
(lOμ, C18, 250X21.2cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the title compound.
HRMS (M+l)=487.0278.
Step 7: 8-(3-bromo-5-chlorophenoxy)-7-methyl-3-(lH-pyrazolo[3,4-b]pyridin-3- ylmethyl)[l,2,4]triazolo[4,3-a]pyridine
Figure imgf000107_0001
A mixture of N'-[3-(3-bromo-5-chlorophenoxy)-4-methylpyridin-2 -yl]-2-(lH- pyrazolo[3,4-b]pyridin-3-yl)acetohydrazide (44mg, 0.090 mmol) in phosphorus oxychloride (250 μL, 2.6 mmol) was heated to 120°C for 35 minutes, after which the excess reagent was removed in vacuo and the residue partitioned between saturated aqueous NaHCθ3 (2OmL) and CH2CI2 (2x20mL). The combined extracts were concentrated in vacuo and the residue was purified on a Luna column (lOμ, C 18, 250x21.2cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the title compound. LRMS (M+l)=470.7.
Step 8: 3-chloro-5-{[7-methyl-3-(lH-pyrazolo[3,4-b]pyridin-3- ylmethyl)[l ,2,4]triazolo[4,3-a]pyridin-8-yl]oxy}benzonitrile trifluoroacetate
To a suspension of 8-(3-bromo-5-chlorophenoxy)-7-methyl-3-(lH-pyrazolo[3,4- b]pyridin-3-ylmethyl)[l,2,4]triazolo[4,3-a]pyridine (18.5mg, 0.039 mmol) and zinc cyanide (6.94 mmol, 0.059 mmol) in DMF (500 μL) was added palladium tetratriphenylphosphine (13.68mg, 0.012 mmol) and the mixture was heated to 90°C for 2 hours, after which it was cooled to 25°C, filtered through Gelman Acrodisc and purified on a Luna column (1 Oμ, C 18, 250x21.2cm) eluting with 5-95% ACN/water with 0.1%TFA) to give the title compound. lH NMR (CD3OD): δ 8.60 (d, IH5 J=8Hz), 8.47 (d, IH, J=5Hz), 8.28 (d, IH, J=7Hz), 7.36 (m, IH), 7.27 (m, IH), 7.19 (m, IH), 6.92 (m, IH), 6.89 (d, IH, J=7Hz), 5.02 (s, 2H) and 2.31 (s, 3H) ppm. LRMS (M+l)=416.0.
EXAMPLE 27
3-chloro-5-{[6-chloro-l-(lH-pyrazolo[3,4-b]pyridine-3-ylmethyl)-l,2,3,4-tetrahydroquinolin-5- yl] oxy } benzonitrile
Step 1 : Quinolin-5-yl acetate
TEA (960 μL, 6.89 mmol) was added to 5 hydroxy quinoline (1.0 g, 6.89 mmol) in 20 mL of DCM, after which the mixture was cooled to 0°C and acetyl chloride was added dropwise (490 μL, 6.89 mmol). The reaction mixture was stirred for 1 hour at room temperature and then quenched with saturated aqueous sodium bicarbonate. The mixture was extracted with DCM, dried over sodium sulfate and concentrated. The crude acetate was purified on a silica gel column (10% to 80% EtOAc/hexanes) to afford the title product. LRMS (M+l) = 188.3
Step 2: 1, 2,3, 4-tetrahydroquinolin-5-yl acetate
In accordance with J Org. Chem. 1978, 43 (10), 1975-1980, Ptθ2 (120 mg, 1.06 mmol) and concentrated HCl (20 μL) were added to a solution of quinolin-5-yl acetate (1.0 g, 5.34 mmol) in EtOH (30 mL) and the mixture was purged with N2 followed by H2- The mixture was then stirred at room temperature for 48 hours, at which point the starting material had been consumed as determined by LC-MS. The reaction mixture was then filtered through celite, and washed with MeOH, chloroform, and a small amount of TEA. The filtrate was concentrated under reduced pressure, and the resulting residue was purified on a silica gel column (10% to 80% EtOAc/hexanes) to afford the title product. LRMS (M+l) = 192.3
Step 3: t-butyl 5-(acetyloxy)-3,4-dihydroquinoline-l(2H)-carboxylate
To a cooled (O0C) solution of l,2,3,4-tetrahydroquinolin-5-yl acetate (5 g, 26.1 mmol) in 50 mL of acetonitrile was added TEA (3.46 mL, 26.1 mmol) followed by DMAP (3.19 g, 26.1 mmol). The mixture was stirred for 10 minutes after which Boc anhydride (11.4 g, 52.3 mmol) dissolved in acetonitrile (50 mL) was added. The mixture was warmed to room temperature and held at room temperature overnight. The reaction mixture was then diluted with
EtOAc, washed successively with water and brine, dried over sodium sulfate, and concentrated.
The crude Boc protected dihydroquinoline was purified on a silica gel column (5% to 35%
EtOAc/hexanes) to afford the title product.
LRMS (M+l) = 236.2 (M-56, loss of t-butyl)
Step 4: t-butyl 5-hydroxy-3,4-dihydroquinoline-l(2H)-carboxylate
Figure imgf000109_0001
To a solution of t-butyl 5-(acetyloxy)-3,4-dihydroquinoline-l(2H)-carboxylate (770 mg, 2.64 mmol) in 10 mL of MeOH was added potassium carbonate (365 mg, 2.64 mmol), and the resulting mixture was stirred for 2 hours at room temperature and then filtered and concentrated in vacuo. The crude material was purified on a silica gel column (5% to 35% EtOAc/hexanes) to afford the desired product. LRMS (M+l) = 194.2 (M-56, loss of t-butyl)
Step 5: 6-chloro-t-butyl 5-hydroxy-3,4-dihydroquinoline-l(2H)-carboxylate t-butyl 5-hydroxy-3,4-dihydroquinoline-l(2H)-carboxylate (530 mg, 2.13 mmol) was dissolved in 20 mL of THF, after which NCS (284 mg, 2.13 mmol) was added and the mixture heated to reflux for 2 hours. The mixture was then cooled to room temperature and concentrated, and the crude reaction mixture was purified on a silica gel column (5% to 35% EtOAc/hexanes) to afford the desired product. LRMS (M+l) = 228.2 (M-56, loss of t-butyl)
Step 6: 3-chloro-5-[(6-chloro-l ,2,3,4-tetrahydroquinolin-5-yl)oxy]benzonitrile
Potassium carbonate (344 mg, 1.06 mmol) and 3-chloro-5-fluoro benzonitrile (164 mg, 1.06 mmol) were added to a solution of 6-chloro-t-butyl 5-hydroxy-3,4- dihydroquinoline-l(2H)-carboxylate (300 mg, 1.06 mmol) in DMSO (10 mL) in a process vial, and the mixture was heated to 1400C for 10 minutes in a microwave reactor. The mixture was then cooled to room temperature, diluted with EtOAc, washed 3 times with water and once with brine, dried over sodium sulfate and concentrated. The crude material was purified on a silica gel column (5% to 35% EtOAc/hexanes) to afford the Boc protected intermediate. This material was dissolved in DCM (3 mL), after which TFA was added dropwise until the Boc-group had been removed as indicated by LC-MS. The mixture was then quenched with saturated sodium bicarbonate, extracted with chloroform, dried over sodium sulfate and concentrated in vacuo. The crude free base was used without further purification. HRMS (M+l) = 319.0
Step 7 : 3 -chloro-5 - { [6-chloro- 1 -( 1 H-pyrazolo [3 ,4-b]pyridine-3 -ylmethyl)- 1,2,3,4- tetrahydroquinolin-5-yl]oxy}benzonitrile
3-chloro-5-[(6-chloro- 1 ,2,3,4-tetrahydroquinolin-5-yl)oxy]benzonitrile (120 mg, 0.376 mmol) was dissolved in DMSO (2 mL). To the resulting solution was added CS2CO3 (245 mg, 0.751 mmol) followed by t-butyl 3 -(bromomethyl)-l H-pyrazolo [3, 4-b]pyridine-l- carboxylate (234 mg, 0.751 mmol). The mixture was stirred overnight at room temperature, diluted with EtOAc, washed 3 times with water and once with brine, dried over sodium sulfate, and concentrated. The crude material was purified on a silica gel column (10% to 85% EtOAc/hexanes) to afford the Boc-protected intermediate. The intermediate was then dissolved in DCM (1 mL) and TFA was added dropwise to the solution until deprotection was observed by LC-MS. The mixture was then quenched with saturated sodium bicarbonate, extracted with DCM, dried over sodium sulfate, and concentrated. The crude product was purified via reverse phase HPLC (5% to 95% ACN/water/.05% TFA) to afford the desired product as a TFA salt. lH NMR (CDCI3): δ 8.59 (d, IH), 8.0 (d, IH), 7.1 (m, 3H), 6.92 (s, IH), 6.8 (d, IH), 4.8 (s, 2H),
3.40 (t, 2H), 2.58 (t, 2H), 1.98 (t, 2H). HRMS = 450.0
EXAMPLE 28 3 -chloro-5 - { [5 -chloro- 1 -(2 -hydroxy ethyl)- IH-1 ,2 ,3 -benzotriazol-4-yl] oxy } benzonitrile
Figure imgf000110_0001
To a stirred solution of [5-chloro-4-(3-chloro-5-cyanophenoxy)- IH-1, 2,3- benzotriazol-1-yl] acetic acid (50 mg, 0.138 mmol) (see step 2 in Example 16) at room temperature was added BΗ3-TΗF complex (0.275 ml, 0.275 mmol). After 24 hours, the reaction was quenched with saturated aqueous sodium carbonate (1 mL) and extracted with ethyl acetate (2x20 mL). The combined organic fractions were dried (MgSO-O, filtered and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel eluting with 0-5%MeOH/CH2Cl2 to afford the title compound. lH NMR (DMSO-d6) δ 7.90 (d, J=8.9Hz, IH), 7.82 (m, IH), 7.76 (d, J=8.9Hz, IH), 7.54 (m, IH), 7.51 (m, IH), 5.00 (t, J=5.6Hz, IH), 4.78 (t, J=5.1Hz, 2H), 3.90 (dd, J=5.5Hz, J=5.1Hz, 2H). LRMS (M+1) = 348.9.
EXAMPLE 29
5- { [5 -chloro- 1 -( 1 H-pyrazolo [3 ,4-ό]pyridin-3 -ylmethyl)- IH-1 ,2,3 -benzotriazol-4- yl]oxy } isophthalonitrile
Figure imgf000110_0002
A partially purified product prepared in the manner described in Example 4A, step 5, except on a larger scale, was found to contain approximately 10 mol% 5-[(5-chloro-lZ7-l,2,3- benzotriazol-4-yl)oxy]isophthalonitrile in addition to 3-chloro-5-[(5-chloro-lH-l,2,3- benzotriazol-4-yl)oxy]benzonitrile. A solution of tert-butyl 3-(bromomethyl)-lH-pyrazolo[3,4- Z>]pyridine-l-carboxylate (Intermediate 1 ; 23 g, 74 mmol) in DMF (100 mL) was added to a suspension of the partially purified product (25 g, 82 mmol) and cesium carbonate (28 g, 86 mmol) in DMF (80 mL) at room temperature, and the resulting mixture was stirred for 1 hour at room temperature. The reaction mixture was then quenched with aqueous saturated ammonium chloride (200 mL), diluted with water (100 mL) and extracted with ethyl acetate (2 x 700 mL). The combined organic fractions were washed with dilute brine (3 x 500 mL), dried over MgSθ4, filtered and concentrated under reduced pressure. The resulting residue was adsorbed onto silica gel and subjected to automated silica gel chromatography eluting with a gradient of 25-50% ethyl acetate in hexanes to afford the crude title product. This mixture was then purified by reverse phase column chromatography eluting with 5-95% CΗ3CN/Η2O (0.1% TFA) to yield the title compound. lH NMR (DMSO-dό) δ 8.53 (dd, J=4.6Hz, J=1.5Hz, IH), 8.22 (m, IH), 8.15 (dd, J=8.2Hz, J=I.5Hz, IH), 8.00 (m, 2H), 7.92 (d, J=8.9Hz, IH), 7.78 (d, J=8.9Hz, IH), 7.21 (dd, J=8.0Hz, J=4.5Hz, IH), 6.39 (s, 2H). LRMS (M+ 1) = 426.9.
EXAMPLE 30 Part A - Capsule Composition
A capsule formulation suitable for oral administration can be prepared by filling standard two-piece gelatin capsules each with 100 mg of the title compound of Example 1, 150 mg of lactose, 50 mg of cellulose, and 3 mg of stearic acid. Encapsulated oral compositions containing any one of the title compounds of Examples 2 to 29 can be similarly prepared.
Part B - Compressed Tablet Composition
Ingredient Amt per batch Amount per Tablet
(wt.%) (mg)
Compound of Example 1 12.5 125.0
HPMCAS-LF 50.0 500.0
Lactose monohydrate 33.25 332.5
SiC"2, colloidal 0.25 2.5
Croscarmellose sodium 3.00 30.0
Magnesium stearate (intragranular) 0.50 5.0
Magnesium stearate (extragranular) 0.50 5.0
Total: 100 1000 Compressed tablets containing 125 mg of the compound set forth in Example 1 (i.e., Compound 1) were prepared as follows: Compound 1 and HPMCAS-LF were dissolved in acetone (66.4 g acetone per 1 g of Compound 1) and the resulting solution was spray dried using a Niro SDMicro Spray Dryer (outlet gas temperature = 53-63°C; process nitrogen = 30 kg/hour; atomizing nitrogen = 2 kg/hour; solution feed rate = 10-15 g/minutes; inlet gas temperature = 97°C-113°C). The resulting powder was combined with lactose monohydrate, colloidal Siθ2, and croscarmellose sodium and the combination was blended in a V blender (Patterson Kelley) for 10 minutes. The blend was then lubricated for 5 minutes with intragranular magnesium stearate in the same blender, after which the blend was roller compacted into ribbons using a roller compactor (TFC Labo) fitted with a knurled roll at 4.0 MPa of pressure. The ribbons were then milled using a rotary fine granulator (TFC Labo) fitted with a 1.0 mm screen. The granules were then lubricated with extragranular magnesium stearate in the V-blender for 5 minutes. The lubricated granules were then compressed on a tablet press (Manesty Single Station F-press) using capsule shaped tooling to provide tablets with a hardness range of 14.5-29.3 kP.
Tablets containing 25 mg of Compound 1 were prepared in the same manner as the 125 mg tablets, wherein the lubricated granules were compressed on a tablet press employing standard round concave tooling to provide tablets with a hardness of 6.1-22.7 kP. Tablets containing 5 mg of Compound 1 were also prepared in the same manner except that 20 wt.% HPCMAS-LF, 35 wt.% microcrystalline cellulose, and 35.75 wt.% lactose monohydrate were employed in the preparation of the lubricated granules (the identity and concentration of the remaining components were unchanged). The lubricated granules were compressed on a tablet press employing standard round concave tooling to provide tablets with a hardness of 3.5-5.1 kP.
EXAMPLE 31
ECL Assay for Inhibition of HIV Reverse Transcriptase
An assay to determine the in vitro inhibition of HTV reverse transcriptase by compounds of the present invention was conducted as follows: HTV-I RT enzyme (0.1 nM) was combined with inhibitor or DMSO (10%) in assay buffer (50 mM Tris-HCl, pH 7.8, 1 mM dithiothreitol, 6 mM MgCl2, 80 mM KCl, 0.025% CHAPS, 0.1 mM EGTA), and the mixture preincubated for 30 minutes at room temperature in microtiter plates (Costar #3359). 100 μL reaction mixtures were initiated with a combination of primer-template substrate (10 nM final concentration) and dNTPs (0.6 μM dNTPs, 1.25 μM BrdUTP ). The heterodimeric nucleic acid substrate was generated by annealing the DNA primer pD500 (described in Shaw-Reid et al., J Biol. Chem. , 278: 2777-2780; obtained from Integrated DNA Technologies) to t500, a 500 nucleotide RNA template created by in vitro transcription (see Shaw-Reid et al., J Biol. Chem., 278: 2777-2780). After 1 hour incubation at 370C, reactions were quenched by 10 μL of 1 N NaOH. Microti ter plates were incubated for an additional 30 minutes at room temperature and then neutralized with 10 μL of 1 N HCl. A mixture of detection buffer containing ruthenylated anti-BrdU antibody and streptavidin coated magnetic beads were added to the plate and incubated at room temperature for 1.5 hours prior to quantification via electrochemiluminescence instrument. Representative compounds of the present invention exhibit inhibition of the reverse transcriptase enzyme in this assay. For example, the title compounds set forth above in Examples 1-4 were tested in the assay and all were found to have IC50 values of less than 10 micromolar. Furthermore, the title compounds set forth above in Examples 1-7, 9-13 and 15-29 (Note - Examples 8 and 14 are prodrugs.) were tested in the assay and were found to have IC50 values as set forth in Table B below.
Analogous assays were conducted substituting mutant HIV strains to determine the in vitro inhibition of compounds of the present invention against mutant HIV reverse transcriptase. In one strain the reverse transcriptase has the Yl 81C mutation and in the other strain the reverse transcriptase has the K103N mutation. The mutations were generated with the QUIKCHANGE site-directed mutagenesis kit (Stratagene). Representative compounds of the present invention exhibit inhibition of the reverse transcriptase enzyme in these assays. For example, the title compounds set forth above in Examples 1-4 were tested in the assays and were found to have IC50 values of less than 10 micromolar in the Yl 81C assay and of less than 10 micromolar in the K103N assay. Furthermore, the title compounds set forth above in Examples 1-7, 9-13 and 15-29 were tested in the assays and were found to have IC50 values as set forth in
Table B:
Table B
Figure imgf000113_0001
Figure imgf000114_0001
1. WT - wild-type
2. The IC50 values reported for Examples 2, 5-7, 10, 15-18, 20 and 22-29 are the results for a single run, and the values for the other examples are based on the results of at least 2 runs.
EXAMPLE 32 Assay for inhibition of HIV replication
Assays for the inhibition of acute HIV-I infection of T-lymphoid cells (alternatively referred to herein as the "spread assay") were conducted in accordance with Vacca, J.P. et al., Proc. Natl. Acad. Sci. USA 1994, 91.: 4096. The assays tested for inhibition of wild type HIV-I and of HTV strains containing the Y181C or K103N mutation. Representative compounds of the present invention exhibit inhibition of HFV replication in the assay employing wild-type HTV-I and the mutant strains. For example, the compounds set forth in Examples 1 to 4 were found to have CIC95 values of less than 10 micromolar in the assay employing the wild type strain. The compounds of Examples 1-4 exhibited CIC95 values of less than 10 micromolar in the assay employing the Y181C mutant strain. The compounds of Examples 1 to 4 had CIC95 values of less than 10 micromolar in the assay employing the K103N mutant strain. Furthermore, the compounds set forth in Examples 1-7, 9-13 and 15-29 were found to have CIC95 values as set forth in Table C below in the assay employing the wild type strain. Table C also reports the CIC95 values of the compounds of Examples 1-7, 9-13 and 15-29 obtained in the assays employing the Y181C mutant strain and the K103N mutant strain.
Table C
Figure imgf000115_0001
Figure imgf000116_0001
1. WT = wild-type; FBS = fetal bovine serum.
2. All of the CIC95 values reported for Examples 2, 6, 15, 16, 20 and 23-29 are the results for a single run. The K103N and Y181C values reported for Examples 5, 7, 17-19 and 21 are the results for a single run. The K103N results reported for Example 22 is for a single run. The Yl 81C results for
Examples 10 and 13 are for a single run. All of the other values are based on the results of at least 2 runs.
EXAMPLE 33 Cytotoxicity
Cytotoxicity was determined by microscopic examination of the cells in each well in the spread assay, wherein a trained analyst observed each culture for any of the following morphological changes as compared to the control cultures: pH imbalance, cell abnormality, cytostatic, cytopathic, or crystallization (i.e., the compound is not soluble or forms crystals in the well). The toxicity value assigned to a given compound is the lowest concentration of the compound at which one of the above changes is observed. Representative compounds of the present invention exhibit no cytotoxicity at concentrations of up to their CIC95 value in the spread assay of Example 32. hi particular, the compounds set forth in Examples 1-7, 9-13 and 15-29 exhibited no cytotoxicity at concentrations of up to 833 nanomolar.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications that come within the scope of the following claims. All publications, patents and patent applications cited herein are incorporated by reference in their entireties into the disclosure.

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof:
Figure imgf000117_0001
wherein:
V is C(RlO), C(O), N(Rl 1), N or N oxide; W is C(R3), C(O), N(Rl 2), N or N oxide; Y is C or N; and Z is C or N, with the proviso that no more than two of V, W, Y and Z contain N;
X is O, S, S(O), S(O)2, N(RA), C(RA)(RB), Or C(O);
Rl is AryA or HetA;
R2, R3 and RlO are each independently selected from the group consisting of: (1) H,
(2) halogen,
(3) CN,
(4) NO2,
(5) C(O)RA, (6) C(O)ORA,
(7) C(O)N(RA)RB,
(8) SRA,
(9) S(O)RA,
(10) S(O)2RA, (11) S(O)2N(RA)RB,
(12) N(RA)RB,
Figure imgf000117_0002
(14) N(RA)C(O)RB,
(15) N(RA)C(O)ORB, (16) N(RA)S(0)2N(RA)RB,
(17) OC(O)N(RA)RB,
( 18) N(RA)C(O)N(RA)RB, (19) Ci_6 alkyl,
(20) Ci-6 haloalkyl,
(21) C2-6 alkenyl,
(22) C2-6 alkynyl, (23) OH,
(24) O-Ci-6 alkyl,
(25) O-C 1 -6 alkyl in which the alkyl is substituted with ORA or N(RA)RB5
(26) O-C 1-6 haloalkyl,
(27) C 1-6 alkyl substituted with from 1 to 3 substituents each of which is independently halogen (provided that the alkyl is further substituted with at least one non-halogen group), OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, Cθ2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB5 N(RA)C02RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB5 OC(O)N(RA)RB5 or N(RA)C(O)N(RA)RB3 (28) CycE,
(29) O-CycE,
(30) C(O)O-CycE,
(31 ) C(O)N(RA)-CycE, and
(32) N(RA)-CycE;
Rl 1 and Rl 2 are each independently selected from the group consisting of H, halogen, Ci -6 alkyl and CycE;
ring A is an unsaturated 6-membered ring wherein " '*---' " denotes the ring contains at least two double bonds;
ring B is fused to ring A and forms together with shared atoms Y and Z of ring A a 4- to 7- membered saturated or unsaturated ring optionally containing from 1 to 3 heteroatoms each of which is independently N, O or S, wherein the total count of heteroatoms in ring B includes either or both Y and Z when either or both are N, and wherein each S is optionally S(O) or S(O)2 and each N is optionally an N-oxide, and wherein from zero to 2 ring carbons are optionally substituted with oxo;
R4 and R^ are each independently selected from the group consisting of: (1) H,
(2) Ci-6 alkyl, (3) C 1-6 alkyl substituted with OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, CN, NO2,
N(RA)RB, C(O)N(RA)RB, C(O)RA, Cθ2RA, SRA, S(O)RA, S(O)2RA,
S(O)2N(RA)RB5 N(RA)C(O)RB, N(RA)C02RB, N(RA)S(0)2RB,
N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, or
N(RA)C(O)C(O)N(RA)RB5
(4) O-Ci_6 alkyl,
(5) C 1-6 haloalkyl,
(6) O-C 1-6 haloalkyl,
(V) OH,
(8) halogen,
(9) CN,
(10) NO2,
(H) C(O)N(RA)RB,
(12) C(O)RA,
(13) C(O)-C 1-6 haloalkyl,
(14) C(O)ORA,
(15) SRA,
(16) S(O)RA5
(17) S(O)2RA,
(18) S(O)2N(RA)RB5
(19) N(RA)RB,
(20) N(RA)S(O)2RB5
(21) N(RA)C(O)RB5
(22) N(RA)C(O)ORB,
(23) N(RA)S(O)2N(RA)RB5
(24) OC(O)N(RA)RB, and
(25) N(RA)C(O)N(RA)RB;
j is an integer equal to zero or 1 ;
k is an integer equal to zero or 1 ;
R6 is attached to the ring atom in B which is adjacent to shared atom Z or which is adjacent to the ring atom that is adjacent to Z, and is: (1)
Figure imgf000120_0001
, wherein each ring N is optionally an N-oxide,
(2) *-CH2C(O)N(RA)-AryB,
(3) *-CH2C(O)N(RA)-HetB,
(4) *-CH2C(O)N(RA)-CI _3 alkylene-AryB, (5) *-CH2C(O)N(RA)-CI _3 alkylene-HetB,
(6) *-CH2C(O)O-Ci-3 alkylene-AryB,
(7) *-CH2C(O)O-Ci-3 alkylene-HetB,
(8) *-CH2-HetB,
(9) *-CH2C(O)-HetB, (10) *-CH2C(O)-HetC, or
(11) *-CH2CH2θH; wherein the asterisk denotes the point of attachment to the rest of the compound;
R7 and R8 are each independently selected from the group consisting of:
(1) H,
(2) OH,
(3) halogen,
(4) CN,
(5) NO2,
(6) Ci-6 alkyl,
(7) C 1-6 alkyl substituted with OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, CN,
NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA,
S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB,
N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB5 OC(O)N(RA)RB5
N(RA)C(O)N(RA)RB5 Or N(RA)C(O)C(O)N(RA)RB,
(8) O-CI-6 alkyl,
(9) O-Ci-6 alkyl in which the alkyl is substituted with O-Ci-6 alkyl,
N(RA)RB, C(O)N(RA)RB5 C(O)RA, or CO2RA,
(10) C 1-6 haloalkyl,
(H) 0-C 1-6 haloalkyl,
(12) N(RC)RD,
(13) N(RA)-Ci.6 alkylene-N(RC)RD5
(14) C(O)N(RA)RB5
(15) C(O)RA5 (16) C(O)-C i -6 haloalkyl,
(17) C(O)ORA
(18) SRA,
(19) S(O)RA (20) S(O)2RA,
(21) S(O)2N(RA)RB,
(22) CycE,
(23) O-CycE,
(24) C(O)O-CycE, (25) C(O)N(RA)-CycE,
(26) N(RA)-CycE,
(27) Ci _6 alkyl substituted with CycE,
(28) O-C i -6 alkyl substituted with N(RA)-CycE,
(29) O-C i -6 alkyl substituted with C(O)-CycE, (30) HetE,
(31) N(RA)S(O)2RB,
(32) N(RA)C(O)RB, and
(33) N(RA)C(O)N(RA)RB;
R9 is H or C 1-6 alkyl;
each RA is independently H, Ci -6 alkyl, or Ci -6 haloalkyl;
each RB is independently H, Cl -6 alkyl, or C 1-6 haloalkyl;
each RC is independently H, Ci -6 alkyl, or Ci -6 haloalkyl;
each RD is independently H, Ci -6 alkyl, or Ci -6 haloalkyl;
alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated or mono-unsaturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2; wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Ci -6 alkyl, (2) C 1-6 fluoroalkyl, (3) (CH2) 1-2G wherein G is OH, O-C 1-6 alkyl, O-C 1-6 fluoroalkyl, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, or SO2RA, (4) O-Ci-6 alkyl, (5) O-C 1-6 fluoroalkyl, (6) OH, (7) oxo, (8) halogen, (9) C(O)N(RA)RB5 (1O) C(O)RA, (i i) C(0)-Ci_6 fluoroalkyl, (12) C(O)ORA, Or (13) S(0)2RA;
AryA is aryl optionally substituted with a total of from 1 to 6 substituents, wherein: (i) from zero to 6 substituents are each independently:
(1) Ci-6 alkyl,
(2) C 1 -6 alkyl substituted with OH, 0-C i -6 alkyl, 0-C I -6 haloalkyl, CN, N02, N(RA)RB, C(O)N(RA)RB5 C(O)RA, Cθ2RA, SRA, S(O)RA, S(O)2RA, S(0)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB5 N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB,
N(RA)C(O)N(RA)RB, or N(RA)C(O)C(O)N(RA)RB,
(3) O-Ci-6 alkyl,
(4) 0-C i _6 alkyl, in which the alkyl is substituted with OH, 0-C I -6 alkyl, 0-C 1-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(0)2RA, S(0)2N(RA)RB, N(RA)C(O)RB,
N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, Or N(RA)C(O)C(O)N(RA)RB,
(5) C 1-6 haloalkyl,
(6) 0-C 1-6 haloalkyl, (7) OH,
(8) halogen,
(9) CN,
(10) NO2,
(11) N(RA)RB, (12) C(O)N(RA)RB,
(13) C(O)RA,
(14) C(O)-C 1-6 haloalkyl,
(15) C(O)ORA,
(16) OC(O)N(RA)RB, (17) SRA
(18) S(O)RA5
(19) S(O)2RA
Figure imgf000122_0001
(21) N(RA)S(O)2RB5 (22) N(RA)S(O)2N(RA)RB5
(23) N(RA)C(O)RB,
(24) N(RA)C(O)N(RA)RB, (25) N(RA)C(O)-C(O)N(RA)RB5
Figure imgf000123_0001
(27) C2-6 alkenyl substituted with CN, N02, N(RA)RB5 OΓ C(O)N(RA)RB5 OΓ
(28) C2-6 alkynyl substituted with CN, NO2, N(RA)RB, Or C(O)N(RA)RB, and
(ϋ) from zero to 2 substituents are each independently:
(1) CycE,
(2) AryE,
(3) 0-AryE,
(4) HetE,
(5) HetF,
(6) C 1-6 alkyl substituted with CycE, AryE, O- AryE, HetE, or HetF,
(7) C2-6 alkenyl substituted with AryE,
(8) C2-6 alkynyl substituted with AryE, or
(9) C2-6 alkynyl substituted with HetE;
HetA is heteroaryl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently: (1) Ci-6 alkyl,
(2) C 1 -6 alkyl substituted with OH, O-C 1 -6 alkyl, O-C 1 -6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA, Cθ2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB5 N(RA)C(O)RB, N(RA)C02RB, N(RA)S(0)2RB, N(RA)S(O)2N(RA)RB5 OC(O)N(RA)RB, N(RA)C(O)N(RA)RB5 or N(RA)C(O)C(O)N(RA)RB5
(3) O-Ci-6 alkyl,
(4) O-C 1 -6 alkyl, in which the alkyl is substituted with OH, O-C 1 -6 alkyl, O-C 1-6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA, CO2RA, SRA5 S(O)RA5 S(0)2RA, S(0)2N(RA)RB, N(RA)C(O)RB, N(RA)C02RB, N(RA)S(0)2RB, N(RA)S(0)2N(RA)RB,
OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, Or N(RA)C(0)C(0)N(RA)RB,
(5) C 1-6 haloalkyl,
(6) O-C 1-6 haloalkyl,
(7) OH, (8) oxo,
(9) halogen,
(10) CN, (H) NO2,
(12) N(RA)RB,
(13) C(O)N(RA)RB5
(14) C(O)RA5
(15) C(O)-C 1-6 haloalkyl,
(16) C(O)ORA,
(17) OC(O)N(RA)RB5
(18) SRA,
(19) S(O)RA5
(20) S(O)2RA,
(21) S(O)2N(RA)RB,
(22) N(RA)S(O)2RB,
(23) N(RA)S(O)2N(RA)RB5
(24) N(RA)C(O)RB5
(25) N(RA)C(O)N(RA)RB3
(26) N(RA)C(O)-C(O)N(RA)RB5 or
(27) N(RA)CO2RB5 and
(ϋ) from zero to 2 substituents are each independently:
(1) CycE,
(2) AryE,
(3) O-AryE,
(4) He(E,
(5) HetF, or
(6) C 1-6 alkyl substituted with CycE, AryE, O-AryE, HetE, or HetF;
aryl is (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocylic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
heteroaryl is (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, (ii) a 9- or 10-membered bicyclic fused ring system, or (iii) an 11- to 16-membered tricyclic fused ring system, wherein the fused ring system of (ii) or (iii) contains from 1 to 6 heteroatoms independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatom, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2; AryB independently has the same definition as AryE;
HetB independently has the same definition as HetE;
HetC independently has the same definition as HetF;
each CycE is independently C3-8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci -6 alkyl, OH, O-Ci-6 alkyl, Cl -6 haloalkyl, or O-Ci-6 haloalkyl;
each AryE is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, CN, NO2, Ci -6 alkyl, Ci -6 haloalkyl, OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, SO2RA, Sθ2N(RA)RB, Or SO2N(RA)C(O)RB;
each HetE is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, CN, NO2, Ci-6 alkyl, Cl -6 haloalkyl, O-C 1 _6 alkyl, O-C 1 _6 haloalkyl, OH, N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C02RB,
C(O)N(RA)RB, C(O)RA, Cθ2RA, SO2RA, Sθ2N(RA)RB, Or phenyl, with the proviso that no more than 1 of the optional substituents is phenyl; and
each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(0)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 4 substituents, each of which is independently halogen, CN, Ci -6 alkyl, OH, oxo, O-Ci-6 alkyl, C 1-6 haloalkyl, O-Ci-6 haloalkyl, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or
Figure imgf000125_0001
and provided that: (A) when ring B is
Figure imgf000126_0001
and R.4 is other than H, then R.6 is not
Figure imgf000126_0002
and
(B) when ring B is
Figure imgf000126_0003
wherein the asterisks on ring B denote the points of attachment to ring A.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
Figure imgf000126_0004
3. A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
Figure imgf000126_0005
(lid),
Figure imgf000127_0001
(IVb),
Figure imgf000127_0002
Figure imgf000127_0003
(IVC), (Va),
Figure imgf000127_0004
4. A compound according to claim 3, or a pharmaceutically acceptable salt thereof, which is a compound of Formula He, Formula IK, or Formula Vila.
5. A compound according to claim 4, or a pharmaceutically acceptable salt thereof, which is a compound of Formula He or Formula Hi.
6. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X is O;
Rl is AryA
R2, R3 and RlO are each independi
(1) H,
(2) halogen,
(3) N(RA)RB5
(4) Ci_6 alkyl,
(5) C 1-6 fluoroalkyl,
(6) O-Ci_6 alkyl, and
(7) O-C 1-6 fluoroalkyl;
Rl 1 and Rl 2 are each independently H or C 1-6 alkyl;
R4 and R5 are each independently selected from the group consisting of:
(1) H,
(2) C 1-6 alkyl,
(3) O-C 1-6 alkyl,
(4) C 1-6 fluoroalkyl,
(5) O-C 1-6 fluoroalkyl, and
(6) halogen;
R6 is:
Figure imgf000128_0001
Figure imgf000129_0001
(3) *-CH2C(O)N(RA)-AryB,
(4) *-CH2C(O)N(RA)-HetB,
(5) *-CH2C(O)N(RA)-Ci-3 alkylene-AryB,
(6) *-CH2C(O)N(RA)-Ci-3 alkylene-HetB,
(7) *-CH2C(O)O-Ci-3 alkylene-AryB,
(8) *-CH2-HetB,
(9) *-CH2C(O)-HetB,
(10) *-CH2C(O)-HetC, or
(H) *-CH2CH2θH;
L is N or N oxide;
R7 and R8 are each i ndependently selected from the gro
(1) H,
(2) OH,
(3) halogen,
(4) CN,
(5) NO2,
(6) C 1-6 alkyl,
(7) O-Ci-6 alkyl,
Figure imgf000129_0002
(10) Ci-6 fluoroalkyl,
(H) O-Ci-6 fluoroalkyl,
(12) N(RC)RD,
(13) N(RA)-(CH2)2-3-N(RC)RD)
(14) C(O)N(RA)RB5
(15) C(O)RA5
(16) C(O)ORA5
(17) SRA5
(18) S(O)RA,
Figure imgf000129_0003
R9 is H or Ci-4 alkyl;
AryA is phenyl or naphthyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently Ci-6 alkyl, O-Ci-6 alkyl, CF3, OCF3, OH, halogen, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA5 C(O)CF3, Cθ2RA, Sθ2RA, CH=CH- (CH2)0-2CN, C≡C— (CH2)1-2N(RA)RB , Or Ci-6 alkylene-N(RA)RB.
AryB is phenyl which is optionally substituted with from 1 to 2 substituents each of which is independently Cl, Br, F, CN, NO2, C1.4 alkyl, CF3, OH, O-Ci-4 alkyl, OCF3, C(O)N(RA)RB5 C(O)RA5 CO2RA, SO2RA, or S02N(RA)RB;
HetB is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, pyridyl and pyrimidinyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents, each of which is independently Cl, Br, F, CN, NO2, C 1-4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3, C(O)N(RA)RB5 C(O)RA CO2RA, SO2RA, Sθ2N(R A)RB5 or phenyl, with the proviso that no more than 1 of the optional substituents is phenyl;
HetC is a saturated heterocyclic ring selected from the group consisting of 1-pyrrolidinyl, 1- piperidinyl, 4-morpholinyl, 4-thiomorpholinyl in which the S is optionally oxidized to S(O) or S(0)2, and 1-piperazinyl, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 2 substituents each of which is Cl, Br, F, CN, C 1.4 alkyl, OH, oxo, O-Ci-4 alkyl, CF3, OCF3, C(O)N(RA)RB5 C(O)RA5 CO2RA Sθ2RA, or Sθ2N(RA)RB;
each RA is independently H or Cl -6 alkyl;
each RB is independently H or Cl -6 alkyl;
each RC is independently H or Cl -6 alkyl;
each RD is independently H or Ci_6 alkyl; and
alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a 4- to 7-membered, saturated monocyclic ring optionally containing 1 heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(0)2; and wherein the monocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently: (1) Ci-4 alkyl, (2) CF3, (3) C(O)N(RA)RB5 (4) C(O)RA, (5) C(O)-CF3, (6) C(O)ORA, or (7) S(O)2RA;
and provided that:
(A) when ring B is
Figure imgf000131_0001
and R4 is other than H, then R6 is not
Figure imgf000131_0002
or and
(B) when ring B is
Figure imgf000131_0003
or
Figure imgf000131_0004
7. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein:
V is CH;
W is C(R3);
either (i) Z and Y are both C and ring A is benzo, or (ii) Z is N and Y is C and ring A is pyrido or dihydropyrido; and
ring B is a 4- to 7-membered saturated or unsaturated ring containing from 1 to 3 N atoms.
8. A compound according to claim 7, or a pharmaceutically acceptable salt thereof, which is a compound of Formula DC:
Figure imgf000132_0001
wherein:
Tl and T2 and T3 are each independently H, Ci .4 alkyl, halogen, CN, CH=CH-CN, C(O)RA, Or
Figure imgf000132_0002
R2 and R3 are each independently selected from the group consisting of:
(1) H,
(2) halogen,
(3) N(RA)RB,
(4) C 1.4 alkyl,
(5) CF3,
(6) O-Ci-4 alkyl, and
(7) OCF3;
R6 IS:
Figure imgf000132_0003
Figure imgf000133_0001
(10) *-CH2CH2θH;
Jl and J2 are each independently H, Cl, Br, F, CN, NO2, Cl .4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3, C(O)N(RA)RB5 C(O)RA, CO2RA, Sθ2RA, or SO2N(RA)RB;
J3 is H, Cl, Br, F, CN, C1.4 alkyl, OH, oxo, O-Ci-4 alkyl, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(RA)RB5 C(O)RA5 CO2RA, SO2RA, or Sθ2N(RA)RB;
L is N or N oxide;
Q is:
(1) -CH(R4)-,
(2) -C(R4)=C(R5)-,
(3) -CH(R4)-CH(R5)-, (4) -C(R4)=C(R5)-CH2-,
(5) -CH(R4)-CH(R5)-CH2-,
(6) -C(R4)=C(R5)-CH=CH-,
(7) -CH(R4)-CH(R5)-CH=CH-,
(8) -C(R4)=C(R5)-CH2CH2-, (9) -CH(R4)-CH(R5)-CH2CH2-,
(10) -C(R4)=N-, (11) -N=C(R4)-, or
(12) -N=N-; wherein the left-most atom in Q is the atom directly attached to the fused benzo;
R4 and R.5 are each independently selected from the group consisting of:
(1) H,
(2) Ci-4 alkyl,
(3) O-Ci-4 alkyl,
(4) CF3, (5) OCF3, and
(6) halogen;
R7 and R8 are each independently selected from the group consisting of:
(1) H, (2) OH,
(3) halogen,
(4) CN,
(5) NO2,
(6) Ci-4 alkyl, (7) O-Ci-4 alkyl,
(8) O(CH2)2.3N(RA)RB,
Figure imgf000134_0001
(10) CF3, (H) OCF3, (12) O(CH2)1-2CF3,
(12) N(RC)RD,
(13) N(RA)-(CH2)2-3-N(RC)RD, and
(14) C(O)N(RA)RB;
each RA is independently H or Cl .4 alkyl;
each RB is independently H or C 1-4 alkyl;
each RC is independently H or C 1-4 alkyl;
each RD is independently H or C 1-4 alkyl; and alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
Figure imgf000135_0001
-O a anndd
and provided that (A) when Q is -N=C(R4)- and R4 is other than H, then R6 is not
Figure imgf000135_0002
9. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein Q is -CH2CH2CH2-, -CH=N-, -C(Cl)=N-, -N=CH-, or -N=N-.
10. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, which is a compound of Formula EXa:
Figure imgf000135_0003
and provided that when Q is -N=C(R4)-, then R4 is H.
11. A compound according to claim 10, or a pharmaceutically acceptable salt thereof, which is a compound of Formula EXb:
Figure imgf000135_0004
wherein:
Q is:
(1) -CH=CH-,
(2) -CH=CH-CH2-,
(3) -CH=CH-CH=CH-, (4) -CH2CH2-CH=CH-,
(5) -CH=CH-CH2CH2-,
(6) -C(R4)=N-,
(7) -N=CH-,
(8) -N=N-, or
(9) CH2CH2CH2;
Tl is H or Cl;
R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and Cl .4 alkyl;
R4 is H, C 1-4 alkyl, Cl, Br, or F; and
one of R7 and R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(0)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and the other of R7 and R8 is H.
12. A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein Q is CH2CH2CH2, -CH=N-, -C(Cl)=N-, -N=CH-, or -N=N-.
13. A compound according to claim 10, or a pharmaceutically acceptable salt thereof, which is a compound of Formula FXc:
Figure imgf000136_0001
wherein:
Q is:
(1) -CH=CH-,
(2) -CH=CH-CH2-,
(3) -CH=CH-CH=CH-,
(4) -CH2CH2-CH=CH-, (5) -CH=CH-CH2CH2-,
(6) -C(R4)=N-,
(7) -N=CH-,
(8) -N=N-, or (9) CH2CH2CH2;
Tl is H or Cl;
T2 is CN, CH(O), CH2NH2, or CH2N(H)CH3 ;
R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and Cl .4 alkyl;
R4 is H, C 1-4 alkyl, Cl, Br, or F; and
R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2-
14. A compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein Q is CH2CH2CH2, -CH=N-, -C(Cl)=N-, -N=CH-, or -N=N-.
15. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, which is a compound of Formula DCd:
Figure imgf000137_0001
wherein Tl and T2 are each independently H, Cl .4 alkyl, halogen, CN, or CH=CH-CN;
and provided that when Q is -N=C(R4)-, then R4 is H.
16. A compound according to claim 15, or a pharmaceutically acceptable salt thereof, which is a compound of Formula DCe:
Figure imgf000138_0001
wherein:
Q is:
(1) -CH=CH-,
(2) -CH=CH-CH2-,
(3) -CH=CH-CH=CH-,
(4) -CH2CH2-CH=CH-,
(5) -CH=CH-CH2CH2-,
(6) -C(R4)=N-,
(7) -N-CH-, or
(8) -N=N-;
R2 and R3 are each independently selected from the group consisting of H, Cl, Br, F and C 1.4 alkyl;
R4 is H, C 1.4 alkyl, Cl, Br, or F; and
R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2.
17. A compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein:
Q is -CH=N-, -C(Cl)=N-, -N=CH-, or -N=N-;
R2 is Br or Cl;
R3 is H; and
R8 is H or NH2.
18. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, which is a compound of Formula X:
Figure imgf000139_0001
wherein
Tl and T2 and T3 are each independently H, C 1-4 alkyl, halogen, CN, CH=CH-CN, C(O)RA, Or (CH2)1-2N(RA)RB;
R2 and R3 are each independently selected from the group consisting of:
(1) H,
(2) halogen,
(3) N(RA)RB5
(4) Ci-4 alkyl, (5) CF3,
(6) O-Ci-4 alkyl, and
(7) OCF3;
R6 is:
Figure imgf000139_0002
Figure imgf000140_0001
Jl and J2 are each independently H, Cl, Br, F, CN, NO2, C 1.4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or SO2N(RA)RB;
J3 is H, Cl, Br, F, CN, Ci-4 alkyl, OH, oxo, O-C1.4 alkyl, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, or SO2N(RA)RB;
L is N or N oxide;
R7 and R8 are each independently selected fi
(1) H,
(2) OH,
(3) halogen,
(4) CN,
(5) NO2,
(6) C 1-4 alkyl,
(7) O-C 1-4 alkyl,
Figure imgf000140_0002
(10) CF3,
(H) OCF3, (12) O(CH2)1-2CF3,
(12) N(RC)RD,
(13) N(RA)-(CH2)2-3-N(RC)RD, and
(14) C(O)N(RA)RB;
each RA is independently H or C 1.4 alkyl;
each RB is independently H or C 1.4 alkyl;
each RC is independently H or C 1.4 alkyl;
each RD is independently H or Ci .4 alkyl; and
alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
\/ , ^ , and ^^ .
19. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, which is a compound of Formula XI:
Figure imgf000141_0001
wherein:
U is CH or N;
Tl and T2 and T3 are each independently H, C 1.4 alkyl, halogen, CN, CH-CH-CN, C(O)RA, Or
Figure imgf000141_0002
R2 and R3 are each independently selected from the group consisting of:
(1) H, (2) halogen, (3) N(RA)RB5
(4) Ci-4 alkyl,
(5) CF3,
(6) O-Ci-4 alkyl, and
(7) OCF3;
R6 IS:
Figure imgf000142_0001
Jl and J2 are each independently H, Cl, Br, F, CN, NO2, C 1.4 alkyl, CF3, OH, O-C1.4 alkyl, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA Sθ2RA, or Sθ2N(RA)RB; J3 is H, Cl, Br, F, CN, Ci-4 alkyl, OH, oxo, O-Ci-4 alkyl, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, Cθ2RA, Sθ2RA, or SO2N(RA)RB;
L is N or N oxide;
R7 and R8 are each independently selected from the group consisting of:
(1) H,
(2) OH,
(3) halogen, (4) CN,
(5) NO2,
(6) Ci-4 alkyl,
(7) O-Ci-4 alkyl,
Figure imgf000143_0001
(10) CF3,
(H) OCF3,
(12) O(CH2)1-2CF3,
(12) N(RC)RD, (13) N(RA)-(CH2)2-3 -N(RC)RD, and
(14) C(O)N(RA)RB;
each RA is independently H or Cl .4 alkyl;
each RB is independently H or C 1.4 alkyl;
each RC is independently H or Ci .4 alkyl;
each RD is independently H or Cl -.4 alkyl; and
alternatively and independently each pair of RC and RD together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
\/ , ^ , and \-V .
20. A compound according to claim 1 selected from the group consisting of:
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000145_0002
, and pharmaceutically acceptable salts thereof.
21. A compound of Formula I -P :
Figure imgf000145_0003
wherein: R6P is
Figure imgf000146_0001
;
R9P is PO(OH)O- M+; PO(O-)2 -2M+; PO(O-)2 -M2+; or an acid salt of:
Figure imgf000146_0002
M+ is a pharmaceutically acceptable monovalent counterion; M2+ is a pharmaceutically acceptable divalent counterion; Rl5 is H, Ci-6 alkyl, (CH2)2-3CF3, AryA, or HetA;
Rl6a and Rl6b are each independently H, Ci-6 alkyl, (CH2)2-3CF3, AryA, or HetA; each Rl 7 is independently H or C 1-6 alkyl; each Rl 8 is independently H or C 1-6 alkyl; alternatively, Rl 5 together with an Rl? or Rl8 and the atoms to which each is attached and any carbons in a chain therebetween form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 5 is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, Rl 6a together with an Rl? or Rl 8 and the atoms to which each is attached and any carbons in a chain therebetween form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 6a is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, an Rl 7 together with the Rl 8 attached to the same carbon atom form a 5- or 6-membered, saturated monocyclic ring optionally containing a heteroatom, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) Or S(O)2; Rl9 is H or C 1-6 alkyl;
R20 is H or C 1-6 alkyl;
R21 is H or Ci-6 alkyl;
R22a and R22b are each independently H, C 1-6 alkyl, (CH2)2-3CF3, AryA, or HetA;
R23 is H or Ci-6 alkyl; R24 is H or C 1-6 alkyl; alternatively, Rl 9 together with R23 or R24 and the atoms to which each is attached form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which Rl 9 is attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, R20 and R21 together with the carbon atom to which both are attached form a 5- or 6-membered, saturated monocyclic ring optionally containing a heteroatom, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) Or S(O)2; alternatively, R22a together with an R20 or R21 and the atoms to which each is attached form a 5- to 7-membered, saturated or unsaturated monocyclic ring optionally containing a heteroatom in addition to the N atom to which R22a 1S attached, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O) or S(O)2; alternatively, R23 and R24 together with the carbon atom to which both are attached form a 5- or
6-membered, saturated monocyclic ring optionally containing a heteroatom, wherein the optional heteroatom is selected from N, O and S, where the S is optionally oxidized to S(O)
Or S(O)2; wherein the monocyclic ring formed by combining Rl 5 together with an Rl 7 Or Rl 8, the monocyclic ring formed by combining Rl 6a together with an Rl7 or Rl8, the monocyclic ring formed by combining Rl 7 together with an Rl 8, the monocyclic ring formed by combining Rl 9 together with an R23 or R24 , the monocyclic ring formed by combining R20 together with an R21, the monocyclic ring formed by combining R22a together with an R20 or R21, and the monocyclic ring formed by combining R23 together with an R24, are each independently and optionally substituted with from 1 to 3 substituents each of which is independently: (1) C 1-6 alkyl, (2) C 1-6 haloalkyl, (3) C 1-6 alkyl substituted with OH, 0-Ci- 6 alkyl, O-C i -6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB5 C(O)RA, CO2RA, SRA,
S(O)RA, SO2RA, or SO2N(RA)RB, (4) O-Ci-6 alkyl, (5) O-Ci-6 haloalkyl, (6) OH, (7) oxo, (8) halogen, (9) CN, (10) NO2, (11) N(RA)RB, (I2) C(O)N(RA)RB, (13) C(O)RA, (14) C(0)-Ci-6 haloalkyl, (15) C(O)ORA, (16) OC(O)N(RA)RB, (17) SRA, (18) S(O)RA, (19.) S(O)2RA, (20) S(O)2N(RA)RB, (2i) N(RA)CORB, or (22) N(RA)SO2RB;
d is an integer equal to 2, 3, or 4; and
all other variables are as defined for a compound of Formula I in claim 1 ;
and provided that:
Figure imgf000148_0001
of attachment to ring A.
22. A compound according to claim 21, which is a compound of Formula
IX-P:
Figure imgf000148_0002
wherein:
Tl and T2 and T3 are each independently H, C 1-4 alkyl, halogen, CN, CH=CH-CN, C(O)RA, Or
Figure imgf000148_0003
R2 and R3 are each independently selected from the group consisting of:
(1) H, (2) halogen,
(3) N(RA)RB5
(4) CM alkyl,
(5) CF3,
(6) O-Ci-4 alkyl, and (7) OCF3;
L is N or N oxide;
Q is: (1) -CH(R4)-,
(2) -C(R4)=C(R5)-, (3) -CH(R4)-CH(R5)-,
(4) -C(R4)=C(R5)-CH2-,
(5) -CH(R4)-CH(R5)-CH2-,
(6) -C(R4)=C(R5)-CH=CH-, (7) -CH(R4)-CH(R5)-CH=CH-,
(8) -C(R4)=C(R5)-CH2CH2-,
(9) -CH(R4)-CH(R5)-CH2CH2-,
(10) -C(R4)=N-,
(11) -N=CH-, or (12) -N=N-; wherein the left-most atom in Q is the atom directly attached to the fused benzo;
R4 and R5 are each independently selected from the group consisting of:
(1) H, (2) Ci-4 alkyl,
(3) O-Ci-4 alkyl,
(4) CF3,
(5) OCF3, and
(6) halogen;
R? and R8 are each independently selected from the group consisting of:
(1) H,
(2) OH,
(3) halogen,
(4) CN,
(5) NO2,
(6) Ci-4 alkyl,
(7) O-Ci-4 alkyl,
Figure imgf000149_0001
(10) CF3,
(H) OCF3,
(12) O(CH2)1-2CF3,
(12) N(RC)RD5
(13) N(RA)-(CH2)2-3-N(RC)RD, and
(14) C(O)N(RA)RB; each RA is independently H or C 1.4 alkyl;
each RB is independently H or C 1.4 alkyl;
each RC is independently H or C 1.4 alkyl;
each RD is independently H or Ci -.4 alkyl;
alternatively and independently each pair of RC and RP together with the N atom to which they are both attached form a saturated monocyclic ring selected from the group consisting of:
Figure imgf000150_0001
R9P is PO(OH)O- -M+; PO(O-)2 -2M+; PO(O-)2 -M2+; or an acid salt of:
Figure imgf000150_0002
M+ is a pharmaceutically acceptable monovalent counterion;
M2+ is a pharmaceutically acceptable divalent counterion;
Rl 5 is H or C 1-4 alkyl
Rl 6a and Rl 6b are each independently H or C 1.4 alkyl;
Rl 9 is H or C i_4 alkyl; R20 is H or C 1-4 alkyl;
R22a and R22b are each independently H or Cl .4 alkyl; and d is an integer equal to 2, 3 or 4.
23. A compound of according to claim 21 , which is a compound of Formula IXa-P:
Figure imgf000150_0003
wherein:
Q is:
(1) -CH=CH-,
(2) -CH=CH-CH2-,
(3) -CH=CH-CH=CH-,
(4) -CH2CH2-CH=CH-,
(5) -CH=CH-CH2CH2-,
(6) -C(R4)=N-,
(7) -N=CH-, or
(8) -N=N-;
R2 and R.3 are each independently selected from the group consisting of H, Cl, Br, F and Ci -4 alkyl;
R4 is H, C 1-4 alkyl, Cl, Br, or F; and
R8 is H, OH, Cl, Br, F, CH3, OCH3, O(CH2)2-3NH2, CF3, OCF3, OCH2CF3, NH2, N(H)CH3, N(CH3)2, C(O)NH2, C(O)N(H)CH3, or C(O)N(CH3)2; and
R9P is PO(OH)O- M+; P0(0-)2 -2M+; PO(O-)2 -M2+; or an acid salt of:
Figure imgf000151_0001
24. A compound according to claim 23, which is:
Figure imgf000151_0002
25. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
26. A method for the treatment or prophylaxis of HIV-I infection, or the treatment or prophylaxis or delay in the onset or progression of AIDS due to HIV-I, wherein the method comprises administering to a subject in need thereof an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
PCT/US2007/025012 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors WO2008076225A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009538427A JP5123949B2 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors
CA002673093A CA2673093A1 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors
AU2007334598A AU2007334598B2 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors
EP07862604.1A EP2121638B1 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87462906P 2006-12-13 2006-12-13
US60/874,629 2006-12-13

Publications (2)

Publication Number Publication Date
WO2008076225A2 true WO2008076225A2 (en) 2008-06-26
WO2008076225A3 WO2008076225A3 (en) 2008-08-07

Family

ID=39277099

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/024974 WO2008076223A1 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors
PCT/US2007/025012 WO2008076225A2 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024974 WO2008076223A1 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors

Country Status (29)

Country Link
US (2) US7781454B2 (en)
EP (1) EP2121638B1 (en)
JP (1) JP5123949B2 (en)
KR (1) KR20090087481A (en)
CN (1) CN101558050A (en)
AR (1) AR064199A1 (en)
AU (1) AU2007334598B2 (en)
BR (1) BRPI0720196A2 (en)
CA (1) CA2673093A1 (en)
CL (1) CL2007003594A1 (en)
CR (1) CR10843A (en)
DO (1) DOP2009000138A (en)
EA (1) EA200970572A1 (en)
EC (1) ECSP099373A (en)
GE (1) GEP20115320B (en)
GT (1) GT200900158A (en)
HN (1) HN2009001160A (en)
IL (1) IL199103A0 (en)
MA (1) MA31036B1 (en)
MX (1) MX2009006285A (en)
NI (1) NI200900103A (en)
NO (1) NO20092636L (en)
NZ (1) NZ577637A (en)
PE (1) PE20081448A1 (en)
SV (1) SV2009003294A (en)
TN (1) TN2009000243A1 (en)
TW (1) TW200831085A (en)
WO (2) WO2008076223A1 (en)
ZA (1) ZA200903395B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049987A3 (en) * 2009-10-20 2011-09-09 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8299101B2 (en) 2007-03-07 2012-10-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2014058747A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
EP2924034A1 (en) 2010-03-30 2015-09-30 Merck Canada Inc. Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor
WO2015153304A1 (en) 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN105906482A (en) * 2016-05-19 2016-08-31 江苏优嘉植物保护有限公司 Method for preparing 2,5-dichlorophenol from 2,5-dichloro phenol ether
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2020254603A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
JP5269087B2 (en) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド Inhibitors of human immunodeficiency virus replication
WO2009067166A2 (en) * 2007-11-20 2009-05-28 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2009117278A2 (en) * 2008-03-20 2009-09-24 Merck & Co., Inc. Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
US20140206717A1 (en) * 2011-08-16 2014-07-24 John Higgins Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
PL2861566T3 (en) 2012-06-13 2017-06-30 F.Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
CN103848827A (en) * 2012-11-30 2014-06-11 南京大学 Application of benzotriazole derivatives in anti-cancer drugs
CN103848826A (en) * 2012-11-30 2014-06-11 南京大学 Preparation method and use of 1,3,4-oxadiazole derivative having benzotriazole structure
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
MX2016005186A (en) 2013-11-26 2016-07-08 Hoffmann La Roche NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL.
HUE046820T2 (en) 2014-03-26 2020-03-30 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MX2016010675A (en) 2014-03-26 2016-11-10 Hoffmann La Roche Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors.
MA41898A (en) 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
MX2020004504A (en) 2015-09-04 2021-11-10 Hoffmann La Roche Phenoxymethyl derivatives.
CN107614505B (en) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 Novel bicyclic compounds as dual ATX/CA inhibitors
RU2018112230A (en) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг BICYCLE COMPOUNDS AS ATX INHIBITORS
CN115124538A (en) 2015-09-24 2022-09-30 豪夫迈·罗氏有限公司 Bicyclic compounds as ATX inhibitors
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN110392679B (en) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 Heterocyclic compounds useful as dual ATX/CA inhibitors
CN114031619A (en) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 Preparation method of intermediate of Tecatinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
SU1049487A1 (en) * 1982-06-24 1983-10-23 Новокузнецкий научно-исследовательский химико-фармацевтический институт Process for preparing o-aminoketones of benzimidazole series
US5358950A (en) * 1991-07-05 1994-10-25 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
US6369235B1 (en) * 1997-02-25 2002-04-09 The United States Of America As Represented By The Department Of Health And Human Services Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
JP2006500355A (en) 2002-08-07 2006-01-05 イデニクス（ケイマン）リミテツド Substituted phenylindoles for the treatment of HIV
MXPA05003660A (en) 2002-10-21 2005-06-08 Warner Lambert Co Tetrahydroquinoline derivatives as crth2 antagonists.
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MXPA05009459A (en) 2003-03-03 2006-05-17 Array Biopharma Inc P38 inhibitors and methods of use thereof.
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
SE0303180D0 (en) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
BRPI0508220A (en) 2004-02-27 2007-07-17 Hoffmann La Roche fused heteroaryl pyrazole derivatives
JP2007523938A (en) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー Condensed derivatives of pyrazole
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2005115147A2 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
EP1753730A1 (en) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN1993332B (en) 2004-07-27 2011-04-06 弗·哈夫曼-拉罗切有限公司 Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
WO2006102112A2 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
CA2612573A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1899340A4 (en) 2005-06-28 2009-09-16 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP1898928A2 (en) 2005-06-28 2008-03-19 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
AR057455A1 (en) 2005-07-22 2007-12-05 Merck & Co Inc INHIBITORS OF HIV REVERSE TRANSCRIPTASE AND PHARMACEUTICAL COMPOSITION
WO2008019968A1 (en) 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
MX2009005047A (en) * 2006-11-16 2009-05-25 Hoffmann La Roche Substituted 4-imidazoles.
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P. L. GOULD, INT. J. PHARM., vol. 33, 1986, pages 201 - 217
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8299101B2 (en) 2007-03-07 2012-10-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US11071729B2 (en) 2007-09-14 2021-07-27 Addex Pharmaceuticals S.A. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9737533B2 (en) 2009-05-12 2017-08-22 Janssen Pharmaceuticals. Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US10071095B2 (en) 2009-05-12 2018-09-11 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2011049987A3 (en) * 2009-10-20 2011-09-09 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
EP2924034A1 (en) 2010-03-30 2015-09-30 Merck Canada Inc. Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2014058747A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
US9469634B2 (en) 2012-10-08 2016-10-18 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
EP3656384A1 (en) 2012-10-08 2020-05-27 Merck Sharp & Dohme Corp. Combinations comprising 5-phenoxy-3h-pyrimidin-4-one derivatives and their use for the prophylaxis or treatment of infection by hiv
US9718819B2 (en) 2012-10-08 2017-08-01 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
EP3295942A1 (en) 2012-10-08 2018-03-21 Merck Sharp & Dohme Corp. Combinations comprising 5-phenoxy-3h-pyrimidin-4-one derivatives and their use for the prophylaxis or treatment of infection by hiv
US10189831B2 (en) 2012-10-08 2019-01-29 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10584129B2 (en) 2013-06-04 2020-03-10 Janssen Pharmaceuticals Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11103506B2 (en) 2014-01-21 2021-08-31 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US12048696B2 (en) 2014-01-21 2024-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2015153304A1 (en) 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
US10004740B2 (en) 2014-04-01 2018-06-26 Merck Sharp & Dohme Corp. Prodrugs of HIV reverse transcriptase inhibitors
EP3785714A1 (en) 2014-04-01 2021-03-03 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
CN105906482A (en) * 2016-05-19 2016-08-31 江苏优嘉植物保护有限公司 Method for preparing 2,5-dichlorophenol from 2,5-dichloro phenol ether
WO2020254603A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS

Also Published As

Publication number Publication date
NO20092636L (en) 2009-09-08
GT200900158A (en) 2009-10-14
JP5123949B2 (en) 2013-01-23
HN2009001160A (en) 2011-10-11
US20100286192A1 (en) 2010-11-11
JP2010510989A (en) 2010-04-08
EA200970572A1 (en) 2009-12-30
TN2009000243A1 (en) 2010-10-18
CN101558050A (en) 2009-10-14
CA2673093A1 (en) 2008-06-26
MA31036B1 (en) 2009-12-01
ZA200903395B (en) 2010-05-26
EP2121638B1 (en) 2016-05-25
DOP2009000138A (en) 2009-11-15
CL2007003594A1 (en) 2008-05-30
ECSP099373A (en) 2009-07-31
PE20081448A1 (en) 2008-10-19
NZ577637A (en) 2011-05-27
CR10843A (en) 2009-08-12
AU2007334598A1 (en) 2008-06-26
MX2009006285A (en) 2009-06-23
EP2121638A2 (en) 2009-11-25
AR064199A1 (en) 2009-03-18
TW200831085A (en) 2008-08-01
WO2008076223A1 (en) 2008-06-26
KR20090087481A (en) 2009-08-17
IL199103A0 (en) 2010-03-28
BRPI0720196A2 (en) 2013-12-31
US20080275097A1 (en) 2008-11-06
GEP20115320B (en) 2011-10-25
SV2009003294A (en) 2009-11-09
AU2007334598B2 (en) 2013-01-17
NI200900103A (en) 2010-01-26
US7781454B2 (en) 2010-08-24
WO2008076225A3 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
AU2007334598B2 (en) Non-nucleoside reverse transcriptase inhibitors
CA2971640C (en) Cot modulators and methods of use thereof
TWI478714B (en) N-containing heteroaryl derivatives as jak3 kinase inhibitors
KR101959590B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
AU2008326784B2 (en) Non-nucleoside reverse transcriptase inhibitors
AU2008273017B2 (en) Heterocyclic compounds useful as Raf kinase inhibitors
AU2009281822B2 (en) cMET inhibitors
TWI713952B (en) Compounds and compositions as inhibitors of bromodomain proteins
JP7026194B2 (en) Azabenzimidazole and its use as an AMAP receptor regulator
WO2017024021A1 (en) 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024013A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023972A1 (en) 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
BR112015010102B1 (en) HETEROCYCLIC COMPOUND SUBSTITUTED BY amide AND PHARMACEUTICAL COMPOSITION COMPRISING IT
JP2018521025A (en) Benzoxazinone derivatives and analogs thereof as modulators of TNF activity
EP1833828A2 (en) Condensed pyridines as kinase inhibitors
WO2017024025A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
CA2763821A1 (en) 1h-imidazo[4,5-c]quinolinone derivatives
KR20220061958A (en) Heterobicyclic amides as inhibitors of CD38
US10759799B2 (en) Indazole containing macrocycles and therapeutic uses thereof
BR112020020708A2 (en) CYCLIC UREA FUSED DERIVATIVES AS CRHR2 ANTAGONIST
CA3229566A1 (en) Sos1 inhibitor and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780046416.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862604

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007334598

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009538427

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2673093

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007334598

Country of ref document: AU

Date of ref document: 20071206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4535/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007862604

Country of ref document: EP